🏷

Classifications

Harrison's Part

ISDS Skeletal Nosology

📘

Definitions

1

Cardinal Clinical Triad of Sotos Syndrome

GeneReviews treats three features together as cardinal: the distinctive facial appearance, learning disability, and overgrowth of height and/or head circumference at or above 2 SD. The triad is a clinical-recognition construct that prompts molecular testing; it is not the diagnostic criterion, which is molecular. It is also not fully sensitive - a tenth of NSD1-positive individuals have normal height and head circumference.

DIAGNOSTIC_CRITERIA Clinical recognition prompting NSD1 molecular testing

Inclusion criteria

Distinctive facial appearance Broad prominent forehead with dolichocephaly, sparse frontotemporal hair, downslanting palpebral fissures, malar flushing, long narrow face, tall chin.
Learning disability From early developmental delay to mild-to-severe intellectual impairment. This clinical-recognition criterion deliberately retains the source's composite scope: binding it only to Intellectual disability would exclude developmental delay. The component phenotypes have separate HPO bindings; this is a composite-criterion modeling decision, not a claim that HPO lacks these terms.
Overgrowth Height and/or head circumference at or above 2 SD above the mean.

Show evidence (2 references)

PMID:20301652 SUPPORT Human Clinical

"These three clinical features (distinctive facial features, learning disability, and overgrowth) are considered the cardinal features of Sotos syndrome."

States the triad exactly as this definition records it.

PMID:15942875 SUPPORT Human Clinical

"Facial dysmorphism, learning disability, and childhood overgrowth were present in 90% of the individuals."

Quantifies the triad's sensitivity in molecularly confirmed cases, which is the basis for the caveat in the description.

👪

Inheritance

1

Autosomal Dominant HP:0000006

Sotos syndrome is autosomal dominant. Approximately 95% of affected individuals have a de novo alteration and about 5% have an affected parent. Each child of an affected individual has a 50% chance of inheriting the alteration; severity cannot be predicted reliably across generations. Recurrence in clinically unaffected parents is uncommon but possible through parental gonadal mosaicism, and negative blood testing does not exclude that possibility. The low observed vertical transmission rate may partly reflect reproductive fitness, but its explanation remains uncertain.

Autosomal dominant inheritance Expressivity: VARIABLE De novo rate: ~95%

Show evidence (4 references)

PMID:20301652 SUPPORT Human Clinical

"Sotos syndrome is inherited in an autosomal dominant manner. About 5% of individuals diagnosed with Sotos syndrome have an affected parent; approximately 95% of individuals have the disorder as the result of a de novo genetic alteration."

GeneReviews establishes both the inheritance mode and the de novo proportion.

PMID:20301652 SUPPORT Human Clinical

"Phenotypic expression can vary from one generation to the next; thus, it is not possible to accurately predict phenotype based on the prenatal finding of a Sotos syndrome-related genetic alteration."

Supports the variable-expressivity assignment and the counselling limitation that follows from it.

PMID:36708490 SUPPORT Human Clinical

"Gentling results indicated that the fetus and the patient inherited the same maternal chromosome 5. The heterozygous mutation of NSD1 gene c.4138delG is the pathogenic mutation of this Sots syndrome patient, and the mother may be germinal mosaicism."

Recurrence of the same variant in two pregnancies despite negative parental blood testing supports suspected maternal germline mosaicism. This report supersedes the 2007 statement that germline mosaicism had never been reported; it does not estimate a population recurrence risk.

+ 1 more reference

◆

Subtypes

2

Intragenic NSD1 loss-of-function variant

~83% of clinically diagnosed Sotos syndrome in the predominantly non-Japanese diagnostic series NSD1 hgnc:14234

Sotos syndrome caused by a heterozygous intragenic NSD1 variant - truncating variants distributed throughout the gene, or missense variants confined to the functional domains. This is the majority class in European-ancestry cohorts, where it accounts for roughly 83% of clinically diagnosed individuals, and is associated with more prominent overgrowth and less severe learning disability than the microdeletion class.

Show evidence (2 references)

PMID:15942875 SUPPORT Human Clinical

"Furthermore, our data suggest that 93% of patients who have been clinically diagnosed with Sotos syndrome have identifiable NSD1 abnormalities, of which 83% are intragenic mutations and 10% are 5q35 microdeletions."

The 83% intragenic and 10% deletion estimates sum to the 93% molecular yield among clinically diagnosed individuals, not percentages within the NSD1-positive subgroup.

PMID:15942875 SUPPORT Human Clinical

"Truncating NSD1 mutations occurred throughout the gene, but pathogenic missense mutations occurred only in functional domains (P < 2 x 10(-16))."

Supports the described distribution of intragenic variant classes across the gene.

Recurrent 5q35 microdeletion encompassing NSD1

~10% of clinically diagnosed Sotos syndrome in the predominantly non-Japanese diagnostic series; ~52% of Japanese patients in the older referral series NSD1 hgnc:14234

Sotos syndrome caused by a contiguous 5q35 deletion encompassing NSD1. The recurrent deletion arises through non-allelic homologous recombination at flanking low-copy repeats. Frequencies vary between referral series and populations; Korean cohorts have reported both deletion-predominant and intragenic-variant-predominant distributions. Deletions are associated with less prominent overgrowth and more severe learning disability at group level. A scoliosis series also found greater progression in the deletion group. The absence of a deletion-size correlation does not exclude contributions from neighboring genes.

Show evidence (3 references)

PMID:14517949 SUPPORT Human Clinical

"A large difference in the frequency of microdeletions between Japanese and non-Japanese patients was noted: 49 (52%) of the 95 Japanese patients and only one (6%) of the 17 non-Japanese had microdeletions."

Directly quantifies the population skew that defines the clinical relevance of this subtype.

PMID:15942875 SUPPORT Human Clinical

"Patients with microdeletions had less-prominent overgrowth (P = .0003) and more-severe learning disability (P = 3 x 10(-9)) than patients with mutations."

The primary genotype-phenotype contrast justifying curation of the two molecular classes as subtypes.

PMID:15942875 SUPPORT Human Clinical

"However, all features present in patients with microdeletions were also observed in patients with mutations, and there was no correlation between deletion size and the clinical phenotype, suggesting that the deletion of additional genes in patients with 5q35 microdeletions has little specific..."

Reports the original authors’ interpretation of overlapping phenotypes and lack of a deletion-size correlation; this does not prove that neighboring genes have no phenotypic contribution.

?

Discussions and Knowledge Gaps

10

How faithfully does the heterozygous Nsd1 mouse reproduce growth and neurobehavioral phenotypes across ages and genetic backgrounds?

HUMAN MODEL MISMATCH OPEN sotos_mouse_model_does_not_show_overgrowth

Attached to

animal_models#Nsd1 heterozygous mouse (CRISPR exon 3) phenotypes#Childhood Overgrowth pathophysiology#Dysregulated Developmental Transcriptional Program

The cached primary abstract documents behavioral abnormalities in a heterozygous Nsd1 mouse but does not supply growth measurements. Absence of a growth result from an abstract is not evidence of a tested negative result. Model findings should be interpreted at the measured phenotype level; this abstract alone cannot establish a dissociation between the human growth and neurobehavioral arms.

Deliberately framed around what the cached abstract supports. Secondary summaries of this paper report explicit negative findings for overgrowth and macrocephaly from full text that is not in the reference cache; if that text is later cached, this discussion and the model link should both be revisited, and the link may become FAILS_TO_RECAPITULATE.

Does the proposed MAPK/ERK–chondrocyte maturation pathway mediate human Sotos overgrowth, and which NSD1-dependent changes are necessary?

KNOWLEDGE GAP OPEN sotos_overgrowth_mechanism_unexplained

Attached to

pathophysiology#Dysregulated Developmental Transcriptional Program phenotypes#Childhood Overgrowth phenotypes#Advanced Bone Age

A source-supported provisional growth pathway is represented: altered MAPK/ERK signaling in patient-derived fibroblasts may affect hypertrophic chondrocyte differentiation. The study did not measure affected growth plates, and kinase-significance estimates depended on outlier exclusion. Patient blood profiling additionally identifies skeletal-development genes, but neither study establishes the tissue-specific mediators of statural growth or explains macrocephaly. The remaining gap is experimental confirmation and anatomical attribution, not absence of a published growth hypothesis.

Proposed experiments

NSD1-haploinsufficient human chondrocyte and growth-plate model

sotos-growth-plate-chondrocyte-model

Differentiate isogenic NSD1+/- and corrected human iPSC lines into chondrocytes and cartilage organoids, and compare proliferation, hypertrophic transition timing, H3K36me2 distribution and intergenic DNA methylation across matched differentiation stages.

Readouts

Chondrocyte proliferative and hypertrophic-transition kinetics by NSD1 genotype

phenotypes#Advanced Bone Age

H3K36me2 and CpG-methylation state at growth-regulatory loci in chondrocytes

pathophysiology#Dysregulated Developmental Transcriptional Program

Decision criterion

A reproducible genotype-dependent acceleration of hypertrophic transition, reversed by isogenic correction and accompanied by a chromatin change at identifiable growth-regulatory loci, would establish a candidate skeletal overgrowth mechanism. Normal chondrocyte behaviour despite the expected chromatin defect would push the explanation towards an endocrine or systemic route.

Show evidence (2 references)

PMID:23155469 SUPPORT INDIRECT In Vitro

"In analogy, we propose that deregulation of the MAPK/ERK pathway in SoS results in altered hypertrophic differentiation of NSD1 expressing chondrocytes and may be a determining factor in statural overgrowth and accelerated skeletal maturation in SoS."

An explicit causal hypothesis links altered signaling to growth-plate differentiation and the two clinical outcomes. Patient growth plates were not studied; normal human growth plates established NSD1 localization.

PMID:35094088 SUPPORT INDIRECT Human Clinical

"We identified other transcriptionally and epigenetically deregulated genes that are known to regulate skeletal overgrowth and craniofacial anomalies, suggesting that perturbation of these genes contributes to the SS phenotypes."

The patient blood study proposes developmental target-gene dysregulation as an explanation for growth and craniofacial findings; the specific tissue and individual facial components were not experimentally resolved.

Is the peripheral-blood DNA methylation episignature a step in the causal chain that produces the Sotos phenotype, or a robust biomarker of NSD1 loss measured in the wrong tissue?

KNOWLEDGE GAP OPEN sotos_episignature_causal_status

Attached to

pathophysiology#Intergenic DNA Hypomethylation from Loss of DNMT3A Recruitment

The intergenic hypomethylation node is curated as mechanism because the H3K36me2-DNMT3A dependency was established experimentally and the same hypomethylation is observed in patient tissue. But the diagnostic episignature is measured in peripheral blood, and the phenotype is generated in developing brain, heart and skeleton. Whether the methylation change in the relevant developing tissues is a cause of the transcriptional dysregulation or a parallel consequence of the same histone lesion is not settled by any cited study. The same open question is recorded at module level for the chromatinopathies generally; this entry inherits it rather than resolving it, and the episignature is therefore curated under `diagnosis` as a classifier rather than as a downstream pathophysiology node.

Show evidence (1 reference)

PMID:26690673 SUPPORT Human Clinical

"As DNAm can be tissue and cell-type specific, we tested fibroblast-derived DNA from three SS patients with truncating mutations in NSD1 in comparison to four control fibroblast samples."

The authors themselves treat tissue specificity as the live question and address it only with three fibroblast samples - no developing brain, cardiac or skeletal tissue is examined.

Which NSD1-dependent developmental processes generate the individual facial, hair and palatal components of the Sotos gestalt?

KNOWLEDGE GAP OPEN sotos_phenotype_causality_craniofacial

Attached to

phenotypes#Sparse Frontotemporal Hair phenotypes#Downslanting Palpebral Fissures phenotypes#Broad Forehead phenotypes#Prominent Forehead phenotypes#Dolichocephaly phenotypes#Long Face phenotypes#Tall Chin phenotypes#High Arched Palate

Patient transcriptional profiles support a provisional craniofacial-development hypothesis, represented for the overall gestalt. The reviewed sources do not establish which downstream genes or regional developmental processes generate each facial, hair or palatal component.

Which NSD1-loss pathways cause head enlargement, ventricular enlargement and callosal dysmorphism, and do these findings share a regional developmental origin?

KNOWLEDGE GAP OPEN sotos_phenotype_causality_brain_size

Attached to

phenotypes#Macrocephaly phenotypes#Ventriculomegaly phenotypes#Abnormal Corpus Callosum Morphology

The imaging study raises a PI3K/AKT/mTOR growth hypothesis by extrapolating from NSD1 overexpression and other megalencephaly disorders; this does not establish a forward NSD1-loss mechanism in the human brain. Regional growth, ventricular CSF-space anatomy and callosal development remain incompletely attributed. Cortical-migration hypotheses are represented for cortical folding, but do not by themselves establish the cause of these separate findings.

Which neuronal mechanisms mediate seizures, ADHD, anxiety, aggression, self-injury and language delay, and what explains altered sleep timing beyond the proposed respiratory contribution?

KNOWLEDGE GAP OPEN sotos_phenotype_causality_neurobehavior

Attached to

phenotypes#Seizures phenotypes#Attention Deficit Hyperactivity Disorder phenotypes#Anxiety phenotypes#Delayed Speech and Language Development phenotypes#Aggressive Behavior phenotypes#Self-Injurious Behavior phenotypes#Sleep Disturbance

Candidate synaptic and neuronal-migration mechanisms are represented for the broad cognitive phenotype, but the reviewed sources do not establish their mediation of seizures, ADHD, anxiety or language delay specifically. The 77-person imaging cohort found no significant seizure–cortical-malformation association; co-occurrence is therefore insufficient to add that edge. Aggression and self-injury are clinically observed, but the reviewed behavioral studies do not establish which NSD1-dependent neuronal process mediates either finding. Sleep scores correlate with behavior, but this does not establish a directed sleep-to-aggression or sleep-to-ADHD mechanism. The proposed palatal-anatomy contribution is represented for sleep breathing problems; it does not explain early sleep timing or the full sleep phenotype.

How do skeletal patterning, neighboring-gene effects and neuromuscular function contribute to scoliosis, joint laxity and flat feet?

KNOWLEDGE GAP OPEN sotos_phenotype_causality_musculoskeletal

Attached to

phenotypes#Scoliosis phenotypes#Joint Hyperlaxity phenotypes#Pes Planus

Scoliosis severity has a deletion-subtype association and joint laxity can coexist with flat feet, but the reviewed Sotos sources do not establish a tissue-specific causal chain among these observations. Neighboring-gene effects, skeletal patterning and neuromuscular contributions remain unresolved; a generic growth or hypotonia edge would exceed the evidence.

Which cardiac developmental defects mediate septal abnormalities and persistent ductal patency in NSD1-related Sotos syndrome?

KNOWLEDGE GAP OPEN sotos_phenotype_causality_cardiac_anatomy

Attached to

phenotypes#Atrial Septal Defect phenotypes#Ventricular Septal Defect phenotypes#Patent Ductus Arteriosus

Failure to activate cardiac developmental programs is represented as a provisional explanation for congenital heart defects overall. Stem-cell experiments do not resolve septal patterning or ductal closure, and the clinical series does not establish the specific intermediary causing each anatomical lesion.

What explains neonatal jaundice, middle-ear susceptibility, gastrointestinal dysfunction and vesicoureteral reflux in Sotos syndrome?

KNOWLEDGE GAP OPEN sotos_phenotype_causality_other_clinical

Attached to

phenotypes#Neonatal Jaundice phenotypes#Recurrent Otitis Media phenotypes#Constipation phenotypes#Gastroesophageal Reflux phenotypes#Vesicoureteral Reflux

The reviewed clinical sources document these manifestations and the otitis-to-conductive-hearing-loss consequence, but do not establish the upstream Sotos-specific causal processes. Neonatal bilirubin handling, middle-ear susceptibility, gastrointestinal motility or sphincter function and ureterovesical development remain unassigned; swallowing dysfunction cannot be assumed to cause reflux or constipation.

Which developmental processes cause the individual ocular findings?

KNOWLEDGE GAP OPEN sotos_phenotype_causality_ocular_components

Attached to

phenotypes#Strabismus phenotypes#Hypermetropia phenotypes#Astigmatism

Patient blood transcriptional data identify candidate ocular-development genes and support a provisional link to broad eye abnormalities. Neither that study nor the clinical observations establish the mechanism of ocular alignment or the specific refractive defects; those anatomical and functional attributions remain unresolved.

⚙

Pathophysiology

13

Non-Allelic Homologous Recombination at 5q35 Sos-REP Low-Copy Repeats

The recurrent Sotos deletion is generated by a structural-variant mechanism rather than by a point mutational process. Two complex mosaic low-copy repeat blocks flank NSD1 - proximal Sos-PREP (~390 kb) and distal Sos-DREP (~429 kb), each built from six subunits, most in inverted orientation. Only the C and C' subunits are directly oriented with respect to each other and they are more than 99% identical; recombination between them yields the common deletion and a patient-specific junction fragment absent from controls. This mechanism explains why the deletion recurs at the same breakpoints across unrelated individuals.

Genetic context NSD1 hgnc:14234 variant_origin: DE_NOVO allelic_event: DELETION allelic_event: COPY_NUMBER_LOSS zygosity: HETEROZYGOUS

A heterozygous contiguous deletion of the 5q35 interval containing NSD1, almost always arising de novo.

Downstream

NSD1 Haploinsufficiency The recombination product removes one entire NSD1 allele, so the structural event and the dosage lesion are the same event viewed at two levels.

Show evidence (2 references)

PMID:15640245 SUPPORT Human Clinical

"We found that Sos-PREP and Sos-DREP are composed of six subunits termed A-F. Each of the homologous subunits, with the exception of one, is located in an inverted orientation and the order of subunits is different between the two Sos-REPs. Only the subunit C' in Sos-DREP is oriented directly..."

Establishes the repeat architecture that makes only one recombination substrate available.

PMID:15640245 SUPPORT Human Clinical

"Using pulsed-field gel electrophoresis analysis in eight Sos patients with a common deletion, we detected an approximately 550 kb junction fragment that we predicted according to the non-allelic homologous recombination (NAHR) mechanism using directly oriented Sos-PREP C and Sos-DREP C' subunits..."

Direct patient-derived evidence that the predicted NAHR product is what the deletion actually is.

NSD1 Haploinsufficiency

The initiating lesion in essentially all Sotos syndrome is loss of one functional copy of NSD1, reached either by an intragenic loss-of-function variant or by the 5q35 microdeletion above. NSD1 is a writer in the four-class scheme of the epigenetic machinery, so this node is the disease-specific instance of the module's dosage-sensitive component loss. Haploinsufficiency - rather than a dominant-negative or gain-of-function mechanism - is established both by the mutational spectrum (nonsense, frameshift and whole-gene deletion all producing the same syndrome) and by the near-exclusive association of NSD1 aberrations with the Sotos phenotype across a large diagnostic series.

NSD1 hgnc:14234

Genetic context NSD1 hgnc:14234 variant_origin: GERMLINE allelic_event: PATHOGENIC_VARIANT allelic_event: NONSENSE_VARIANT allelic_event: FRAMESHIFT_VARIANT allelic_event: DELETION zygosity: HETEROZYGOUS functional_impact_category: LOSS_OF_FUNCTION

Heterozygous germline NSD1 loss of function, usually de novo. The allelic events listed span the two curated subtypes; missense variants also occur but only within the functional domains.

Downstream

Genome-Wide H3K36me2 Depletion NSD1 loss reduces deposition of H3K36me2. This dependence is demonstrated in engineered mouse and human cells; the magnitude and tissue distribution of the change in heterozygous patients are not inferred from complete-loss experiments.

Reduced NSD1 Tumor-Suppressor Function Loss of NSD1 may impair repression of growth-promoting targets. Evidence from Sotos lymphoblastoid cells and transformed-cell perturbations supports this as a provisional susceptibility mechanism.

Show evidence (2 references)

PMID:11896389 SUPPORT Human Clinical

"We identified 1 nonsense, 3 frameshift and 20 submicroscopic deletion mutations of NSD1 among 42 individuals with sporadic cases of Sotos syndrome. The results indicate that haploinsufficiency of NSD1 is the major cause of Sotos syndrome."

The original demonstration, and the reason the mechanism is read as dosage loss: three distinct classes of loss-of-function lesion produce one syndrome.

PMID:15942875 SUPPORT Human Clinical

"Sotos syndrome was clinically diagnosed in 99% of NSD1-positive individuals, independent of the molecular analyses, indicating that NSD1 aberrations are essentially specific to this condition."

Establishes the specificity of the gene-disease relationship on which this node rests.

Genome-Wide H3K36me2 Depletion

NSD1 is a SET-domain methyltransferase that primarily dimethylates nucleosomal histone H3 lysine 36, and its catalytic domain carries an autoregulatory loop that normally occludes the substrate until the nucleosome stabilises the active conformation. Reduced NSD1 dosage therefore lowers H3K36me2 across the large intergenic euchromatic domains where this mark predominates. Because H3K36me2 is one arm of the permissive-repressive balance, its depletion is not simply a subtraction: at developmental enhancers the same loss permits excessive H3K27me3 and lowers H3K27ac. Catalysis depends on several NSD1 modules together (PHD1-4, PWWP2 and SET), which is why missense variants restricted to those domains behave like truncating alleles - molecular modelling of SET-domain substitutions shows loss of structural stability or steric clash near the S-adenosylmethionine binding site.

chromatin organization GO:0006325 ↕ DYSREGULATED

NSD1 H3K36 dimethyltransferase activity GO:0140954 ↓ DECREASED

Downstream

Intergenic DNA Hypomethylation from Loss of DNMT3A Recruitment H3K36me2 is the chromatin signal that positions DNMT3A over intergenic DNA, so depleting the mark relocates the enzyme and the methylation it deposits.

Loss of Developmental Enhancer Priming At distal enhancers of lineage transcription-factor genes, NSD1-deposited H3K36me2 holds off H3K27me3 and sustains basal H3K27ac; losing the mark collapses that primed state.

Show evidence (4 references)

PMID:21196496 SUPPORT In Vitro

"The Sotos syndrome gene product, NSD1, is a SET domain histone methyltransferase that primarily dimethylates nucleosomal histone H3 lysine 36 (H3K36)."

Establishes the enzymatic identity and product specificity that this node depletes.

PMID:21196496 SUPPORT In Vitro

"The 1.7 Å structure of the catalytic domain of NSD1 presented here shows that a regulatory loop adopts a conformation that prevents free access of H3K36 to the bound S-adenosyl-L-methionine."

Structural basis for the autoregulated catalysis described in this node.

PMID:40118455 SUPPORT In Vitro

"Disruption of either one of these Nsd1 modules severely abrogated H3K36me2 in mESCs and significantly impaired appropriate induction of developmental genes upon mESC differentiation."

Supports the multi-module catalytic requirement, which is the mechanistic reason domain-restricted missense variants are pathogenic.

+ 1 more reference

Intergenic DNA Hypomethylation from Loss of DNMT3A Recruitment

DNMT3A reads H3K36me2 through its PWWP domain and is thereby concentrated in intergenic euchromatin. When NSD1 dosage falls, DNMT3A redistributes to H3K36me3-marked gene bodies and intergenic CpG methylation is lost. This is the mechanistic bridge between a histone-modifier disorder and a DNA-methylation phenotype, and it is the reason Sotos syndrome and Tatton-Brown-Rahman syndrome (germline DNMT3A) overlap clinically: the two genes act in one pathway, at consecutive steps. Peripheral blood from Sotos patients shows this intergenic hypomethylation directly, and it is the substrate of the diagnostic episignature - 99.3% of the signature's CpG sites lose rather than gain methylation. In patient tissue the hypomethylation is concentrated at the promoters of the transcriptionally deregulated genes themselves. Note that dismech does not treat the blood episignature as a step in the brain's causal chain; see the knowledge-gap discussion on this entry.

epigenetic regulation of gene expression GO:0040029 ↕ DYSREGULATED

DNMT3A de novo CpG methyltransferase activity at intergenic euchromatin GO:0003886 ↓ DECREASED

Downstream

Dysregulated Developmental Transcriptional Program A proposed route links altered promoter DNA methylation to PRC2-mediated silencing of developmental genes. Patient blood profiles support the association, while functional confirmation in affected developing tissues is still required.

Show evidence (4 references)

PMID:31485078 SUPPORT Human Clinical

"Blood samples from patients with Sotos syndrome and NSD1-mutant tumours also exhibit hypomethylation of intergenic DNA."

Shows the predicted DNA-methylation consequence in human Sotos tissue, not only in the mouse system in which the mechanism was worked out.

PMID:31485078 SUPPORT In Vitro

"The PWWP domain of DNMT3A shows dual recognition of H3K36me2 and H3K36me3 in vitro, with a higher binding affinity towards H3K36me2 that is abrogated by TBRS-derived missense mutations."

Identifies the reader module that couples the two marks and explains why DNMT3A-mutant overgrowth phenocopies NSD1-mutant overgrowth.

PMID:26690673 SUPPORT Human Clinical

"We identified 7,085 CpG sites distributed across the genome that we refer to as the NSD1+/−-specific signature; 7,038 CpG sites (99.3%) demonstrated loss of DNAm"

Quantifies the directionality of the human methylation change as overwhelmingly loss, matching the hypomethylation mechanism of this node.

+ 1 more reference

Loss of Developmental Enhancer Priming

Independently of the DNA-methylation arm, NSD1 occupies the distal enhancers of lineage-specifying transcription-factor genes while cells are still pluripotent and holds them in a primed state that can respond rapidly to differentiation cues. Losing NSD1 leaves those enhancers unable to support the rapid induction of their genes, so the defect is one of responsiveness at the moment of lineage commitment rather than of steady-state expression alone. This is a distinct claim from intergenic hypomethylation and is evidenced in a different system, which is why it is a separate node.

epigenetic regulation of gene expression at developmental enhancers GO:0040029 ↕ DYSREGULATED

Downstream

Dysregulated Developmental Transcriptional Program

Show evidence (1 reference)

PMID:40118455 SUPPORT In Vitro

"Time-course transcriptomic profiling following the mESC differentiation revealed that Nsd1 not only facilitates the basal expression but also permits the differentiation-accompanied rapid induction of a suite of meso-endoderm lineage-specifying transcription factor genes such as T and Gata4."

Separates the two things Nsd1 does at these loci - basal expression and inducibility - which is the specific content of this node.

Dysregulated Developmental Transcriptional Program

The convergence point of both chromatin arms, and the node this entry shares with every other chromatinopathy. Transcriptomic profiling of Sotos patients identifies a signature that separates them from controls; most deregulated genes are underexpressed, and they are predominantly bivalent genes enriched for regulators of development and neural synapse function. The methylation signature points the same way: its CpG sites sit near genes for cellular morphogenesis, differentiation, neuronal differentiation and axonogenesis, and cell adhesion. One downstream target has been identified specifically - Nsd1 knockdown downregulates Apc2, a cytoskeletal regulator in neurons, and biallelic APC2 loss independently produces Sotos-like features in humans.

regulation of DNA-templated transcription GO:0006355 ↕ DYSREGULATED nervous system development GO:0007399 ↓ DECREASED

Animal models

Nsd1 heterozygous mouse (CRISPR exon 3) Mouse partially recapitulates Halving Nsd1 dose in the mouse produces behavioural change but, on the published account, only a partial resemblance to the human phenotype. The model therefore supports the transcriptional-program node as dose-sensitive without establishing that the human syndrome follows from it in full.

Downstream

Impaired Cortical Neuronal Migration and Laminar Positioning The APC2 arm of the transcriptional program is the one with a demonstrated cellular readout, established by rescue rather than by correlation.

Impaired Mesendodermal Lineage Differentiation

Distinctive Facial Appearance Deregulation of craniofacial developmental genes is proposed to contribute to the facial gestalt. The individual routes to forehead width, head shape, hair distribution and chin height remain unresolved.

Neonatal Hypotonia Reduced COL6A1 expression is a proposed contributor to hypotonia or weakness; neonatal tissue specificity and the central versus peripheral contribution remain unresolved.

Autism Spectrum Behaviour Dysregulation of neurodevelopmental targets including CTTNBP2 and NEO1 is a proposed contributor to autistic features; behavioral consequences were not experimentally rescued in patients.

Ophthalmological Abnormalities Dysregulation of ocular-development genes including NECTIN3 and GPC4 is a proposed contributor to ocular abnormalities; the study does not resolve individual eye findings.

Hypodontia Underexpression of tooth-development genes GREM2 and TSPEAR is proposed to contribute to tooth agenesis. The patient blood study identifies this phenotype-specific candidate route, but does not test tooth germs or demonstrate mediation of premolar development.

Proposed Disruption of Synaptic Development Reduced expression of bivalent synaptic-development genes may impair assembly of developing neural circuits.

Dysregulated FGF-MAPK-ERK Signaling NSD1-associated transcriptional dysregulation includes FGF/MAPK-related genes, supported by patient fibroblast profiling and NSD1 knockdown experiments; the net pathway response is context-dependent.

Show evidence (3 references)

PMID:35094088 SUPPORT Human Clinical

"Most abnormally expressed genes displayed reduced expression in SS; these downregulated genes consisted mostly of bivalent genes and were enriched for regulators of development and neural synapse function."

Direct human transcriptomic evidence naming both the direction of change and the gene classes affected - the strongest support for this node.

PMID:26690673 SUPPORT Human Clinical

"The results demonstrate enrichment for genes with roles in cellular morphogenesis and differentiation, as well as neuronal differentiation/axonogenesis and cell adhesion/cell signalling"

An independent human data type (methylation rather than expression) converging on the same functional categories.

PMID:25753423 SUPPORT In Vitro

"Endogenous Apc2 expression was downregulated by the knockdown of Nsd1, indicating that APC2 is a downstream effector of NSD1 in neurons."

Identifies a specific transcriptional target of NSD1 in the relevant cell type.

Impaired Cortical Neuronal Migration and Laminar Positioning

Mechanism confidence: Provisional

Nsd1 knockdown in embryonic mouse cortex reduces Apc2 expression and impairs neuronal migration and laminar positioning; forced Apc2 expression rescues the migration defect. This supports an NSD1–APC2 neural pathway in a model. The reported human APC2 siblings lacked NSD1 mutations and had a distinct recessive Sotos-like disorder, so their phenotype does not directly establish this mechanism in NSD1-related Sotos syndrome.

cortical projection neuron CL:0000540

cerebral cortex cell migration GO:0021795 ↓ DECREASED

Downstream

Intellectual Disability The authors propose that altered APC2-dependent neuronal migration contributes to intellectual disability in Sotos syndrome. Rescue experiments establish the migration route in embryonic mice; the full route to human intellectual disability remains provisional.

Dysgyria Disordered neuronal migration and cortical positioning are proposed to contribute to abnormal cortical folding. The imaging study discusses the NSD1–APC2 model as a possible correlate; it does not demonstrate this route in patient cortex or distinguish the mechanism of each malformation subtype.

Polymicrogyria Disordered neuronal migration and cortical positioning are proposed to contribute to abnormal cortical folding. The imaging study discusses the NSD1–APC2 model as a possible correlate; it does not demonstrate this route in patient cortex or distinguish the mechanism of each malformation subtype.

Show evidence (2 references)

PMID:25753423 SUPPORT INDIRECT Human Clinical

"We conducted an etiological study on two siblings with Sotos features without mutations in NSD1 and detected a homozygous frameshift mutation in the APC2 gene by whole-exome sequencing, which resulted in the loss of function of cytoskeletal regulation in neurons."

The two NSD1-negative siblings had biallelic APC2 disease. This provides indirect evidence about the candidate effector, not human confirmation of the NSD1-mediated pathway.

PMID:25753423 SUPPORT Model Organism

"Apc2-deficient (Apc2-/-) mice exhibited impaired learning and memory abilities along with an abnormal head shape."

Provides the organism-level cognitive readout of the cellular defect in an animal model.

Impaired Mesendodermal Lineage Differentiation

Mechanism confidence: Provisional

Nsd1-deficient mouse embryonic stem cells fail to induce mesendodermal developmental programs normally. Human NSD1-deficient iPSCs also show impaired endodermal and mesodermal commitment. These are cellular models, not observations of malformed organs in patients; their relevance to congenital heart and renal anomalies is a developmental hypothesis.

mesodermal cell differentiation GO:0048333 ↓ DECREASED endodermal cell differentiation GO:0035987 ↓ DECREASED

Downstream

Congenital Heart Defects Failure to activate cardiac lineage regulators is proposed to contribute to congenital heart defects. The mouse stem-cell study explicitly relates its differentiation defects to the clinical cardiac phenotype, but does not reproduce an anatomical human heart defect.

Renal Anomalies Impaired induction of renal developmental regulators, including Lhx1, provides a provisional route from NSD1 loss to abnormal kidney development. Evidence comes from differentiating mouse stem cells; human renal tissue and anatomical mediation remain untested.

Show evidence (2 references)

PMID:42157059 SUPPORT In Vitro

"Notably, the loss of functional NSD1 altered the differentiation potential of iPSCs, with aberrant endodermal and mesodermal lineage commitment."

Human cell-based evidence for the lineage-commitment defect claimed by this node.

PMID:40118455 SUPPORT In Vitro

"We found Nsd1 to be indispensable for the faithful differentiation of mESCs into three primary germ layers, particularly, meso-endodermal cell lineages related to the development of the heart and the skeletal system."

Names the affected lineages and the organs they build, which is what makes this node relevant to the cardiac phenotype.

Reduced NSD1 Tumor-Suppressor Function

Mechanism confidence: Provisional

NSD1 loss may reduce transcriptional repression of growth-promoting targets such as MEIS1. NSD1 depletion and restoration alter proliferation in neuroblastoma cells; Sotos lymphoblastoid cells also show reduced NSD1 recruitment and increased MEIS1 expression. These experiments support a proposed tumor-suppressor role, but do not establish the penetrance, second-hit requirements or tumor spectrum of germline NSD1 haploinsufficiency. The reported H3K36/H4K20 changes in this older tumor study were principally trimethylation readouts, distinct from the H3K36 dimethylation mechanism above.

chromatin organization GO:0006325 ↕ DYSREGULATED

Downstream

Neoplasia Loss of a context-dependent tumor-suppressor function is proposed to increase susceptibility to some tumors. Somatic cancer-cell findings do not establish all clinical tumors as NSD1-mediated.

Show evidence (2 references)

PMID:20018718 SUPPORT In Vitro

"We also demonstrate that the epigenetic inactivation of NSD1 in transformed cells leads to the specifically diminished methylation of the histone lysine residues H4-K20 and H3-K36. The described phenotype is also observed in Sotos syndrome patients with NSD1 genetic disruption."

Establishes both the chromatin consequence in tumour cells and the explicit statement that Sotos patients share it - the bridge this node depends on.

PMID:20018718 SUPPORT In Vitro

"Furthermore, we show that the restoration of NSD1 expression induces tumor suppressor-like features, such as reduced colony formation density and inhibition of cellular growth."

Functional demonstration that NSD1 acts as a growth suppressor in these lineages.

Proposed Disruption of Synaptic Development

Mechanism confidence: Provisional

Silencing of developmental genes that govern synaptic assembly is proposed to impair neural circuit development. This hypothesis arises from enrichment of downregulated synaptic genes in patient blood and remains untested in Sotos neural tissue.

Downstream

Intellectual Disability Impaired formation of developing neural circuits is proposed to contribute to the cognitive developmental phenotype. Human tissue and behavioral mediation remain unresolved.

Global Developmental Delay Impaired formation of developing neural circuits is proposed to contribute to the cognitive developmental phenotype. Human tissue and behavioral mediation remain unresolved.

Show evidence (1 reference)

PMID:35094088 SUPPORT INDIRECT Human Clinical

"This suggests that cognitive impairment in SS could be caused by the silencing of bivalent genes that orchestrate synaptic assembly, since disrupted synaptic assembly is a feature of many neurodevelopmental disorders (71)."

The patient-transcriptome analysis proposes impaired synaptic assembly as a cognitive mechanism; synapses were not directly examined in the sampled blood.

Dysregulated FGF-MAPK-ERK Signaling

Mechanism confidence: Provisional

Patient-derived fibroblasts show altered FGF-MAPK/ERK-related expression and phosphorylation. Reduced kinase activation became significant after excluding one outlier; RASIP1 overexpression in HEK293 cells instead increased a reporter response. The net effect is therefore not represented as a universal RASIP1-driven decrease across tissues.

Downstream

Altered Growth-Plate Chondrocyte Maturation The authors propose that altered MAPK/ERK signaling changes hypertrophic chondrocyte differentiation. This extrapolation from fibroblasts and established growth-plate biology remains provisional.

Show evidence (1 reference)

PMID:23155469 SUPPORT INDIRECT In Vitro

"In order to elucidate biological pathways explaining how NSD1 haploinsufficiency results in phenotypic features such as overgrowth in SoS a comprehensive study of dermal fibroblasts from SoS patients was performed. We obtained evidence that SoS syndrome is associated with a deregulation of the..."

The study used fibroblasts from nine NSD1-confirmed patients and nine matched controls, with pathway, knockdown and phosphorylation experiments. The net signaling effect is tissue-dependent.

Altered Growth-Plate Chondrocyte Maturation

Mechanism confidence: Provisional

Altered FGF-MAPK/ERK signaling is proposed to change hypertrophic chondrocyte differentiation in the epiphyseal growth plate. NSD1 expression was demonstrated in normal human hypertrophic chondrocytes, but altered maturation was not directly measured in Sotos growth plates.

Downstream

Tall Stature Altered growth-plate maturation is proposed to contribute to statural overgrowth and accelerated skeletal maturation; the quantitative effect in patients is unresolved.

Childhood Overgrowth Altered growth-plate maturation is proposed to contribute to statural overgrowth and accelerated skeletal maturation; the quantitative effect in patients is unresolved.

Advanced Bone Age Altered growth-plate maturation is proposed to contribute to statural overgrowth and accelerated skeletal maturation; the quantitative effect in patients is unresolved.

Show evidence (1 reference)

PMID:23155469 SUPPORT INDIRECT In Vitro

"In analogy, we propose that deregulation of the MAPK/ERK pathway in SoS results in altered hypertrophic differentiation of NSD1 expressing chondrocytes and may be a determining factor in statural overgrowth and accelerated skeletal maturation in SoS."

An explicit causal hypothesis links altered signaling to growth-plate differentiation and the two clinical outcomes. Patient growth plates were not studied; normal human growth plates established NSD1 localization.

Impaired Sucking and Swallowing

Mechanism confidence: Established

Difficulty with sucking and swallowing compromises oral feeding in affected infants. Clinical reports support the feeding consequence but do not establish a specific NSD1-dependent neural or muscular route.

Downstream

Feeding Difficulties Impaired sucking and swallowing limit effective oral intake and can necessitate assisted feeding.

Show evidence (1 reference)

PMID:17825104 SUPPORT Human Clinical

"Sucking and swallowing difficulties need adjustments of baby food. Alternate methods of feeding may need to be considered such as the use of a nasogastric tube."

The review documents functional oral feeding impairment requiring altered feeding; its molecular cause is not localized.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

52

Cardiovascular 4

Congenital Heart Defects Abnormal heart morphology HP:0001627

Show evidence (3 references)

PMID:38535015 SUPPORT Human Clinical

"The prevalence of heart defects (HDs) in individuals with Sotos syndrome is estimated to be around 15-40%. Septal defects and patent ductus arteriosus are the most commonly diagnosed malformations, but complex defects have also been reported."

Gives the literature frequency range and the commonest anatomic types.

PMID:38535015 SUPPORT Human Clinical

"A total of 27/45 (60.0%) of the patients had heart defects, isolated or combined with other defects, including septal defects (12 patients), aortic anomalies (9 patients), mitral valve and/or tricuspid valve dysplasia/insufficiency (1 patient), patent ductus arteriosus (3 patients), left..."

The single-centre figure and the anatomic breakdown quoted in the description.

PMID:38535015 SUPPORT Human Clinical

"The prevalences of HD in the two subgroups (deletion versus intragenic mutation) were similar (66.7% (4/6) in the deletion group versus 58.91% (23/39) in the intragenic variant group)."

Supports the explicit negative claim that cardiac risk does not separate the two molecular subtypes.

Atrial Septal Defect HP:0001631

Show evidence (1 reference)

PMID:38535015 SUPPORT Human Clinical

"The predominant cardiac anomalies observed in the current study are septal defects, encompassing both atrial ostium secundum (ASDos) and ventricular (VSD) variations."

Both atrial and ventricular septal defects were observed in the molecularly confirmed 45-person cardiology cohort; no population frequency is assigned.

Ventricular Septal Defect HP:0001629

Show evidence (1 reference)

PMID:38535015 SUPPORT Human Clinical

"The predominant cardiac anomalies observed in the current study are septal defects, encompassing both atrial ostium secundum (ASDos) and ventricular (VSD) variations."

Both atrial and ventricular septal defects were observed in the molecularly confirmed 45-person cardiology cohort; no population frequency is assigned.

Patent Ductus Arteriosus HP:0001643

Show evidence (1 reference)

PMID:38535015 SUPPORT Human Clinical

"Three patients exhibited a patent ductus arteriosus."

The denominator is the 45-person NSD1-confirmed cohort; this observation is not a population frequency estimate.

Digestive 4

Feeding Difficulties FREQUENT HP:0011968

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"Neonates may have jaundice (~65%), hypotonia (~75%), and poor feeding (~70%). These complications tend to resolve spontaneously, but in a small minority intervention is required."

Provides separate neonatal estimates for each named finding, replacing management recommendations and selected otolaryngologic reports as frequency evidence.

Neonatal Jaundice FREQUENT HP:0000952

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"Neonates may have jaundice (~65%), hypotonia (~75%), and poor feeding (~70%). These complications tend to resolve spontaneously, but in a small minority intervention is required."

Provides separate neonatal estimates for each named finding, replacing management recommendations and selected otolaryngologic reports as frequency evidence.

Constipation HP:0002019

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"Some associated features, such as constipation and hearing problems caused by chronic otitis media, are common."

The clinical synthesis establishes constipation and separately identifies an otitis-related hearing mechanism.

Gastroesophageal Reflux HP:0002020

Show evidence (1 reference)

PMID:17825104 SUPPORT Human Clinical

"Another common problem is gastro- esophageal reflux which causes heartburn, vomiting, esophageal irritation and respiratory problems."

The review explicitly describes gastroesophageal reflux and its consequences. The PDF line-break hyphen is preserved verbatim.

Ear 3

Hearing Impairment HP:0000365

Show evidence (1 reference)

PMID:31479583 SUPPORT Human Clinical

"Reassuringly, adults with Sotos syndrome are generally healthy with few new medical issues; however, lymphedema, poor dentition, hearing loss, contractures and tremor have developed in a small number of individuals."

Documents hearing loss in molecularly confirmed adults. The otolaryngologic review’s 14% covers all otologic conditions and is not a hearing-loss frequency.

Recurrent Otitis Media HP:0000403

Sequelae: Conductive Hearing Impairment Hearing Impairment

Show evidence (1 reference)

PMID:17825104 SUPPORT Human Clinical

"Recurrent upper respiratory infections and otitis media are frequent, leading to some degree of conductive hearing loss."

The clinical review explicitly connects recurrent otitis media to conductive hearing loss.

Conductive Hearing Impairment HP:0000405

Show evidence (1 reference)

PMID:17825104 SUPPORT Human Clinical

"Recurrent upper respiratory infections and otitis media are frequent, leading to some degree of conductive hearing loss."

The clinical review explicitly connects recurrent otitis media to conductive hearing loss.

Eye 4

Ophthalmological Abnormalities Abnormality of the eye HP:0000478

Show evidence (2 references)

url:https://repository.uantwerpen.be/docstore/d%3Airua%3A25028 SUPPORT Human Clinical

"Ophthalmological findings were present in 37.6%."

This author manuscript and PMID:39147584 are the same AJNR study (DOI:10.3174/ajnr.A8364), not independent cohorts. The full paper reports ocular findings in the genetically confirmed 77-person MRI-selected cohort (29/77, rounded to 37.7% in its table). It does not support assigning the 71% mixed NSD1/NFIX cohort estimate to Sotos syndrome alone.

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"The following features are seen in ≥2% and <15% of individuals with Sotos syndrome ...: • Ocular. Astigmatism, cataracts, myopia, strabismus, nystagmus, hypermetropia"

The full introductory proposition and ocular list identify these findings in Sotos syndrome. The reported interval crosses repository frequency-band boundaries, so no individual band is assigned.

Strabismus HP:0000486

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"The following features are seen in ≥2% and <15% of individuals with Sotos syndrome ...: • Ocular. Astigmatism, cataracts, myopia, strabismus, nystagmus, hypermetropia"

The full introductory proposition and ocular list identify these findings in Sotos syndrome. The reported interval crosses repository frequency-band boundaries, so no individual band is assigned.

Hypermetropia HP:0000540

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"The following features are seen in ≥2% and <15% of individuals with Sotos syndrome ...: • Ocular. Astigmatism, cataracts, myopia, strabismus, nystagmus, hypermetropia"

The full introductory proposition and ocular list identify these findings in Sotos syndrome. The reported interval crosses repository frequency-band boundaries, so no individual band is assigned.

Astigmatism HP:0000483

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"The following features are seen in ≥2% and <15% of individuals with Sotos syndrome ...: • Ocular. Astigmatism, cataracts, myopia, strabismus, nystagmus, hypermetropia"

The full introductory proposition and ocular list identify these findings in Sotos syndrome. The reported interval crosses repository frequency-band boundaries, so no individual band is assigned.

Genitourinary 2

Renal Anomalies Abnormal renal morphology HP:0012210

Show evidence (1 reference)

PMID:39494594 SUPPORT Human Clinical

"Renal anomalies such as horseshoe kidney, cystic lesion, renomegaly, small kidney size, or ureteropelvic junction obstruction were observed in six (11%) patients."

Documents renal structural findings in the molecularly confirmed Korean cohort; the aggregate also includes junction obstruction and does not quantify each lesion.

Vesicoureteral Reflux HP:0000076

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"Some individuals may have quiescent vesicoureteral reflux and may present in adulthood with renal impairment."

Describes occurrence and possible later renal complications; it does not quantify reflux specifically.

Head and Neck 11

Distinctive Facial Appearance VERY_FREQUENT Abnormal facial shape HP:0001999

Show evidence (3 references)

PMID:20301652 SUPPORT Human Clinical

"Sotos syndrome is characterized by a distinctive facial appearance (broad, prominent forehead with a dolichocephalic head shape, sparse frontotemporal hair, downslanting palpebral fissures, malar flushing, long and narrow face, tall chin); learning disability (early developmental delay,..."

The complete clinical-characteristics sentence identifies the facial finding in Sotos syndrome without transferring the overall gestalt frequency to an individual component.

PMID:15942875 SUPPORT Human Clinical

"Facial dysmorphism, learning disability, and childhood overgrowth were present in 90% of the individuals."

Supports the VERY_FREQUENT band with a cohort figure for the cardinal triad taken together.

PMID:31479583 SUPPORT Human Clinical

"There is a distinctive facial appearance in adults with a tall, square, prominent chin."

Establishes that the gestalt persists into adulthood in a recognisable, altered form.

Sparse Frontotemporal Hair Sparse scalp hair HP:0002209

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"The head is dolichocephalic and the forehead broad and prominent. Often the hair in the frontotemporal region is sparse. The palpebral fissures are usually downslanting."

Describes the individual craniofacial observations; the frequency of the complete gestalt cannot be assigned to each finding.

Downslanting Palpebral Fissures Downslanted palpebral fissures HP:0000494

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"The head is dolichocephalic and the forehead broad and prominent. Often the hair in the frontotemporal region is sparse. The palpebral fissures are usually downslanting."

Describes the individual craniofacial observations; the frequency of the complete gestalt cannot be assigned to each finding.

Macrocephaly VERY_FREQUENT HP:0000256

Show evidence (3 references)

PMID:17825104 SUPPORT Human Clinical

"Sotos syndrome is an overgrowth condition characterized by cardinal features including excessive growth during childhood, macrocephaly, distinctive facial gestalt and various degrees of learning difficulty, and associated with variable minor features."

Names macrocephaly among the cardinal features in a clinical review.

PMID:39494594 SUPPORT Human Clinical

"Females with SS displayed higher height before 17.0, greater weight before 10.5, and larger head circumference before 12.0 compared to controls."

Anthropometric confirmation of increased head circumference against matched controls.

PMID:39494594 SUPPORT Human Clinical

"At their last visit (8.1 ± 5.6 years), tall stature and macrocephaly were observed in 23 (40%), and 51 (89%) patients, respectively."

Macrocephaly in 51/57 patients (89%) supports VERY_FREQUENT (80–99%) in this molecularly confirmed Korean cohort at last visit (8.1 ± 5.6 years). The 57 patients, not the 339 repeated anthropometric measurements, form the denominator. Tertiary-center ascertainment and age limit generalization.

High Arched Palate High palate HP:0000218

Sequelae: Sleep Disturbance

Show evidence (1 reference)

PMID:33640723 SUPPORT Human Clinical

"Our review found multiple otolaryngologic conditions present in patients with SOTOS1, including hearing loss, otitis, hyperthyroidism, hypothyroidism, head & neck tumors, congenital malformations (high arched palate, cleft lip and palate, macroglossia), feeding difficulties, respiratory..."

Explicitly includes high palate; the combined head-and-neck-malformation percentage does not quantify high palate.

Broad Forehead HP:0000337

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"The head is dolichocephalic and the forehead broad and prominent. Often the hair in the frontotemporal region is sparse. The palpebral fissures are usually downslanting."

Describes the individual craniofacial observations; the frequency of the complete gestalt cannot be assigned to each finding.

Dolichocephaly HP:0000268

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"The head is dolichocephalic and the forehead broad and prominent. Often the hair in the frontotemporal region is sparse. The palpebral fissures are usually downslanting."

Describes the individual craniofacial observations; the frequency of the complete gestalt cannot be assigned to each finding.

Long Face HP:0000276

Show evidence (1 reference)

PMID:20301652 SUPPORT Human Clinical

"Sotos syndrome is characterized by a distinctive facial appearance (broad, prominent forehead with a dolichocephalic head shape, sparse frontotemporal hair, downslanting palpebral fissures, malar flushing, long and narrow face, tall chin); learning disability (early developmental delay,..."

The complete clinical-characteristics sentence identifies the facial finding in Sotos syndrome without transferring the overall gestalt frequency to an individual component.

Tall Chin HP:0400000

Show evidence (2 references)

PMID:20301652 SUPPORT Human Clinical

"Sotos syndrome is characterized by a distinctive facial appearance (broad, prominent forehead with a dolichocephalic head shape, sparse frontotemporal hair, downslanting palpebral fissures, malar flushing, long and narrow face, tall chin); learning disability (early developmental delay,..."

The complete clinical-characteristics sentence identifies the facial finding in Sotos syndrome without transferring the overall gestalt frequency to an individual component.

PMID:31479583 SUPPORT Human Clinical

"There is a distinctive facial appearance in adults with a tall, square, prominent chin."

Establishes that the gestalt persists into adulthood in a recognisable, altered form.

Prominent Forehead HP:0011220

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"The head is dolichocephalic and the forehead broad and prominent. Often the hair in the frontotemporal region is sparse. The palpebral fissures are usually downslanting."

Describes the individual craniofacial observations; the frequency of the complete gestalt cannot be assigned to each finding.

Hypodontia HP:0000668

Show evidence (2 references)

PMID:19876911 SUPPORT Human Clinical

"We investigated the dental manifestations of this disorder and found one or several premolar teeth were absent in 9 out of 13 (69%) affected children and adolescents. A heterozygous mutation in the NSD1 gene was identified in 12 patients, including all patients with hypodontia."

This primary dental investigation establishes premolar agenesis in NSD1-positive patients. The observed 9/13 proportion is retained with its selected clinical sample and molecularly characterized subset, rather than generalized to all Sotos syndrome.

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"The following features are seen in ≥2% and <15% of individuals with Sotos syndrome ...: • Nail and tooth anomalies. Hypoplastic nails, hypodontia"

The complete introductory proposition and tooth-anomaly list support clinical occurrence. The range is preserved in the description without forcing a frequency category or substituting poor dentition for hypodontia.

Limbs 1

Pes Planus HP:0001763

Show evidence (1 reference)

PMID:20301652 SUPPORT Human Clinical

"Major features of Sotos syndrome include behavioral findings (most notably autism spectrum disorder), advanced bone age, cardiac anomalies, cranial MRI/CT abnormalities, joint hyperlaxity with or without pes planus, maternal preeclampsia, neonatal complications, renal anomalies, scoliosis, and seizures."

Explicitly includes pes planus in the clinical feature spectrum; this co-occurrence does not by itself establish a causal hypermobility-to-flatfoot edge.

Musculoskeletal 4

Advanced Bone Age Accelerated skeletal maturation HP:0005616

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"Bone age often reflects the accelerated growth velocity and is advanced in 75%-80% of prepubertal children."

This estimate is explicitly restricted to prepubertal children.

PMID:39494594 SUPPORT Human Clinical

"Among 33 children (20 males and 13 females) for whom BA was evaluated at their last visit, BA was advanced than CA in eight (40%) males (13.0 ± 2.6 years vs. 10.5 ± 2.5 years, p = 0.011) and one (8%) female (9.0 years vs. 5.6 years)."

The source supplies the evaluated denominators and timing. Its two-year threshold differs from some historical definitions.

Scoliosis FREQUENT HP:0002650

Show evidence (2 references)

PMID:33332788 SUPPORT Human Clinical

"Scoliosis was observed in 26 patients (41%), with a significantly higher ratio of microdeletions than mutations. The 10 patients with progressive scoliosis all had NSD1 microdeletions."

Carries both the frequency band and the genotype association, including the complete concordance of progressive cases with the deletion class.

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"Present in about 30% of affected individuals, scoliosis is rarely severe enough to require bracing or surgery."

The clinical synthesis supports a FREQUENT band independently of the selected scoliosis series. Severity varies and can be greater in deletion cohorts.

Joint Hyperlaxity Joint hypermobility HP:0001382

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"Joint laxity is reported in at least 20% of individuals with Sotos syndrome."

The lower-bound estimate supports joint hypermobility but does not define a bounded frequency category.

Neonatal Hypotonia FREQUENT HP:0001319

Sequelae: Motor Delay

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"Neonates may have jaundice (~65%), hypotonia (~75%), and poor feeding (~70%). These complications tend to resolve spontaneously, but in a small minority intervention is required."

Provides separate neonatal estimates for each named finding, replacing management recommendations and selected otolaryngologic reports as frequency evidence.

Nervous System 16

Intellectual Disability HP:0001249

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"Most individuals with Sotos syndrome have some degree of intellectual impairment. The spectrum is broad and ranges from a mild learning disability (affected individuals would be expected to live independently and have their own families) to a severe learning disability (affected individuals..."

Supports the broad clinical range, without using a mixed Sotos–Malan developmental-delay/intellectual-disability percentage to quantify intellectual disability alone.

PMID:15942875 SUPPORT Human Clinical

"Patients with microdeletions had less-prominent overgrowth (P = .0003) and more-severe learning disability (P = 3 x 10(-9)) than patients with mutations."

The primary genotype-phenotype contrast justifying curation of the two molecular classes as subtypes.

Autism Spectrum Behaviour Autistic behavior HP:0000729

Show evidence (4 references)

PMID:38150933 SUPPORT Human Clinical

"72.7% of SoS children presented mild to moderate levels of ASD symptoms as measured by the ADOS-2."

In the convenience sample of 33 Sotos children, 72.7% had mild-to-moderate ADOS-2 symptoms. This measures symptom severity in the sample, not population prevalence or the proportion with a clinical ASD diagnosis.

PMID:38150933 SUPPORT Human Clinical

"No statistically significant differences emerged between the SoS and ASD groups within the SRS total score domain (p = 0.95)."

The SRS total-score comparison detected no difference between the matched Sotos and idiopathic-ASD groups (p = 0.95). A nonsignificant difference neither proves equivalent symptom burden nor estimates ASD prevalence.

PMID:38150933 SUPPORT Human Clinical

"Oneway ANOVA analysis showed that SoS individuals presenting lower IQ demonstrated higher ASD symptom's level (p = 0.01)."

Within the Sotos sample, lower IQ was associated with higher ASD symptom levels (ANOVA p = 0.01). This is a cognitive-severity association, not evidence that lower IQ causes autistic behavior.

+ 1 more reference

Seizures HP:0001250

Show evidence (1 reference)

PMID:17825104 SUPPORT Human Clinical

"Other inconstant clinical abnormalities include scoliosis, cardiac and genitourinary anomalies, seizures and brisk deep tendon reflexes."

Records seizures as an established but inconstant feature - which is why no frequency band is set here.

Ventriculomegaly HP:0002119

Show evidence (1 reference)

PMID:39147584 SUPPORT Human Clinical

"Macrocephaly, ventriculomegaly, and corpus callosal dysmorphism are typical neuroimaging features that have been described in the medical literature."

Supports actual structural findings, replacing a treatment recommendation as the evidence for their occurrence.

Attention Deficit Hyperactivity Disorder OCCASIONAL HP:0007018

Show evidence (1 reference)

PMID:39494594 SUPPORT Human Clinical

"Two (4%) patients were diagnosed with autism spectrum disorder, and eight (14%) were diagnosed with attention deficit hyperactivity disorder."

Eight ADHD diagnoses among 57 molecularly confirmed NSD1-related patients (14%) support OCCASIONAL (5–29%) in this retrospective Korean series. Diagnoses were recorded during follow-up, with last-visit mean age 8.1 years; this is not standardized lifetime ascertainment or a mixed NSD1–NFIX denominator.

Anxiety HP:0000739

Show evidence (1 reference)

PMID:38673476 SUPPORT Human Clinical

"Children express autistic behavior, ADHD, anxiety based on phobias, and early bedtime-wake times."

Supports anxiety as a reported feature; the former 35.5% combined impulsivity/anxiety endpoint in a mixed NSD1–NFIX cohort does not quantify anxiety alone.

Global Developmental Delay HP:0001263

Show evidence (1 reference)

PMID:35094088 SUPPORT Human Clinical

"Clinically, SS is primarily characterized by generalized overgrowth including tall stature and macrocephaly, global developmental delay often culminating in intellectual disability, distinct facial features, as well supranuclear hypotonia (7)."

Explicitly distinguishes early global developmental delay from later intellectual disability in NSD1-related Sotos syndrome.

Motor Delay HP:0001270

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"Delay of early developmental milestones is very common, and motor skills may appear particularly delayed because of a child's large size, hypotonia, and poor coordination."

The clinical synthesis identifies contributors to delayed motor milestones; it does not attribute all cognitive or language delay to hypotonia.

Delayed Speech and Language Development HP:0000750

Show evidence (1 reference)

PMID:17825104 SUPPORT Human Clinical

"Delay in expressive language and motor development during the infancy is particularly common."

Documents delayed expressive language and motor development in the clinical review.

Dysgyria HP:0032398

Sequelae: Hippocampal Malrotation

Show evidence (1 reference)

PMID:39147584 SUPPORT Human Clinical

"In addition to previously described features, malformations of cortical development were identified in most patients (95.0%), typically dysgyria (92.2%) and polymicrogyria (22.1%), varying in location and distribution."

These proportions describe 77 genetically diagnosed individuals selected for retrospective MRI review; they are not assigned as population frequencies.

Polymicrogyria HP:0002126

Show evidence (1 reference)

PMID:39147584 SUPPORT Human Clinical

"In addition to previously described features, malformations of cortical development were identified in most patients (95.0%), typically dysgyria (92.2%) and polymicrogyria (22.1%), varying in location and distribution."

These proportions describe 77 genetically diagnosed individuals selected for retrospective MRI review; they are not assigned as population frequencies.

Hippocampal Malrotation HP:0034396

Show evidence (1 reference)

PMID:39147584 SUPPORT Human Clinical

"Incomplete rotation of the hippocampus was observed in 50.6% of patients and was associated with other imaging findings, in particular with dysgyria (100% versus 84.2%, P = .012)."

Incomplete hippocampal rotation was identified in 39/77 MRI-selected, molecularly confirmed individuals. The selected denominator and possible normal variation preclude assigning a population frequency.

Abnormal Corpus Callosum Morphology HP:0001273

Show evidence (1 reference)

url:https://repository.uantwerpen.be/docstore/d%3Airua%3A25028 SUPPORT Human Clinical

"Structural anomalies were noted in most of the patients including ... corpus callosum abnormality (68.8%), ... and hypertelorism (58.4%)."

This author manuscript and PMID:39147584 are the same AJNR study (DOI:10.3174/ajnr.A8364), not independent cohorts. The full-text result gives the callosal proportion in the genetically confirmed MRI-selected cohort. Explicit ellipses omit other findings and intervening PDF gutter numbers; this is not a population frequency.

Sleep Disturbance HP:0002360

Show evidence (5 references)

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"Behavioral findings. A wide range of behavioral findings are common at all ages. Autism spectrum disorder, phobias, sleep disturbances, hyperactivity, and aggression have been described"

The clinical-description section establishes occurrence of sleep disturbance; the broad behavioral-feature frequency is not a sleep-specific estimate.

PMID:33893755 SUPPORT Human Clinical

"Subjects with SS showed more sleep disturbance than typically developing individuals (TD), although their sleep onset was less likely to be delayed and their sleep duration was longer."

The cross-sectional questionnaire study included definite, probable and possible Sotos diagnoses and used historical comparators. It supports disturbed sleep without equating early waking with reduced sleep duration.

PMID:33893755 SUPPORT Human Clinical

"Individuals with SS exhibited early bed and rise times, frequently used transitional objects, displayed repetitive motion at sleep onset, and did not show a decrease in sleep duration with age."

This identifies the sleep-timing pattern. It does not establish terminal insomnia or a diagnosed circadian-rhythm disorder; the broader sleep-disturbance binding retains that distinction.

+ 2 more references

Aggressive Behavior HP:0000718

Show evidence (3 references)

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"Behavioral findings. A wide range of behavioral findings are common at all ages. Autism spectrum disorder, phobias, sleep disturbances, hyperactivity, and aggression have been described"

GeneReviews lists aggression in the clinical description, independently of its separate management recommendation.

PMID:26418839 SUPPORT Human Clinical

"Individuals with Sotos syndrome showed an increased risk of self-injurious behavior, physical aggression, and destruction of property relative to the Down syndrome group but not a greater risk of stereotyped behavior."

Sheth and colleagues report physical aggression from parent/carer questionnaires. The clinical observation is valid human evidence; the comparison does not establish a population frequency or a molecular mechanism.

url:https://pure-oai.bham.ac.uk/ws/files/27013518/Sheth_et_cl_in_press_the_behavioral_characteristics_of_sotos_syndrome_AJMG.pdf SUPPORT Human Clinical

"Although NSD1 gene status was not av ailable, all participants had a confirmed diagnosis of Sotos syndrome by a clinical geneticist or pediatrician ."

The author manuscript of PMID:26418839 explicitly states clinical confirmation with unavailable NSD1 status. This is the same study, not an independent cohort; its diagnostic scope is preserved.

Self-Injurious Behavior HP:0100716

Show evidence (2 references)

PMID:26418839 SUPPORT Human Clinical

"Individuals with Sotos syndrome showed an increased risk of self-injurious behavior, physical aggression, and destruction of property relative to the Down syndrome group but not a greater risk of stereotyped behavior."

Sheth and colleagues report self-injury from parent/carer questionnaires. The clinical observation is valid human evidence; the comparison does not establish a population frequency or a molecular mechanism.

url:https://pure-oai.bham.ac.uk/ws/files/27013518/Sheth_et_cl_in_press_the_behavioral_characteristics_of_sotos_syndrome_AJMG.pdf SUPPORT Human Clinical

"Although NSD1 gene status was not av ailable, all participants had a confirmed diagnosis of Sotos syndrome by a clinical geneticist or pediatrician ."

The author manuscript of PMID:26418839 explicitly states clinical confirmation with unavailable NSD1 status. This is the same study, not an independent cohort; its diagnostic scope is preserved.

Growth 2

Childhood Overgrowth VERY_FREQUENT HP:0001548

Show evidence (3 references)

PMID:20301652 SUPPORT Human Clinical

"Sotos syndrome is characterized by a distinctive facial appearance (broad, prominent forehead with a dolichocephalic head shape, sparse frontotemporal hair, downslanting palpebral fissures, malar flushing, long and narrow face, tall chin); learning disability (early developmental delay,..."

Defines the combined height and/or head-circumference overgrowth endpoint; this is not a frequency estimate for tall stature alone.

PMID:15942875 SUPPORT Human Clinical

"However, both the height and head circumference of 10% of the individuals were within the normal range, indicating that overgrowth is not obligatory for the diagnosis of Sotos syndrome."

Bounds the claim: a cardinal feature that is nonetheless absent in a tenth of molecularly confirmed cases.

PMID:31479583 SUPPORT Human Clinical

"In our cohort, median height in adult women is +1.9 SD and men +0.5 SD."

Median adult heights in the 44-person NSD1 cohort do not establish that all adults have normal height.

Tall Stature HP:0000098

Show evidence (2 references)

PMID:39494594 SUPPORT Human Clinical

"At their last visit (8.1 ± 5.6 years), tall stature and macrocephaly were observed in 23 (40%), and 51 (89%) patients, respectively."

These separate endpoints were recorded in 57 molecularly confirmed Korean patients at their last visit; the age distribution and tertiary-center ascertainment limit generalization.

PMID:31479583 SUPPORT Human Clinical

"In our cohort, median height in adult women is +1.9 SD and men +0.5 SD."

Median adult heights in the 44-person NSD1 cohort do not establish that all adults have normal height.

Neoplasm 1

Neoplasia VERY_RARE Neoplasm HP:0002664

Show evidence (2 references)

PMID:17825104 SUPPORT Human Clinical

"Cohen reviewed the reported neoplasias critically and suggested a tumor frequency in patients with Sotos syndrome of about 3.9% (more than in the general population) [29]."

A historical clinical synthesis supports a frequency below 5%, with limitations of reported-case ascertainment.

url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf SUPPORT Human Clinical

"Tumors occur in approximately 3% of persons with Sotos syndrome."

The current clinical synthesis supports the low overall tumor frequency; it does not establish specific risks for every reported tumor.

🧬

Genetic Associations

1

NSD1 (Haploinsufficiency (loss-of-function variants and whole-gene deletion))

Gene: NSD1 hgnc:14234 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (5 references)

PMID:11896389 SUPPORT Human Clinical

"We isolated NSD1 from the 5q35 breakpoint in an individual with Sotos syndrome harboring a chromosomal translocation."

Records how the gene was mapped to the disease, via a translocation breakpoint.

PMID:15942875 SUPPORT Human Clinical

"Furthermore, our data suggest that 93% of patients who have been clinically diagnosed with Sotos syndrome have identifiable NSD1 abnormalities, of which 83% are intragenic mutations and 10% are 5q35 microdeletions."

Supports the detection rate quoted in `frequency` and the split between lesion classes.

PMID:23190751 SUPPORT Human Clinical

"NSD1 abnormalities were identified in 15 (83%) patients. Among them, eight patients (53%) had 5q35 microdeletions and the other seven patients (47%) had seven different NSD1 intragenic mutations including four novel mutations."

An East Asian cohort showing the inverted lesion-class ratio relative to European series - independent replication of the ancestry effect.

+ 2 more references

💊

Medical Actions

3

Genetic Counseling

Action: Genetic Counseling NCIT:C15240

Platform: Behavioral / lifestyle

Counseling covers autosomal dominant inheritance, the approximately 95% de novo rate, and the 50% transmission risk for children of an affected individual. Expression varies between generations, so a prenatal molecular diagnosis cannot predict severity. Prenatal and preimplantation testing are possible once the familial alteration is identified. For clinically unaffected parents, recurrence assessment includes the possibility of gonadal mosaicism even when parental blood testing is negative.

Show evidence (2 references)

PMID:20301652 SUPPORT Human Clinical

"Each child of an individual with Sotos syndrome has a 50% chance of inheriting the causative genetic alteration. Once the Sotos syndrome-related genetic alteration has been identified in an affected family member, prenatal and preimplantation genetic testing are possible."

Supports both the recurrence-risk figure and the reproductive-testing options counselled about.

PMID:36708490 SUPPORT Human Clinical

"Gentling results indicated that the fetus and the patient inherited the same maternal chromosome 5. The heterozygous mutation of NSD1 gene c.4138delG is the pathogenic mutation of this Sots syndrome patient, and the mother may be germinal mosaicism."

Recurrence of the same variant in two pregnancies despite negative parental blood testing supports suspected maternal germline mosaicism. This report supersedes the 2007 statement that germline mosaicism had never been reported; it does not estimate a population recurrence risk.

Developmental and Educational Intervention

Action: Speech Language Therapy NCIT:C159273

Platform: Behavioral / lifestyle

Referral to appropriate specialists for learning disability and speech delay is the mainstay of management. There is no disease-modifying therapy; care is supportive, multidisciplinary and organised around the affected domains. The neuropsychological profile argues for targeting language, visuospatial ability and mathematics specifically rather than delivering generic support.

Target Phenotypes: Intellectual disability HP:0001249

Show evidence (3 references)

PMID:20301652 SUPPORT Other

"Treatment of manifestations: Referral to appropriate specialists for management of learning disability / speech delays, behavioral findings, cardiac abnormalities, renal anomalies, scoliosis, and seizures"

The GeneReviews management recommendation from which this treatment entry derives.

PMID:17825104 SUPPORT Other

"An adequate psychological and educational program with speech therapy and motor stimulation plays an important role in the global development of the patients."

States that speech therapy, as part of a structured educational and psychological program, materially affects global developmental outcome — which is the claim this treatment entry makes. Replaces an earlier three-word quote from the same review ("Management is multidisciplinary.") that named no intervention and so could not support the entry on its own.

PMID:38673476 SUPPORT Other

"Comprehensive assistance is needed for Sotos syndrome patients in responding to areas of difficulty."

Supports targeting intervention at identified areas of difficulty rather than generically.

Multisystem Surveillance and Supportive Care

Action: Supportive Care NCIT:C15747

Regular general paediatric review, more frequent for younger children, those with many medical complications and families needing more support, and less frequent for older children and those with fewer complications. Two specific points sharpen this generic recommendation: echocardiography at diagnosis with cardiological follow-up, given the high heart-defect rate; and spinal surveillance weighted towards the deletion subtype, in which progressive scoliosis concentrates. GeneReviews also gives an explicit non-intervention rule - ventricular dilatation on brain MRI without raised intracranial pressure should not be treated. Neuropsychiatric evaluation after 12 months includes screening for sleep, attention, anxiety and autistic symptoms. Ongoing review includes aggression and self-injury, with pediatric psychiatric input for serious aggressive or destructive behavior. These GeneReviews recommendations reflect expert clinical experience rather than a published practice guideline.

Show evidence (6 references)

PMID:20301652 SUPPORT Other

"Surveillance: Regular review by a general pediatrician for younger children, individuals with many medical complications, and families requiring more support than average; less frequent review of older children / teenagers and those individuals without many medical complications."

The GeneReviews surveillance schedule this entry records.

PMID:38535015 SUPPORT Other

"An accurate and detailed echocardiogram should be performed in patients with Sotos syndrome at diagnosis, and a specific cardiological follow-up program is needed."

The cardiac-surveillance recommendation, from the cohort that found a 60% heart-defect rate.

PMID:20301652 SUPPORT Other

"intervention is not recommended if the brain MRI shows ventricular dilatation without increased intracranial pressure"

An explicit do-not-treat rule, curated because avoiding an unnecessary shunt is a management action in its own right.

+ 3 more references

🔬

Diagnosis

2

Molecular Genetic Confirmation

The diagnosis is established by identifying a heterozygous NSD1 pathogenic variant or a deletion encompassing NSD1. Because the two lesion classes need different assays, testing has to cover both sequence variants and copy number - sequencing alone will miss the deletion class, which is the majority class in Japanese and Korean patients.

molecular genetic testing NCIT:C19770

Results: Detection of a heterozygous NSD1 pathogenic variant, or of a 5q35 deletion encompassing NSD1, establishes the diagnosis.

Show evidence (3 references)

PMID:20301652 SUPPORT Human Clinical

"The diagnosis of Sotos syndrome is established in a proband with a heterozygous NSD1 pathogenic variant or a deletion encompassing NSD1 identified by molecular genetic testing."

The GeneReviews diagnostic criterion, naming both lesion classes.

PMID:17825104 SUPPORT Human Clinical

"FISH analysis, MLPA or multiplex quantitative PCR allow the detection of total/partial NSD1 deletions, and direct sequencing allows detection of NSD1 mutations."

Spells out the two assay classes, which is the point the description makes about sequencing alone being insufficient.

PMID:42618064 SUPPORT Human Clinical

"Molecular analyses included whole-exome sequencing, clinical exome sequencing, targeted gene panels, multiplex ligation-dependent probe amplification, and chromosomal microarray analysis."

Shows the contemporary assay combination used to cover both lesion classes.

NSD1 DNA Methylation Episignature Analysis

Genome-wide DNA methylation profiling of peripheral blood detects a NSD1-specific signature of 7,085 CpG sites, almost all hypomethylated. In the defining study the signature classified every sample in independent validation cohorts correctly, distinguished Sotos syndrome from benign NSD1 variants and from the clinically overlapping Weaver syndrome, and reclassified NSD1 missense variants of uncertain significance in agreement with blinded expert clinical review. It remains an adjunct to variant interpretation, not a replacement for the molecular diagnostic criterion above. Long-read nanopore sequencing has since been shown to recover an equivalent signature, and even a single-locus mark at the NSD1 CpG island, which would let genotype and methylation be assessed in one assay.

DNA methylation episignature analysis NCIT:C63328

Results: A positive Sotos score supports pathogenicity of an NSD1 sequence variant and argues against clinically overlapping overgrowth syndromes.

Show evidence (5 references)

PMID:26690673 SUPPORT Human Clinical

"By interrogating DNAm in SS patients, we identify a genome-wide, highly significant NSD1(+/-)-specific signature that differentiates pathogenic NSD1 mutations from controls, benign NSD1 variants and the clinically overlapping Weaver syndrome."

States exactly what the signature discriminates, which is the diagnostic claim here.

PMID:26690673 SUPPORT Human Clinical

"Validation studies of independent cohorts of SS and controls assigned 100% of these samples correctly."

The validation performance quoted in the description.

PMID:26690673 SUPPORT Human Clinical

"As shown in Fig. 2, the NSD1+/−-specific signature allowed clear classification of VOUS as pathogenic or benign; 9/16 samples received positive SS scores clustering with the NSD1+/− pathogenic variants; these mutations were classified as pathogenic."

Supports the variant-reclassification use, with the actual counts.

+ 2 more references

📈

Progression

2

Childhood

Age: Early childhood through mid adolescence

Height excess tends to attenuate with age. The Korean growth-chart estimates differed by age, sex and measure, and were based largely on childhood follow-up; their age-specific significance thresholds do not establish that overgrowth or macrocephaly ends at a fixed age in every patient.

Show evidence (1 reference)

PMID:39494594 SUPPORT Human Clinical

"Males with SS demonstrated higher height before the age of 12.0, greater weight before 10.0, and larger head circumference before 15.5 compared to age- and sex-matched controls."

Reports age-specific comparisons within this Korean cohort; lack of a significant difference at later ages does not define a universal clinical endpoint.

Adulthood

Age: Adults

Adults are generally healthy with few new medical problems, and the height excess is modest by adulthood (median +1.9 SD in women, +0.5 SD in men). Reproductive rates are low. A minority develop new problems - lymphoedema, poor dentition, hearing loss, contractures, tremor.

Show evidence (2 references)

PMID:31479583 SUPPORT Human Clinical

"In our cohort, median height in adult women is +1.9 SD and men +0.5 SD."

The adult stature figures quoted here.

PMID:31479583 SUPPORT Human Clinical

"Reassuringly, adults with Sotos syndrome are generally healthy with few new medical issues; however, lymphedema, poor dentition, hearing loss, contractures and tremor have developed in a small number of individuals."

Supports both the reassuring general statement and the specific minority complications.

📊

Prevalence

1

Worldwide

Birth Prevalence 7.1 per 100,000 1–9 per 100,000 (births)

The widely quoted figure is approximately 1 in 14,000 live births, which normalises to about 7.1 per 100,000. Several sources are cited, but they are not independent measurements: the Choufani source attributes the estimate to unpublished data and the later papers cite the same lineage of figures. An earlier Orphanet review stated plainly that the exact prevalence is unknown. Treat this as the field's conventional estimate rather than a population-based ascertainment study.

Show evidence (3 references)

PMID:26690673 SUPPORT Human Clinical

"Sotos syndrome (OMIM 117550) is an autosomal dominant condition with an estimated prevalence of 1:14,000 live births (Rahman, unpublished data)."

Gives the quoted birth-prevalence figure and, in the same sentence, its provenance as unpublished data - which is why this record is not presented as a measured population rate.

PMID:37384309 SUPPORT Human Clinical

"SS is the most frequent genetic cause of overgrowth, with an estimated incidence of 1/14.000 live births"

A second clinical source repeating the same estimate and situating Sotos syndrome as the commonest genetic overgrowth diagnosis.

PMID:17825104 SUPPORT Human Clinical

"The exact prevalence remains unknown but hundreds of cases have been reported."

Cited deliberately as a counterweight: the Orphanet review declined to give a prevalence at all, which is why this record is banded rather than reported as a measured rate.

🌍

Epidemiology

1

Ancestry-Dependent Lesion-Class Distribution

The proportion of Sotos syndrome caused by the 5q35 microdeletion rather than an intragenic variant differs markedly by population. In the Japanese referral series 52% of patients had a microdeletion against 6% of non-Japanese patients, and a Korean series found 53% of NSD1-positive patients had a deletion. This matters operationally: a diagnostic strategy that sequences NSD1 without a copy-number assay will miss most cases in these populations. The authors of the Japanese series were careful to note that patient-selection bias may contribute, since the flanking low-copy repeats mediating the deletion are present in different populations.

Show evidence (3 references)

PMID:14517949 SUPPORT Human Clinical

"A large difference in the frequency of microdeletions between Japanese and non-Japanese patients was noted: 49 (52%) of the 95 Japanese patients and only one (6%) of the 17 non-Japanese had microdeletions."

The primary observation of the population difference.

PMID:14517949 SUPPORT Human Clinical

"Such LCRs seem to be present in different populations. Thus the different frequency of microdeletions between Japanese and non-Japanese cases in our study may have been caused by patient-selection bias."

The authors' own caveat, quoted so the entry does not overstate the effect as a settled population-genetic fact.

PMID:23190751 SUPPORT Human Clinical

"The mutation spectrum of Korean patients with Sotos syndrome was similar to that of previous studies for Japanese patients."

Independent East Asian replication of the deletion-predominant pattern.

🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Sotos Syndrome:

Beckwith-Wiedemann Syndrome and Other Overgrowth Differentials

Overlapping Features Beyond the chromatin overgrowth syndromes, the Orphanet review lists Beckwith-Wiedemann syndrome, fragile X syndrome, Simpson-Golabi-Behmel syndrome and 22q terminal deletion syndrome as the main differentials. These are mechanistically unrelated to NSD1 and are separated by targeted molecular testing rather than by phenotype.

Distinguishing Features

Distinct molecular aetiologies - 11p15 imprinting, FMR1 repeat expansion, GPC3, 22q13 deletion
None carries the NSD1 blood methylation episignature

Show evidence (1 reference)

PMID:17825104 SUPPORT Human Clinical

"The main differential diagnoses are Weaver syndrome, Beckwith-Wiedeman syndrome, Fragile X syndrome, Simpson-Golabi-Behmel syndrome and 22qter deletion syndrome."

The review's own list of differentials, recorded here without adding conditions it does not name.

🐁

Animal Models

1

Nsd1 heterozygous mouse (CRISPR exon 3)

The only reported constitutive heterozygous mouse for the Sotos gene, made to ask whether Nsd1 haploinsufficiency reproduces the human syndrome. Nsd1 expression in the mouse brain is predominantly neuronal, and the heterozygotes show behavioural changes reminiscent of some of the human deficits. Homozygous loss is embryonic lethal, so heterozygosity is the only postnatal window on this gene.

Species

Mouse

Genotype

Nsd1 heterozygous loss-of-function (CRISPR-targeted)

Genes

NSD1 hgnc:14234

Publication

PMID:31909872

Pathograph links

Dysregulated Developmental Transcriptional Program partially recapitulates fidelity: low observes: organism Halving Nsd1 dose in the mouse produces behavioural change but, on the published account, only a partial resemblance to the human phenotype. The model therefore supports the transcriptional-program node as dose-sensitive without establishing that the human syndrome follows from it in full.

Limitations: The published abstract claims only "behavioral characteristics reminiscent of some of the deficits" and reports no overgrowth or macrocephaly, which are two of the three cardinal human features the same abstract names. The more specific negative results attributed to this model in secondary summaries - absent overgrowth and macrocephaly, absent gross cortical enlargement, reduced SATB2-positive upper-layer neurons - come from full text that is not in the reference cache, so they are deliberately not curated here and the relationship is recorded as partial rather than as an outright failure to recapitulate.

Show evidence (2 references)

PMID:31909872 SUPPORT Model Organism

"We also generated a mouse strain lacking one allele of Nsd1 and analyzed morphological and behavioral characteristics in these mice, showing behavioral characteristics reminiscent of some of the deficits seen in Sotos syndrome patients."

The authors' own summary claim, whose hedging ("some of the deficits") is what fixes this as a partial rather than a full recapitulation.

+ 1 more reference

Show evidence (1 reference)

PMID:31909872 SUPPORT Model Organism

"In children, the three cardinal features of Sotos syndrome are a characteristic facial appearance, learning disability and overgrowth (height and/or head circumference > 2 SDs above average)."

The paper's own statement of the three features a faithful model would have to reproduce, which is the yardstick the reported behavioural-only result is measured against.

{ }

Source YAML

click to show

name: Sotos Syndrome
synonyms:
- Sotos syndrome 1
- SOTOS1
- cerebral gigantism
- NSD1-related Sotos syndrome
- chromosome 5q35 deletion syndrome
creation_date: "2026-09-05T18:00:00Z"
category: Mendelian
description: >-
  Sotos syndrome (MONDO:0019349; OMIM 117550) is an autosomal dominant
  overgrowth-intellectual disability syndrome caused by haploinsufficiency of
  NSD1, the nuclear receptor binding SET domain protein 1 at 5q35. NSD1 is the
  principal writer of histone H3 lysine 36 dimethylation (H3K36me2), a mark
  deposited predominantly across intergenic euchromatin. Three features are
  treated as cardinal: a distinctive facial appearance (broad prominent forehead
  with dolichocephaly, sparse frontotemporal hair, downslanting palpebral
  fissures, malar flushing, long narrow face and a tall chin), learning
  disability ranging from early developmental delay to severe intellectual
  impairment, and childhood overgrowth of height and/or head circumference. A
  broad set of associated features occurs: advanced bone age, autism spectrum
  behaviours, seizures, scoliosis, joint hyperlaxity, congenital cardiac
  anomalies, renal anomalies, cranial imaging abnormalities and neonatal
  complications. Two molecular classes account for essentially all cases -
  intragenic NSD1 loss-of-function variants and a recurrent 5q35 microdeletion
  encompassing NSD1 that arises by non-allelic homologous recombination between
  flanking low-copy repeats. The deletion class is much commoner in Japanese and
  Korean cohorts than in European ones and is associated with more severe
  learning disability, less prominent overgrowth and more progressive scoliosis;
  this is a within-disease genotype axis, curated here as `has_subtypes`, not two
  diseases. NSD1 loss produces a highly specific genome-wide DNA-methylation
  episignature in peripheral blood that is now used diagnostically, including to
  reclassify NSD1 variants of uncertain significance and to separate Sotos
  syndrome from the clinically overlapping Weaver syndrome. The NFIX-related
  "Sotos syndrome 2" phenotype is a separate MONDO concept curated in dismech as
  Malan_Syndrome and is cross-referenced here as a differential diagnosis rather
  than absorbed into this entry.
disease_term:
  preferred_term: Sotos syndrome
  description: >-
    NSD1-related autosomal dominant overgrowth syndrome with a distinctive facial
    gestalt, learning disability and advanced bone age.
  term:
    id: MONDO:0019349
    label: Sotos syndrome
parents:
- Overgrowth Syndrome
- Chromatinopathy

references:
- reference: PMID:20301652
  title: "Sotos Syndrome."
  tags:
  - GeneReviews

classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    notes: >-
      A Mendelian multisystem malformation/overgrowth syndrome; Harrison's covers
      this class of disorder under the genetics Part rather than under a single
      organ system.
  - classification_value: NEUROLOGIC
    notes: >-
      Intellectual disability, autism spectrum behaviour and seizures are core and
      drive most of the long-term clinical burden.
  isds_skeletal_category:
  - classification_value: overgrowth_syndromes_with_skeletal_involvement
    notes: >-
      Nosology of Genetic Skeletal Disorders, 2023 revision (Unger et al.,
      PMID:36779427), group 31 "Overgrowth (tall stature) syndromes and segmental
      overgrowth"; listed as "Sotos (NSD1)". This was group 30 in the 2019
      revision (PMID:31633310).

prevalence:
- population: Worldwide
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 7.1
  notes: >-
    The widely quoted figure is approximately 1 in 14,000 live births, which
    normalises to about 7.1 per 100,000. Several sources are cited, but they are
    not independent measurements: the Choufani source attributes the estimate to
    unpublished data and the later papers cite the same lineage of figures. An
    earlier Orphanet review stated plainly that the exact prevalence is unknown.
    Treat this as the field's conventional estimate rather than a
    population-based ascertainment study.
  evidence:
  - reference: PMID:26690673
    reference_title: "NSD1 mutations generate a genome-wide DNA methylation signature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sotos syndrome (OMIM 117550) is an autosomal dominant condition with an estimated prevalence of 1:14,000 live births (Rahman, unpublished data)."
    explanation: >-
      Gives the quoted birth-prevalence figure and, in the same sentence, its
      provenance as unpublished data - which is why this record is not presented
      as a measured population rate.
  - reference: PMID:37384309
    reference_title: "Beyond the known phenotype of sotos syndrome: a 31-individuals cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SS is the most frequent genetic cause of overgrowth, with an estimated incidence of 1/14.000 live births"
    explanation: >-
      A second clinical source repeating the same estimate and situating Sotos
      syndrome as the commonest genetic overgrowth diagnosis.
  - reference: PMID:17825104
    reference_title: "Sotos syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The exact prevalence remains unknown but hundreds of cases have been reported."
    explanation: >-
      Cited deliberately as a counterweight: the Orphanet review declined to give
      a prevalence at all, which is why this record is banded rather than reported
      as a measured rate.

inheritance:
- name: Autosomal Dominant
  description: >-
    Sotos syndrome is autosomal dominant. Approximately 95% of affected individuals have a de novo alteration and about 5% have an affected parent. Each child of an affected individual has a 50% chance of inheriting the alteration; severity cannot be predicted reliably across generations. Recurrence in clinically unaffected parents is uncommon but possible through parental gonadal mosaicism, and negative blood testing does not exclude that possibility. The low observed vertical transmission rate may partly reflect reproductive fitness, but its explanation remains uncertain.
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  expressivity: VARIABLE
  de_novo_rate: "~95%"
  evidence:
  - reference: PMID:20301652
    reference_title: "Sotos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sotos syndrome is inherited in an autosomal dominant manner. About 5% of individuals diagnosed with Sotos syndrome have an affected parent; approximately 95% of individuals have the disorder as the result of a de novo genetic alteration."
    explanation: GeneReviews establishes both the inheritance mode and the de novo proportion.
  - reference: PMID:20301652
    reference_title: "Sotos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenotypic expression can vary from one generation to the next; thus, it is not possible to accurately predict phenotype based on the prenatal finding of a Sotos syndrome-related genetic alteration."
    explanation: Supports the variable-expressivity assignment and the counselling limitation that follows from it.
  - reference: PMID:36708490
    reference_title: Genetic Analysis of a Case of Sotos Syndrome with Suspected Germinal Mosaicism in Mother.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Gentling results indicated that the fetus and the patient inherited the same maternal chromosome 5. The heterozygous mutation of NSD1 gene c.4138delG is the pathogenic mutation of this Sots syndrome patient, and the mother may be germinal mosaicism.
    explanation: >-
      Recurrence of the same variant in two pregnancies despite negative parental blood testing supports suspected maternal germline mosaicism. This report supersedes the 2007 statement that germline mosaicism had never been reported; it does not estimate a population recurrence risk.
  - reference: PMID:15942875
    reference_title: "Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified only 13 familial cases. The reasons for the low vertical transmission rate are unclear, although familial cases were more likely than nonfamilial cases (P = .005) to carry missense mutations, suggesting that the underlying NSD1 mutational mechanism in Sotos syndrome may influence reproductive fitness."
    explanation: >-
      Quantifies how rare familial transmission is in the largest curated cohort
      and records the authors' reproductive-fitness interpretation without
      asserting it as established.

has_subtypes:
- name: Intragenic NSD1 Variant
  display_name: Intragenic NSD1 loss-of-function variant
  description: >-
    Sotos syndrome caused by a heterozygous intragenic NSD1 variant - truncating variants distributed throughout the gene, or missense variants confined to the functional domains. This is the majority class in European-ancestry cohorts, where it accounts for roughly 83% of clinically diagnosed individuals, and is associated with more prominent overgrowth and less severe learning disability than the microdeletion class.
  genes:
  - preferred_term: NSD1
    term:
      id: hgnc:14234
      label: NSD1
  subtype_frequency: "~83% of clinically diagnosed Sotos syndrome in the predominantly non-Japanese diagnostic series"
  evidence:
  - reference: PMID:15942875
    reference_title: "Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Furthermore, our data suggest that 93% of patients who have been clinically diagnosed with Sotos syndrome have identifiable NSD1 abnormalities, of which 83% are intragenic mutations and 10% are 5q35 microdeletions."
    explanation: >-
      The 83% intragenic and 10% deletion estimates sum to the 93% molecular yield among clinically diagnosed individuals, not percentages within the NSD1-positive subgroup.
  - reference: PMID:15942875
    reference_title: "Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Truncating NSD1 mutations occurred throughout the gene, but pathogenic missense mutations occurred only in functional domains (P < 2 x 10(-16))."
    explanation: Supports the described distribution of intragenic variant classes across the gene.
- name: 5q35 Microdeletion
  display_name: Recurrent 5q35 microdeletion encompassing NSD1
  description: >-
    Sotos syndrome caused by a contiguous 5q35 deletion encompassing NSD1. The recurrent deletion arises through non-allelic homologous recombination at flanking low-copy repeats. Frequencies vary between referral series and populations; Korean cohorts have reported both deletion-predominant and intragenic-variant-predominant distributions. Deletions are associated with less prominent overgrowth and more severe learning disability at group level. A scoliosis series also found greater progression in the deletion group. The absence of a deletion-size correlation does not exclude contributions from neighboring genes.
  genes:
  - preferred_term: NSD1
    term:
      id: hgnc:14234
      label: NSD1
  subtype_frequency: "~10% of clinically diagnosed Sotos syndrome in the predominantly non-Japanese diagnostic series; ~52% of Japanese patients in the older referral series"
  evidence:
  - reference: PMID:14517949
    reference_title: "Fifty microdeletions among 112 cases of Sotos syndrome: low copy repeats possibly mediate the common deletion."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A large difference in the frequency of microdeletions between Japanese and non-Japanese patients was noted: 49 (52%) of the 95 Japanese patients and only one (6%) of the 17 non-Japanese had microdeletions."
    explanation: Directly quantifies the population skew that defines the clinical relevance of this subtype.
  - reference: PMID:15942875
    reference_title: "Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with microdeletions had less-prominent overgrowth (P = .0003) and more-severe learning disability (P = 3 x 10(-9)) than patients with mutations."
    explanation: The primary genotype-phenotype contrast justifying curation of the two molecular classes as subtypes.
  - reference: PMID:15942875
    reference_title: "Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, all features present in patients with microdeletions were also observed in patients with mutations, and there was no correlation between deletion size and the clinical phenotype, suggesting that the deletion of additional genes in patients with 5q35 microdeletions has little specific effect on phenotype."
    explanation: >-
      Reports the original authors’ interpretation of overlapping phenotypes and lack of a deletion-size correlation; this does not prove that neighboring genes have no phenotypic contribution.

pathophysiology:
- name: Non-Allelic Homologous Recombination at 5q35 Sos-REP Low-Copy Repeats
  description: >-
    The recurrent Sotos deletion is generated by a structural-variant mechanism
    rather than by a point mutational process. Two complex mosaic low-copy repeat
    blocks flank NSD1 - proximal Sos-PREP (~390 kb) and distal Sos-DREP (~429 kb),
    each built from six subunits, most in inverted orientation. Only the C and C'
    subunits are directly oriented with respect to each other and they are more
    than 99% identical; recombination between them yields the common deletion and
    a patient-specific junction fragment absent from controls. This mechanism
    explains why the deletion recurs at the same breakpoints across unrelated
    individuals.
  biological_scale: MOLECULAR
  genetic_context:
    gene:
      preferred_term: NSD1
      term:
        id: hgnc:14234
        label: NSD1
    variant_origin: DE_NOVO
    allelic_events:
    - DELETION
    - COPY_NUMBER_LOSS
    zygosity: HETEROZYGOUS
    description: >-
      A heterozygous contiguous deletion of the 5q35 interval containing NSD1,
      almost always arising de novo.
  subtypes:
  - 5q35 Microdeletion
  evidence:
  - reference: PMID:15640245
    reference_title: "Sotos syndrome common deletion is mediated by directly oriented subunits within inverted Sos-REP low-copy repeats."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found that Sos-PREP and Sos-DREP are composed of six subunits termed A-F. Each of the homologous subunits, with the exception of one, is located in an inverted orientation and the order of subunits is different between the two Sos-REPs. Only the subunit C' in Sos-DREP is oriented directly with respect to the subunit C in Sos-PREP. These latter C' and C subunits are greater than 99% identical."
    explanation: Establishes the repeat architecture that makes only one recombination substrate available.
  - reference: PMID:15640245
    reference_title: "Sotos syndrome common deletion is mediated by directly oriented subunits within inverted Sos-REP low-copy repeats."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Using pulsed-field gel electrophoresis analysis in eight Sos patients with a common deletion, we detected an approximately 550 kb junction fragment that we predicted according to the non-allelic homologous recombination (NAHR) mechanism using directly oriented Sos-PREP C and Sos-DREP C' subunits as substrates."
    explanation: Direct patient-derived evidence that the predicted NAHR product is what the deletion actually is.
  downstream:
  - target: NSD1 Haploinsufficiency
    causal_link_type: DIRECT
    description: >-
      The recombination product removes one entire NSD1 allele, so the structural
      event and the dosage lesion are the same event viewed at two levels.
    evidence:
    - reference: PMID:14517949
      reference_title: "Fifty microdeletions among 112 cases of Sotos syndrome: low copy repeats possibly mediate the common deletion."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We previously showed that haploinsufficiency of the NSD1 gene is the major cause of SoS, and submicroscopic deletions at 5q35, including NSD1, were found in about a half (20/42) of our patients examined."
      explanation: States that the 5q35 submicroscopic deletions act by including - and thereby deleting - NSD1.

- name: NSD1 Haploinsufficiency
  conforms_to: "epigenetic_machinery_neurodevelopmental_dysregulation#Epigenetic Machinery Component Haploinsufficiency"
  description: >-
    The initiating lesion in essentially all Sotos syndrome is loss of one
    functional copy of NSD1, reached either by an intragenic loss-of-function
    variant or by the 5q35 microdeletion above. NSD1 is a writer in the four-class
    scheme of the epigenetic machinery, so this node is the disease-specific
    instance of the module's dosage-sensitive component loss. Haploinsufficiency -
    rather than a dominant-negative or gain-of-function mechanism - is established
    both by the mutational spectrum (nonsense, frameshift and whole-gene deletion
    all producing the same syndrome) and by the near-exclusive association of NSD1
    aberrations with the Sotos phenotype across a large diagnostic series.
  biological_scale: MOLECULAR
  gene:
    preferred_term: NSD1
    term:
      id: hgnc:14234
      label: NSD1
  genetic_context:
    gene:
      preferred_term: NSD1
      term:
        id: hgnc:14234
        label: NSD1
    variant_origin: GERMLINE
    allelic_events:
    - PATHOGENIC_VARIANT
    - NONSENSE_VARIANT
    - FRAMESHIFT_VARIANT
    - DELETION
    zygosity: HETEROZYGOUS
    functional_impact_category: LOSS_OF_FUNCTION
    description: >-
      Heterozygous germline NSD1 loss of function, usually de novo. The allelic
      events listed span the two curated subtypes; missense variants also occur
      but only within the functional domains.
  evidence:
  - reference: PMID:11896389
    reference_title: "Haploinsufficiency of NSD1 causes Sotos syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified 1 nonsense, 3 frameshift and 20 submicroscopic deletion mutations of NSD1 among 42 individuals with sporadic cases of Sotos syndrome. The results indicate that haploinsufficiency of NSD1 is the major cause of Sotos syndrome."
    explanation: >-
      The original demonstration, and the reason the mechanism is read as dosage
      loss: three distinct classes of loss-of-function lesion produce one syndrome.
  - reference: PMID:15942875
    reference_title: "Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sotos syndrome was clinically diagnosed in 99% of NSD1-positive individuals, independent of the molecular analyses, indicating that NSD1 aberrations are essentially specific to this condition."
    explanation: Establishes the specificity of the gene-disease relationship on which this node rests.
  downstream:
  - target: Genome-Wide H3K36me2 Depletion
    causal_link_type: DIRECT
    description: >-
      NSD1 loss reduces deposition of H3K36me2. This dependence is demonstrated in engineered mouse and human cells; the magnitude and tissue distribution of the change in heterozygous patients are not inferred from complete-loss experiments.
    evidence:
    - reference: PMID:31485078
      reference_title: The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        A global reduction of H3K36me2 in sgNsd1/2 mMSCs and sgNsd1 mESCs, most prominent at intergenic regions, was observed (Extended Data Fig. 4g,h).
      explanation: >-
        Nsd1 alone was disrupted in mouse embryonic stem cells, whereas both Nsd1 and Nsd2 were disrupted in mesenchymal cells. These cellular perturbations support the biochemical dependence; they do not measure heterozygous human tissue dosage quantitatively.
    - reference: PMID:42157059
      reference_title: "NSD1 governs H3K36me2-mediated DNA methylation and drives endo-mesodermal differentiation of human iPSCs."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "NSD1-KO cells exhibit a substrate-specific decrease in proliferation, reduced H3K36me2 levels, and extensive DNA hypomethylation."
      explanation: Human iPSC knockout confirms that loss of NSD1 function reduces H3K36me2 in human cells.

  - target: Reduced NSD1 Tumor-Suppressor Function
    description: >-
      Loss of NSD1 may impair repression of growth-promoting targets. Evidence from Sotos lymphoblastoid cells and transformed-cell perturbations supports this as a provisional susceptibility mechanism.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: DOI:10.1073/pnas.0906831106
      reference_title: Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Because patients with NSD1 germ-line genetic disruption have an increased risk of developing malignancy before adulthood, including neuroblastoma, Wilms tumors, and hematological malignancies, a tumor-suppressor function for NSD1 might be proposed.
      explanation: >-
        The historical study explicitly proposes a germline tumor-suppressor mechanism and tests NSD1 loss/restoration in sporadic tumor cells. The enumerated historical tumor associations are not used to assert current tumor-specific risks.
      directness: INDIRECT
- name: Genome-Wide H3K36me2 Depletion
  conforms_to: "epigenetic_machinery_neurodevelopmental_dysregulation#Permissive-Repressive Chromatin State Imbalance"
  description: >-
    NSD1 is a SET-domain methyltransferase that primarily dimethylates nucleosomal
    histone H3 lysine 36, and its catalytic domain carries an autoregulatory loop
    that normally occludes the substrate until the nucleosome stabilises the
    active conformation. Reduced NSD1 dosage therefore lowers H3K36me2 across the
    large intergenic euchromatic domains where this mark predominates. Because
    H3K36me2 is one arm of the permissive-repressive balance, its depletion is not
    simply a subtraction: at developmental enhancers the same loss permits
    excessive H3K27me3 and lowers H3K27ac. Catalysis depends on several NSD1
    modules together (PHD1-4, PWWP2 and SET), which is why missense variants
    restricted to those domains behave like truncating alleles - molecular
    modelling of SET-domain substitutions shows loss of structural stability or
    steric clash near the S-adenosylmethionine binding site.
  biological_scale: MOLECULAR
  molecular_functions:
  - preferred_term: NSD1 H3K36 dimethyltransferase activity
    term:
      id: GO:0140954
      label: histone H3K36 dimethyltransferase activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: chromatin organization
    term:
      id: GO:0006325
      label: chromatin organization
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:21196496
    reference_title: "The structure of NSD1 reveals an autoregulatory mechanism underlying histone H3K36 methylation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The Sotos syndrome gene product, NSD1, is a SET domain histone methyltransferase that primarily dimethylates nucleosomal histone H3 lysine 36 (H3K36)."
    explanation: Establishes the enzymatic identity and product specificity that this node depletes.
  - reference: PMID:21196496
    reference_title: "The structure of NSD1 reveals an autoregulatory mechanism underlying histone H3K36 methylation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The 1.7 Å structure of the catalytic domain of NSD1 presented here shows that a regulatory loop adopts a conformation that prevents free access of H3K36 to the bound S-adenosyl-L-methionine."
    explanation: Structural basis for the autoregulated catalysis described in this node.
  - reference: PMID:40118455
    reference_title: "The sotos syndrome gene Nsd1 safeguards developmental gene enhancers poised for transcription by maintaining the precise deposition of histone methylation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Disruption of either one of these Nsd1 modules severely abrogated H3K36me2 in mESCs and significantly impaired appropriate induction of developmental genes upon mESC differentiation."
    explanation: >-
      Supports the multi-module catalytic requirement, which is the mechanistic
      reason domain-restricted missense variants are pathogenic.
  - reference: PMID:27834868
    reference_title: "Steric Clash in the SET Domain of Histone Methyltransferase NSD1 as a Cause of Sotos Syndrome and Its Genetic Heterogeneity in a Brazilian Cohort."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "For six mutations near the ligand-binding site we observed in simulations steric clashes with neighboring side chains near the substrate S-Adenosyl methionine (SAM) binding site, which may disrupt the enzymatic activity of NSD1."
    explanation: >-
      Supplies the structural rationale for SET-domain missense pathogenicity. This
      is molecular-dynamics simulation, not an enzyme assay, hence COMPUTATIONAL.
  downstream:
  - target: Intergenic DNA Hypomethylation from Loss of DNMT3A Recruitment
    causal_link_type: DIRECT
    description: >-
      H3K36me2 is the chromatin signal that positions DNMT3A over intergenic DNA,
      so depleting the mark relocates the enzyme and the methylation it deposits.
    evidence:
    - reference: PMID:31485078
      reference_title: "The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Here we report that NSD1-mediated H3K36me2 is required for the recruitment of DNMT3A and maintenance of DNA methylation at intergenic regions."
      explanation: States the causal dependency of intergenic DNA methylation on NSD1-deposited H3K36me2.
  - target: Loss of Developmental Enhancer Priming
    causal_link_type: DIRECT
    description: >-
      At distal enhancers of lineage transcription-factor genes, NSD1-deposited
      H3K36me2 holds off H3K27me3 and sustains basal H3K27ac; losing the mark
      collapses that primed state.
    evidence:
    - reference: PMID:40118455
      reference_title: "The sotos syndrome gene Nsd1 safeguards developmental gene enhancers poised for transcription by maintaining the precise deposition of histone methylation."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Mechanistically, Nsd1 directly occupies putative distal enhancers of the lineage transcription factor genes under the pluripotent cell state, where it deposits H3K36me2 to antagonize the excessive H3K27me3 and maintains the basal H3K27ac level, thereby safeguarding these gene enhancers at a primed state that responds readily to differentiation cues."
      explanation: >-
        The single sentence that carries this whole edge - it names the mark, the
        antagonism, and the enhancer state that fails when the mark is lost.

- name: Intergenic DNA Hypomethylation from Loss of DNMT3A Recruitment
  description: >-
    DNMT3A reads H3K36me2 through its PWWP domain and is thereby concentrated in
    intergenic euchromatin. When NSD1 dosage falls, DNMT3A redistributes to
    H3K36me3-marked gene bodies and intergenic CpG methylation is lost. This is
    the mechanistic bridge between a histone-modifier disorder and a
    DNA-methylation phenotype, and it is the reason Sotos syndrome and
    Tatton-Brown-Rahman syndrome (germline DNMT3A) overlap clinically: the two
    genes act in one pathway, at consecutive steps. Peripheral blood from Sotos
    patients shows this intergenic hypomethylation directly, and it is the
    substrate of the diagnostic episignature - 99.3% of the signature's CpG sites
    lose rather than gain methylation. In patient tissue the hypomethylation is
    concentrated at the promoters of the transcriptionally deregulated genes
    themselves. Note that dismech does not treat the blood episignature as a step
    in the brain's causal chain; see the knowledge-gap discussion on this entry.
  biological_scale: MOLECULAR
  molecular_functions:
  - preferred_term: DNMT3A de novo CpG methyltransferase activity at intergenic euchromatin
    term:
      id: GO:0003886
      label: DNA (cytosine-5-)-methyltransferase activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: epigenetic regulation of gene expression
    term:
      id: GO:0040029
      label: epigenetic regulation of gene expression
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:31485078
    reference_title: "The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Blood samples from patients with Sotos syndrome and NSD1-mutant tumours also exhibit hypomethylation of intergenic DNA."
    explanation: >-
      Shows the predicted DNA-methylation consequence in human Sotos tissue, not
      only in the mouse system in which the mechanism was worked out.
  - reference: PMID:31485078
    reference_title: "The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The PWWP domain of DNMT3A shows dual recognition of H3K36me2 and H3K36me3 in vitro, with a higher binding affinity towards H3K36me2 that is abrogated by TBRS-derived missense mutations."
    explanation: >-
      Identifies the reader module that couples the two marks and explains why
      DNMT3A-mutant overgrowth phenocopies NSD1-mutant overgrowth.
  - reference: PMID:26690673
    reference_title: "NSD1 mutations generate a genome-wide DNA methylation signature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified 7,085 CpG sites distributed across the genome that we refer to as the NSD1+/−-specific signature; 7,038 CpG sites (99.3%) demonstrated loss of DNAm"
    explanation: >-
      Quantifies the directionality of the human methylation change as
      overwhelmingly loss, matching the hypomethylation mechanism of this node.
  - reference: PMID:35094088
    reference_title: "NSD1 mutations deregulate transcription and DNA methylation of bivalent developmental genes in Sotos syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DNA hypomethylation was strongly enriched within promoters of transcriptionally deregulated genes: overexpressed genes displayed hypomethylation at their transcription start sites while underexpressed genes featured hypomethylation at polycomb binding sites within their promoter CpG island shores."
    explanation: >-
      Ties the methylation loss in patient samples to the specific genes whose
      transcription changes, which is what makes this node mechanistic rather than
      merely correlative.
  downstream:
  - target: Dysregulated Developmental Transcriptional Program
    description: >-
      A proposed route links altered promoter DNA methylation to PRC2-mediated silencing of developmental genes. Patient blood profiles support the association, while functional confirmation in affected developing tissues is still required.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35094088
      reference_title: NSD1 mutations deregulate transcription and DNA methylation of bivalent developmental genes in Sotos syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        These observations lead us to hypothesize that NSD1-deposited H3K36me protects bivalent genes from PRC2-mediated silencing by recruiting DNAm to PRC2 binding sites within their promoters, thereby antagonizing PRC2 activity.
      explanation: >-
        The authors explicitly present the methylation–PRC2–transcription sequence as a hypothesis, rather than a perturbationally established human pathway.
      directness: INDIRECT
    intermediate_mechanisms:
    - Altered PRC2 activity at bivalent developmental promoters
- name: Loss of Developmental Enhancer Priming
  description: >-
    Independently of the DNA-methylation arm, NSD1 occupies the distal enhancers
    of lineage-specifying transcription-factor genes while cells are still
    pluripotent and holds them in a primed state that can respond rapidly to
    differentiation cues. Losing NSD1 leaves those enhancers unable to support the
    rapid induction of their genes, so the defect is one of responsiveness at the
    moment of lineage commitment rather than of steady-state expression alone.
    This is a distinct claim from intergenic hypomethylation and is evidenced in a
    different system, which is why it is a separate node.
  biological_scale: MOLECULAR
  biological_processes:
  - preferred_term: epigenetic regulation of gene expression at developmental enhancers
    term:
      id: GO:0040029
      label: epigenetic regulation of gene expression
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:40118455
    reference_title: "The sotos syndrome gene Nsd1 safeguards developmental gene enhancers poised for transcription by maintaining the precise deposition of histone methylation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Time-course transcriptomic profiling following the mESC differentiation revealed that Nsd1 not only facilitates the basal expression but also permits the differentiation-accompanied rapid induction of a suite of meso-endoderm lineage-specifying transcription factor genes such as T and Gata4."
    explanation: >-
      Separates the two things Nsd1 does at these loci - basal expression and
      inducibility - which is the specific content of this node.
  downstream:
  - target: Dysregulated Developmental Transcriptional Program
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:40118455
      reference_title: "The sotos syndrome gene Nsd1 safeguards developmental gene enhancers poised for transcription by maintaining the precise deposition of histone methylation."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Disruption of either one of these Nsd1 modules severely abrogated H3K36me2 in mESCs and significantly impaired appropriate induction of developmental genes upon mESC differentiation."
      explanation: Connects failure of the primed enhancer state to failed induction of the developmental gene program.

- name: Dysregulated Developmental Transcriptional Program
  conforms_to: "epigenetic_machinery_neurodevelopmental_dysregulation#Dysregulated Neurodevelopmental Transcriptional Program"
  description: >-
    The convergence point of both chromatin arms, and the node this entry shares
    with every other chromatinopathy. Transcriptomic profiling of Sotos patients
    identifies a signature that separates them from controls; most deregulated
    genes are underexpressed, and they are predominantly bivalent genes enriched
    for regulators of development and neural synapse function. The methylation
    signature points the same way: its CpG sites sit near genes for cellular
    morphogenesis, differentiation, neuronal differentiation and axonogenesis, and
    cell adhesion. One downstream target has been identified specifically - Nsd1
    knockdown downregulates Apc2, a cytoskeletal regulator in neurons, and
    biallelic APC2 loss independently produces Sotos-like features in humans.
  biological_scale: MOLECULAR
  biological_processes:
  - preferred_term: regulation of DNA-templated transcription
    term:
      id: GO:0006355
      label: regulation of DNA-templated transcription
    modifier: DYSREGULATED
  - preferred_term: nervous system development
    term:
      id: GO:0007399
      label: nervous system development
    modifier: DECREASED
  evidence:
  - reference: PMID:35094088
    reference_title: "NSD1 mutations deregulate transcription and DNA methylation of bivalent developmental genes in Sotos syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most abnormally expressed genes displayed reduced expression in SS; these downregulated genes consisted mostly of bivalent genes and were enriched for regulators of development and neural synapse function."
    explanation: >-
      Direct human transcriptomic evidence naming both the direction of change and
      the gene classes affected - the strongest support for this node.
  - reference: PMID:26690673
    reference_title: "NSD1 mutations generate a genome-wide DNA methylation signature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The results demonstrate enrichment for genes with roles in cellular morphogenesis and differentiation, as well as neuronal differentiation/axonogenesis and cell adhesion/cell signalling"
    explanation: >-
      An independent human data type (methylation rather than expression)
      converging on the same functional categories.
  - reference: PMID:25753423
    reference_title: "Loss-of-Function Mutation in APC2 Causes Sotos Syndrome Features."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Endogenous Apc2 expression was downregulated by the knockdown of Nsd1, indicating that APC2 is a downstream effector of NSD1 in neurons."
    explanation: Identifies a specific transcriptional target of NSD1 in the relevant cell type.
  downstream:
  - target: Impaired Cortical Neuronal Migration and Laminar Positioning
    causal_link_type: DIRECT
    description: >-
      The APC2 arm of the transcriptional program is the one with a demonstrated
      cellular readout, established by rescue rather than by correlation.
    evidence:
    - reference: PMID:25753423
      reference_title: "Loss-of-Function Mutation in APC2 Causes Sotos Syndrome Features."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Nsd1 knockdown in embryonic mouse brains impaired the migration and laminar positioning of cortical neurons, as observed in Apc2-/- mice, and this defect was rescued by the forced expression of Apc2."
      explanation: >-
        The rescue is what makes this a causal edge rather than a co-occurrence:
        restoring the transcriptional target restores the cellular phenotype.
  - target: Impaired Mesendodermal Lineage Differentiation
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:40118455
      reference_title: "The sotos syndrome gene Nsd1 safeguards developmental gene enhancers poised for transcription by maintaining the precise deposition of histone methylation."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "We found Nsd1 to be indispensable for the faithful differentiation of mESCs into three primary germ layers, particularly, meso-endodermal cell lineages related to the development of the heart and the skeletal system."
      explanation: Links the failed developmental gene induction to a specific lineage-differentiation failure.

  - target: Distinctive Facial Appearance
    description: >-
      Deregulation of craniofacial developmental genes is proposed to contribute to the facial gestalt. The individual routes to forehead width, head shape, hair distribution and chin height remain unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35094088
      reference_title: NSD1 mutations deregulate transcription and DNA methylation of bivalent developmental genes in Sotos syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We identified other transcriptionally and epigenetically deregulated genes that are known to regulate skeletal overgrowth and craniofacial anomalies, suggesting that perturbation of these genes contributes to the SS phenotypes.
      explanation: >-
        The patient blood study proposes developmental target-gene dysregulation as an explanation for growth and craniofacial findings; the specific tissue and individual facial components were not experimentally resolved.
      directness: INDIRECT
  - target: Neonatal Hypotonia
    description: >-
      Reduced COL6A1 expression is a proposed contributor to hypotonia or weakness; neonatal tissue specificity and the central versus peripheral contribution remain unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35094088
      reference_title: NSD1 mutations deregulate transcription and DNA methylation of bivalent developmental genes in Sotos syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Other underexpressed genes are causally implicated in phenotypes less frequently observed in SS (6), including autism spectrum disorder (CTTNBP2 (29), NEO1 (33)), congenital cardiac defects (HEY1 (34), DSC2 (35)), muscle hypotonia or weakness (COL6A1 (36)), ocular defects (NECTIN3 (37), GPC4 (28)) and hypodontia (GREM2 (38), TSPEAR (39)).
      explanation: >-
        Underexpression of COL6A1 in patient blood motivates the authors’ hypotonia/weakness hypothesis. Neither neonatal muscle nor central motor pathways were tested, so the link to neonatal hypotonia remains indirect and does not establish a collagen-myopathy mechanism in Sotos syndrome.
      directness: INDIRECT
  - target: Autism Spectrum Behaviour
    description: >-
      Dysregulation of neurodevelopmental targets including CTTNBP2 and NEO1 is a proposed contributor to autistic features; behavioral consequences were not experimentally rescued in patients.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35094088
      reference_title: NSD1 mutations deregulate transcription and DNA methylation of bivalent developmental genes in Sotos syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Other underexpressed genes are causally implicated in phenotypes less frequently observed in SS (6), including autism spectrum disorder (CTTNBP2 (29), NEO1 (33)), congenital cardiac defects (HEY1 (34), DSC2 (35)), muscle hypotonia or weakness (COL6A1 (36)), ocular defects (NECTIN3 (37), GPC4 (28)) and hypodontia (GREM2 (38), TSPEAR (39)).
      explanation: >-
        Underexpression of CTTNBP2 and NEO1 in patient blood motivates the authors’ autism-related developmental hypothesis. Their functions in other genetic contexts are not proof of mediation of autistic behavior in Sotos neural tissue; behavioral rescue was not tested.
      directness: INDIRECT
  - target: Ophthalmological Abnormalities
    description: >-
      Dysregulation of ocular-development genes including NECTIN3 and GPC4 is a proposed contributor to ocular abnormalities; the study does not resolve individual eye findings.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35094088
      reference_title: NSD1 mutations deregulate transcription and DNA methylation of bivalent developmental genes in Sotos syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Other underexpressed genes are causally implicated in phenotypes less frequently observed in SS (6), including autism spectrum disorder (CTTNBP2 (29), NEO1 (33)), congenital cardiac defects (HEY1 (34), DSC2 (35)), muscle hypotonia or weakness (COL6A1 (36)), ocular defects (NECTIN3 (37), GPC4 (28)) and hypodontia (GREM2 (38), TSPEAR (39)).
      explanation: >-
        Underexpression of NECTIN3 and GPC4 in patient blood motivates the authors’ ocular-development hypothesis. The study does not demonstrate mediation in the developing eye or explain individual alignment and refractive findings.
      directness: INDIRECT
  - target: Hypodontia
    description: Underexpression of tooth-development genes GREM2 and TSPEAR is proposed to contribute to tooth agenesis. The patient blood study identifies this phenotype-specific candidate route, but does not test tooth germs or demonstrate mediation of premolar development.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35094088
      reference_title: NSD1 mutations deregulate transcription and DNA methylation of bivalent developmental genes in Sotos syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Other underexpressed genes are causally implicated in phenotypes less frequently observed in SS (6), including autism spectrum disorder (CTTNBP2 (29), NEO1 (33)), congenital cardiac defects (HEY1 (34), DSC2 (35)), muscle hypotonia or weakness (COL6A1 (36)), ocular defects (NECTIN3 (37), GPC4 (28)) and hypodontia (GREM2 (38), TSPEAR (39)).
      explanation: The authors relate underexpressed GREM2 and TSPEAR to hypodontia among Sotos-associated findings. This supplies a provisional gene-expression hypothesis, while the separate clinical dental series establishes occurrence. Blood expression and other-gene disease associations do not prove causation in Sotos odontogenesis.
      directness: INDIRECT
  - target: Proposed Disruption of Synaptic Development
    description: >-
      Reduced expression of bivalent synaptic-development genes may impair assembly of developing neural circuits.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35094088
      reference_title: NSD1 mutations deregulate transcription and DNA methylation of bivalent developmental genes in Sotos syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        This suggests that cognitive impairment in SS could be caused by the silencing of bivalent genes that orchestrate synaptic assembly, since disrupted synaptic assembly is a feature of many neurodevelopmental disorders (71).
      explanation: >-
        The patient-transcriptome analysis proposes impaired synaptic assembly as a cognitive mechanism; synapses were not directly examined in the sampled blood.
      directness: INDIRECT
  - target: Dysregulated FGF-MAPK-ERK Signaling
    description: >-
      NSD1-associated transcriptional dysregulation includes FGF/MAPK-related genes, supported by patient fibroblast profiling and NSD1 knockdown experiments; the net pathway response is context-dependent.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:23155469
      reference_title: Sotos syndrome is associated with deregulation of the MAPK/ERK-signaling pathway.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        In order to elucidate biological pathways explaining how NSD1 haploinsufficiency results in phenotypic features such as overgrowth in SoS a comprehensive study of dermal fibroblasts from SoS patients was performed. We obtained evidence that SoS syndrome is associated with a deregulation of the MAPK/ERK signaling pathway.
      explanation: >-
        The study used fibroblasts from nine NSD1-confirmed patients and nine matched controls, with pathway, knockdown and phosphorylation experiments. The net signaling effect is tissue-dependent.
      directness: INDIRECT
- name: Impaired Cortical Neuronal Migration and Laminar Positioning
  conforms_to: "epigenetic_machinery_neurodevelopmental_dysregulation#Impaired Neuronal Maturation, Plasticity, and Postnatal Neurogenesis"
  description: >-
    Nsd1 knockdown in embryonic mouse cortex reduces Apc2 expression and impairs neuronal migration and laminar positioning; forced Apc2 expression rescues the migration defect. This supports an NSD1–APC2 neural pathway in a model. The reported human APC2 siblings lacked NSD1 mutations and had a distinct recessive Sotos-like disorder, so their phenotype does not directly establish this mechanism in NSD1-related Sotos syndrome.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: cortical projection neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: cerebral cortex cell migration
    term:
      id: GO:0021795
      label: cerebral cortex cell migration
    modifier: DECREASED
  evidence:
  - reference: PMID:25753423
    reference_title: "Loss-of-Function Mutation in APC2 Causes Sotos Syndrome Features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We conducted an etiological study on two siblings with Sotos features without mutations in NSD1 and detected a homozygous frameshift mutation in the APC2 gene by whole-exome sequencing, which resulted in the loss of function of cytoskeletal regulation in neurons."
    explanation: >-
      The two NSD1-negative siblings had biallelic APC2 disease. This provides indirect evidence about the candidate effector, not human confirmation of the NSD1-mediated pathway.
    directness: INDIRECT
  - reference: PMID:25753423
    reference_title: "Loss-of-Function Mutation in APC2 Causes Sotos Syndrome Features."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Apc2-deficient (Apc2-/-) mice exhibited impaired learning and memory abilities along with an abnormal head shape."
    explanation: Provides the organism-level cognitive readout of the cellular defect in an animal model.
  downstream:
  - target: Intellectual Disability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The authors propose that altered APC2-dependent neuronal migration contributes to intellectual disability in Sotos syndrome. Rescue experiments establish the migration route in embryonic mice; the full route to human intellectual disability remains provisional.
    evidence:
    - reference: PMID:25753423
      reference_title: "Loss-of-Function Mutation in APC2 Causes Sotos Syndrome Features."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: MODEL_ORGANISM
      snippet: "Thus, APC2 is a crucial target of NSD1, which provides an explanation for the intellectual disability associated with Sotos syndrome."
      explanation: >-
        The authors' own causal claim, graded INDIRECT because it is an
        interpretation drawn from mouse and knockdown data rather than a
        measurement in affected humans.

  - target: Dysgyria
    description: >-
      Disordered neuronal migration and cortical positioning are proposed to contribute to abnormal cortical folding. The imaging study discusses the NSD1–APC2 model as a possible correlate; it does not demonstrate this route in patient cortex or distinguish the mechanism of each malformation subtype.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39147584
      reference_title: 'Sotos Syndrome: Deep Neuroimaging Phenotyping Reveals a High Prevalence of Malformations of Cortical Development.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        These findings have yet to be described to this extent and correspond with recent studies that show that NSD1 participates in brain development and has interactions with other known relevant genetic pathways.
      explanation: >-
        The imaging-study conclusion relates the malformations to NSD1-dependent brain development and candidate pathways; the causal mechanism remains an interpretation, not a measurement in patient cortex.
      directness: INDIRECT
    - reference: url:https://repository.uantwerpen.be/docstore/d%3Airua%3A25028
      reference_title: https://repository.uantwerpen.be/docstore/d%3Airua%3A25028
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        A key downstream effector of NSD1 is the APC2 gene.
      explanation: >-
        This author manuscript and PMID:39147584 are the same AJNR study (DOI:10.3174/ajnr.A8364), not independent cohorts. The full-text discussion identifies APC2 as an NSD1 effector in its candidate cortical-migration explanation. Biallelic APC2 disease is distinct from NSD1-related Sotos syndrome; the link remains indirect and model based.
      directness: INDIRECT
  - target: Polymicrogyria
    description: >-
      Disordered neuronal migration and cortical positioning are proposed to contribute to abnormal cortical folding. The imaging study discusses the NSD1–APC2 model as a possible correlate; it does not demonstrate this route in patient cortex or distinguish the mechanism of each malformation subtype.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39147584
      reference_title: 'Sotos Syndrome: Deep Neuroimaging Phenotyping Reveals a High Prevalence of Malformations of Cortical Development.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        These findings have yet to be described to this extent and correspond with recent studies that show that NSD1 participates in brain development and has interactions with other known relevant genetic pathways.
      explanation: >-
        The imaging-study conclusion relates the malformations to NSD1-dependent brain development and candidate pathways; the causal mechanism remains an interpretation, not a measurement in patient cortex.
      directness: INDIRECT
    - reference: url:https://repository.uantwerpen.be/docstore/d%3Airua%3A25028
      reference_title: https://repository.uantwerpen.be/docstore/d%3Airua%3A25028
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        A key downstream effector of NSD1 is the APC2 gene.
      explanation: >-
        This author manuscript and PMID:39147584 are the same AJNR study (DOI:10.3174/ajnr.A8364), not independent cohorts. The full-text discussion identifies APC2 as an NSD1 effector in its candidate cortical-migration explanation. Biallelic APC2 disease is distinct from NSD1-related Sotos syndrome; the link remains indirect and model based.
      directness: INDIRECT
  mechanism_confidence: PROVISIONAL
- name: Impaired Mesendodermal Lineage Differentiation
  description: >-
    Nsd1-deficient mouse embryonic stem cells fail to induce mesendodermal developmental programs normally. Human NSD1-deficient iPSCs also show impaired endodermal and mesodermal commitment. These are cellular models, not observations of malformed organs in patients; their relevance to congenital heart and renal anomalies is a developmental hypothesis.
  biological_scale: CELLULAR
  biological_processes:
  - preferred_term: mesodermal cell differentiation
    term:
      id: GO:0048333
      label: mesodermal cell differentiation
    modifier: DECREASED
  - preferred_term: endodermal cell differentiation
    term:
      id: GO:0035987
      label: endodermal cell differentiation
    modifier: DECREASED
  evidence:
  - reference: PMID:42157059
    reference_title: "NSD1 governs H3K36me2-mediated DNA methylation and drives endo-mesodermal differentiation of human iPSCs."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Notably, the loss of functional NSD1 altered the differentiation potential of iPSCs, with aberrant endodermal and mesodermal lineage commitment."
    explanation: Human cell-based evidence for the lineage-commitment defect claimed by this node.
  - reference: PMID:40118455
    reference_title: "The sotos syndrome gene Nsd1 safeguards developmental gene enhancers poised for transcription by maintaining the precise deposition of histone methylation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We found Nsd1 to be indispensable for the faithful differentiation of mESCs into three primary germ layers, particularly, meso-endodermal cell lineages related to the development of the heart and the skeletal system."
    explanation: Names the affected lineages and the organs they build, which is what makes this node relevant to the cardiac phenotype.
  downstream:
  - target: Congenital Heart Defects
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Failure to activate cardiac lineage regulators is proposed to contribute to congenital heart defects. The mouse stem-cell study explicitly relates its differentiation defects to the clinical cardiac phenotype, but does not reproduce an anatomical human heart defect.
    evidence:
    - reference: PMID:40118455
      reference_title: The sotos syndrome gene Nsd1 safeguards developmental gene enhancers poised for transcription by maintaining the precise deposition of histone methylation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Importantly, the above Nsd1 KO-induced defects largely recapitulate anomalies seen in the Sotos syndrome patients (such as overgrowth, advanced bone age, and congenital heart defects), supporting the relevance of our model system for dissecting the molecular mechanisms underlying pathogenesis of this syndrome.
      explanation: >-
        The authors connect impaired mesendodermal lineage specification with clinical heart defects. Their in vitro system measures differentiation and transcription rather than anatomical malformations, so this is indirect, provisional support.
      directness: INDIRECT
  - target: Renal Anomalies
    description: >-
      Impaired induction of renal developmental regulators, including Lhx1, provides a provisional route from NSD1 loss to abnormal kidney development. Evidence comes from differentiating mouse stem cells; human renal tissue and anatomical mediation remain untested.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:40118455
      reference_title: The sotos syndrome gene Nsd1 safeguards developmental gene enhancers poised for transcription by maintaining the precise deposition of histone methylation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        These above TFs are enriched with those known to control gastrulation and meso-endoderm formation (such as T, Gsc, Eomes, Gata4, Mixl1, Msgn1, and Snai1) (28, 29, 30), along with others reported to direct the organogenesis of various mesoderm-derived tissues such as heart (e.g., Mesp1, Mesp2, Gata6, and Tbx5) (31, 32), kidney (e.g., Lhx1) (33), hematopoietic (e.g., Runx3 and Nfatc2) (34, 35) and skeletal system (e.g., Hand1, Hand2, Twist1, Twist2, Sox9, and Six2) (36).
      explanation: >-
        Nsd1 loss prevents normal induction of developmental regulators including Lhx1. This supports a provisional renal-development route in stem-cell models; the experiment does not produce or explain a specific human kidney malformation.
      directness: INDIRECT
    intermediate_mechanisms:
    - Impaired induction of renal organogenesis regulators including Lhx1
  mechanism_confidence: PROVISIONAL
- name: Reduced NSD1 Tumor-Suppressor Function
  description: >-
    NSD1 loss may reduce transcriptional repression of growth-promoting targets such as MEIS1. NSD1 depletion and restoration alter proliferation in neuroblastoma cells; Sotos lymphoblastoid cells also show reduced NSD1 recruitment and increased MEIS1 expression. These experiments support a proposed tumor-suppressor role, but do not establish the penetrance, second-hit requirements or tumor spectrum of germline NSD1 haploinsufficiency. The reported H3K36/H4K20 changes in this older tumor study were principally trimethylation readouts, distinct from the H3K36 dimethylation mechanism above.
  biological_scale: CELLULAR
  biological_processes:
  - preferred_term: chromatin organization
    term:
      id: GO:0006325
      label: chromatin organization
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:20018718
    reference_title: "Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We also demonstrate that the epigenetic inactivation of NSD1 in transformed cells leads to the specifically diminished methylation of the histone lysine residues H4-K20 and H3-K36. The described phenotype is also observed in Sotos syndrome patients with NSD1 genetic disruption."
    explanation: >-
      Establishes both the chromatin consequence in tumour cells and the explicit
      statement that Sotos patients share it - the bridge this node depends on.
  - reference: PMID:20018718
    reference_title: "Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Furthermore, we show that the restoration of NSD1 expression induces tumor suppressor-like features, such as reduced colony formation density and inhibition of cellular growth."
    explanation: Functional demonstration that NSD1 acts as a growth suppressor in these lineages.
  downstream:
  - target: Neoplasia
    description: >-
      Loss of a context-dependent tumor-suppressor function is proposed to increase susceptibility to some tumors. Somatic cancer-cell findings do not establish all clinical tumors as NSD1-mediated.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: DOI:10.1073/pnas.0906831106
      reference_title: Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Because patients with NSD1 germ-line genetic disruption have an increased risk of developing malignancy before adulthood, including neuroblastoma, Wilms tumors, and hematological malignancies, a tumor-suppressor function for NSD1 might be proposed.
      explanation: >-
        The historical study explicitly proposes a germline tumor-suppressor mechanism and tests NSD1 loss/restoration in sporadic tumor cells. The enumerated historical tumor associations are not used to assert current tumor-specific risks.
      directness: INDIRECT
  mechanism_confidence: PROVISIONAL
- name: Proposed Disruption of Synaptic Development
  description: >-
    Silencing of developmental genes that govern synaptic assembly is proposed to impair neural circuit development. This hypothesis arises from enrichment of downregulated synaptic genes in patient blood and remains untested in Sotos neural tissue.
  biological_scale: CELLULAR
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:35094088
    reference_title: NSD1 mutations deregulate transcription and DNA methylation of bivalent developmental genes in Sotos syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This suggests that cognitive impairment in SS could be caused by the silencing of bivalent genes that orchestrate synaptic assembly, since disrupted synaptic assembly is a feature of many neurodevelopmental disorders (71).
    explanation: >-
      The patient-transcriptome analysis proposes impaired synaptic assembly as a cognitive mechanism; synapses were not directly examined in the sampled blood.
    directness: INDIRECT
  downstream:
  - target: Intellectual Disability
    description: >-
      Impaired formation of developing neural circuits is proposed to contribute to the cognitive developmental phenotype. Human tissue and behavioral mediation remain unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35094088
      reference_title: NSD1 mutations deregulate transcription and DNA methylation of bivalent developmental genes in Sotos syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        This suggests that cognitive impairment in SS could be caused by the silencing of bivalent genes that orchestrate synaptic assembly, since disrupted synaptic assembly is a feature of many neurodevelopmental disorders (71).
      explanation: >-
        The patient-transcriptome analysis proposes impaired synaptic assembly as a cognitive mechanism; synapses were not directly examined in the sampled blood.
      directness: INDIRECT
  - target: Global Developmental Delay
    description: >-
      Impaired formation of developing neural circuits is proposed to contribute to the cognitive developmental phenotype. Human tissue and behavioral mediation remain unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35094088
      reference_title: NSD1 mutations deregulate transcription and DNA methylation of bivalent developmental genes in Sotos syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        This suggests that cognitive impairment in SS could be caused by the silencing of bivalent genes that orchestrate synaptic assembly, since disrupted synaptic assembly is a feature of many neurodevelopmental disorders (71).
      explanation: >-
        The patient-transcriptome analysis proposes impaired synaptic assembly as a cognitive mechanism; synapses were not directly examined in the sampled blood.
      directness: INDIRECT
- name: Dysregulated FGF-MAPK-ERK Signaling
  description: >-
    Patient-derived fibroblasts show altered FGF-MAPK/ERK-related expression and phosphorylation. Reduced kinase activation became significant after excluding one outlier; RASIP1 overexpression in HEK293 cells instead increased a reporter response. The net effect is therefore not represented as a universal RASIP1-driven decrease across tissues.
  biological_scale: CELLULAR
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:23155469
    reference_title: Sotos syndrome is associated with deregulation of the MAPK/ERK-signaling pathway.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In order to elucidate biological pathways explaining how NSD1 haploinsufficiency results in phenotypic features such as overgrowth in SoS a comprehensive study of dermal fibroblasts from SoS patients was performed. We obtained evidence that SoS syndrome is associated with a deregulation of the MAPK/ERK signaling pathway.
    explanation: >-
      The study used fibroblasts from nine NSD1-confirmed patients and nine matched controls, with pathway, knockdown and phosphorylation experiments. The net signaling effect is tissue-dependent.
    directness: INDIRECT
  downstream:
  - target: Altered Growth-Plate Chondrocyte Maturation
    description: >-
      The authors propose that altered MAPK/ERK signaling changes hypertrophic chondrocyte differentiation. This extrapolation from fibroblasts and established growth-plate biology remains provisional.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:23155469
      reference_title: Sotos syndrome is associated with deregulation of the MAPK/ERK-signaling pathway.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        In analogy, we propose that deregulation of the MAPK/ERK pathway in SoS results in altered hypertrophic differentiation of NSD1 expressing chondrocytes and may be a determining factor in statural overgrowth and accelerated skeletal maturation in SoS.
      explanation: >-
        An explicit causal hypothesis links altered signaling to growth-plate differentiation and the two clinical outcomes. Patient growth plates were not studied; normal human growth plates established NSD1 localization.
      directness: INDIRECT
- name: Altered Growth-Plate Chondrocyte Maturation
  description: >-
    Altered FGF-MAPK/ERK signaling is proposed to change hypertrophic chondrocyte differentiation in the epiphyseal growth plate. NSD1 expression was demonstrated in normal human hypertrophic chondrocytes, but altered maturation was not directly measured in Sotos growth plates.
  biological_scale: TISSUE
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:23155469
    reference_title: Sotos syndrome is associated with deregulation of the MAPK/ERK-signaling pathway.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In analogy, we propose that deregulation of the MAPK/ERK pathway in SoS results in altered hypertrophic differentiation of NSD1 expressing chondrocytes and may be a determining factor in statural overgrowth and accelerated skeletal maturation in SoS.
    explanation: >-
      An explicit causal hypothesis links altered signaling to growth-plate differentiation and the two clinical outcomes. Patient growth plates were not studied; normal human growth plates established NSD1 localization.
    directness: INDIRECT
  downstream:
  - target: Tall Stature
    description: >-
      Altered growth-plate maturation is proposed to contribute to statural overgrowth and accelerated skeletal maturation; the quantitative effect in patients is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:23155469
      reference_title: Sotos syndrome is associated with deregulation of the MAPK/ERK-signaling pathway.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        In analogy, we propose that deregulation of the MAPK/ERK pathway in SoS results in altered hypertrophic differentiation of NSD1 expressing chondrocytes and may be a determining factor in statural overgrowth and accelerated skeletal maturation in SoS.
      explanation: >-
        An explicit causal hypothesis links altered signaling to growth-plate differentiation and the two clinical outcomes. Patient growth plates were not studied; normal human growth plates established NSD1 localization.
      directness: INDIRECT
  - target: Childhood Overgrowth
    description: >-
      Altered growth-plate maturation is proposed to contribute to statural overgrowth and accelerated skeletal maturation; the quantitative effect in patients is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:23155469
      reference_title: Sotos syndrome is associated with deregulation of the MAPK/ERK-signaling pathway.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        In analogy, we propose that deregulation of the MAPK/ERK pathway in SoS results in altered hypertrophic differentiation of NSD1 expressing chondrocytes and may be a determining factor in statural overgrowth and accelerated skeletal maturation in SoS.
      explanation: >-
        An explicit causal hypothesis links altered signaling to growth-plate differentiation and the two clinical outcomes. Patient growth plates were not studied; normal human growth plates established NSD1 localization.
      directness: INDIRECT
  - target: Advanced Bone Age
    description: >-
      Altered growth-plate maturation is proposed to contribute to statural overgrowth and accelerated skeletal maturation; the quantitative effect in patients is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:23155469
      reference_title: Sotos syndrome is associated with deregulation of the MAPK/ERK-signaling pathway.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        In analogy, we propose that deregulation of the MAPK/ERK pathway in SoS results in altered hypertrophic differentiation of NSD1 expressing chondrocytes and may be a determining factor in statural overgrowth and accelerated skeletal maturation in SoS.
      explanation: >-
        An explicit causal hypothesis links altered signaling to growth-plate differentiation and the two clinical outcomes. Patient growth plates were not studied; normal human growth plates established NSD1 localization.
      directness: INDIRECT
- name: Impaired Sucking and Swallowing
  description: >-
    Difficulty with sucking and swallowing compromises oral feeding in affected infants. Clinical reports support the feeding consequence but do not establish a specific NSD1-dependent neural or muscular route.
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  evidence:
  - reference: PMID:17825104
    reference_title: Sotos syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sucking and swallowing difficulties need adjustments of baby food. Alternate methods of feeding may need to be considered such as the use of a nasogastric tube.
    explanation: >-
      The review documents functional oral feeding impairment requiring altered feeding; its molecular cause is not localized.
  downstream:
  - target: Feeding Difficulties
    description: >-
      Impaired sucking and swallowing limit effective oral intake and can necessitate assisted feeding.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:17825104
      reference_title: Sotos syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Sucking and swallowing difficulties need adjustments of baby food. Alternate methods of feeding may need to be considered such as the use of a nasogastric tube.
      explanation: >-
        The review documents functional oral feeding impairment requiring altered feeding; its molecular cause is not localized.
phenotypes:
- category: Craniofacial
  name: Distinctive Facial Appearance
  description: >-
    The characteristic facial gestalt includes a broad prominent forehead, dolichocephaly, sparse frontotemporal hair, downslanted palpebral fissures, malar flushing, a long narrow face and tall chin. The gestalt is especially recognizable in early childhood and changes with age. The reported frequency of at least 90% applies to the overall gestalt, not to each component.
  phenotype_term:
    preferred_term: Characteristic Sotos facial gestalt
    term:
      id: HP:0001999
      label: Abnormal facial shape
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:20301652
    reference_title: Sotos Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sotos syndrome is characterized by a distinctive facial appearance (broad, prominent forehead with a dolichocephalic head shape, sparse frontotemporal hair, downslanting palpebral fissures, malar flushing, long and narrow face, tall chin); learning disability (early developmental delay, mild-to-severe intellectual impairment); and overgrowth (height and/or head circumference ≥2 SD above the mean).
    explanation: >-
      The complete clinical-characteristics sentence identifies the facial finding in Sotos syndrome without transferring the overall gestalt frequency to an individual component.
  - reference: PMID:15942875
    reference_title: "Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Facial dysmorphism, learning disability, and childhood overgrowth were present in 90% of the individuals."
    explanation: >-
      Supports the VERY_FREQUENT band with a cohort figure for the cardinal triad
      taken together.
  - reference: PMID:31479583
    reference_title: "The phenotype of Sotos syndrome in adulthood: A review of 44 individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is a distinctive facial appearance in adults with a tall, square, prominent chin."
    explanation: Establishes that the gestalt persists into adulthood in a recognisable, altered form.

- category: Craniofacial
  name: Sparse Frontotemporal Hair
  description: >-
    Sparse scalp hair is especially apparent in the frontotemporal region.
  phenotype_term:
    preferred_term: Sparse frontotemporal scalp hair
    term:
      id: HP:0002209
      label: Sparse scalp hair
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The head is dolichocephalic and the forehead broad and prominent. Often the hair in the frontotemporal region is sparse. The palpebral fissures are usually downslanting.
    explanation: >-
      Describes the individual craniofacial observations; the frequency of the complete gestalt cannot be assigned to each finding.
- category: Craniofacial
  name: Downslanting Palpebral Fissures
  phenotype_term:
    preferred_term: Downslanting palpebral fissures
    term:
      id: HP:0000494
      label: Downslanted palpebral fissures
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The head is dolichocephalic and the forehead broad and prominent. Often the hair in the frontotemporal region is sparse. The palpebral fissures are usually downslanting.
    explanation: >-
      Describes the individual craniofacial observations; the frequency of the complete gestalt cannot be assigned to each finding.
  description: >-
    The lateral canthi lie below the medial canthi, producing the characteristic downslanting fissures.
- category: Growth
  name: Childhood Overgrowth
  description: >-
    Childhood overgrowth is defined by height and/or head circumference at least two standard deviations above age- and sex-matched norms. The combined endpoint occurs in about 90% of NSD1-positive individuals; it does not establish the frequency of tall stature alone. Height may approach the normal range in adulthood, but the adult distribution is broad and macrocephaly often persists.
  phenotype_term:
    preferred_term: Childhood overgrowth
    term:
      id: HP:0001548
      label: Overgrowth
  frequency: VERY_FREQUENT
  diagnostic: true
  subtypes:
  - Intragenic NSD1 Variant
  - 5q35 Microdeletion
  evidence:
  - reference: PMID:20301652
    reference_title: Sotos Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sotos syndrome is characterized by a distinctive facial appearance (broad, prominent forehead with a dolichocephalic head shape, sparse frontotemporal hair, downslanting palpebral fissures, malar flushing, long and narrow face, tall chin); learning disability (early developmental delay, mild-to-severe intellectual impairment); and overgrowth (height and/or head circumference ≥2 SD above the mean).
    explanation: >-
      Defines the combined height and/or head-circumference overgrowth endpoint; this is not a frequency estimate for tall stature alone.
  - reference: PMID:15942875
    reference_title: "Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, both the height and head circumference of 10% of the individuals were within the normal range, indicating that overgrowth is not obligatory for the diagnosis of Sotos syndrome."
    explanation: >-
      Bounds the claim: a cardinal feature that is nonetheless absent in a tenth of
      molecularly confirmed cases.
  - reference: PMID:31479583
    reference_title: 'The phenotype of Sotos syndrome in adulthood: A review of 44 individuals.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In our cohort, median height in adult women is +1.9 SD and men +0.5 SD.
    explanation: >-
      Median adult heights in the 44-person NSD1 cohort do not establish that all adults have normal height.
- category: Growth
  name: Macrocephaly
  description: >-
    Increased head circumference is a cardinal growth feature and often persists after height excess attenuates. The VERY_FREQUENT band is based on 51/57 (89%) molecularly confirmed Korean children at their last visit (mean age 8.1 years), rather than the combined height/head-size overgrowth endpoint; age and referral ascertainment limit generalization.
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  evidence:
  - reference: PMID:17825104
    reference_title: "Sotos syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sotos syndrome is an overgrowth condition characterized by cardinal features including excessive growth during childhood, macrocephaly, distinctive facial gestalt and various degrees of learning difficulty, and associated with variable minor features."
    explanation: Names macrocephaly among the cardinal features in a clinical review.
  - reference: PMID:39494594
    reference_title: "Deciphering Growth Patterns in Korean Children With Sotos Syndrome Through the Development of a Disease-Specific Growth Chart."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Females with SS displayed higher height before 17.0, greater weight before 10.5, and larger head circumference before 12.0 compared to controls."
    explanation: Anthropometric confirmation of increased head circumference against matched controls.

  - reference: PMID:39494594
    reference_title: Deciphering Growth Patterns in Korean Children With Sotos Syndrome Through the Development of a Disease-Specific Growth Chart.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At their last visit (8.1 ± 5.6 years), tall stature and macrocephaly were observed in 23 (40%), and 51 (89%) patients, respectively.
    explanation: >-
      Macrocephaly in 51/57 patients (89%) supports VERY_FREQUENT (80–99%) in this molecularly confirmed Korean cohort at last visit (8.1 ± 5.6 years). The 57 patients, not the 339 repeated anthropometric measurements, form the denominator. Tertiary-center ascertainment and age limit generalization.
  frequency: VERY_FREQUENT
- category: Skeletal
  name: Advanced Bone Age
  description: >-
    Accelerated skeletal maturation is commonly identified before puberty. GeneReviews summarizes 75–80% of prepubertal children, while the Korean study found advancement of more than two years in 8/20 males and 1/13 females assessed at their last visit. Age, assessment threshold and ascertainment differ, so a single lifetime frequency band is not assigned.
  phenotype_term:
    preferred_term: Advanced bone age
    term:
      id: HP:0005616
      label: Accelerated skeletal maturation
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Bone age often reflects the accelerated growth velocity and is advanced in 75%-80% of prepubertal children.
    explanation: >-
      This estimate is explicitly restricted to prepubertal children.
  - reference: PMID:39494594
    reference_title: Deciphering Growth Patterns in Korean Children With Sotos Syndrome Through the Development of a Disease-Specific Growth Chart.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among 33 children (20 males and 13 females) for whom BA was evaluated at their last visit, BA was advanced than CA in eight (40%) males (13.0 ± 2.6 years vs. 10.5 ± 2.5 years, p = 0.011) and one (8%) female (9.0 years vs. 5.6 years).
    explanation: >-
      The source supplies the evaluated denominators and timing. Its two-year threshold differs from some historical definitions.
- category: Neurologic
  name: Intellectual Disability
  description: >-
    Intellectual impairment ranges widely; some individuals have average intellectual functioning. Developmental delay in young children and broader learning difficulties are assessed separately. Microdeletions are associated with greater severity at group level, but intellectual disability also occurs with intragenic variants.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  diagnostic: true
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most individuals with Sotos syndrome have some degree of intellectual impairment. The spectrum is broad and ranges from a mild learning disability (affected individuals would be expected to live independently and have their own families) to a severe learning disability (affected individuals would be unlikely to live independently as adults).
    explanation: >-
      Supports the broad clinical range, without using a mixed Sotos–Malan developmental-delay/intellectual-disability percentage to quantify intellectual disability alone.
  - reference: PMID:15942875
    reference_title: "Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with microdeletions had less-prominent overgrowth (P = .0003) and more-severe learning disability (P = 3 x 10(-9)) than patients with mutations."
    explanation: The primary genotype-phenotype contrast justifying curation of the two molecular classes as subtypes.
- category: Behavioral
  name: Autism Spectrum Behaviour
  description: >-
    Autistic symptoms are common. In a convenience sample of 33 children, 72.7% had mild-to-moderate ADOS-2 symptoms; this is neither a population prevalence nor the proportion meeting a clinical ASD diagnosis. A nonsignificant difference in SRS scores against an ASD comparison group does not establish equivalence.
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  evidence:
  - reference: PMID:38150933
    reference_title: "Short report: Autistic symptoms in Sotos syndrome, preliminary results from a case-control study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "72.7% of SoS children presented mild to moderate levels of ASD symptoms as measured by the ADOS-2."
    explanation: >-
      In the convenience sample of 33 Sotos children, 72.7% had mild-to-moderate ADOS-2 symptoms. This measures symptom severity in the sample, not population prevalence or the proportion with a clinical ASD diagnosis.
  - reference: PMID:38150933
    reference_title: "Short report: Autistic symptoms in Sotos syndrome, preliminary results from a case-control study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "No statistically significant differences emerged between the SoS and ASD groups within the SRS total score domain (p = 0.95)."
    explanation: >-
      The SRS total-score comparison detected no difference between the matched Sotos and idiopathic-ASD groups (p = 0.95). A nonsignificant difference neither proves equivalent symptom burden nor estimates ASD prevalence.
  - reference: PMID:38150933
    reference_title: "Short report: Autistic symptoms in Sotos syndrome, preliminary results from a case-control study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Oneway ANOVA analysis showed that SoS individuals presenting lower IQ demonstrated higher ASD symptom's level (p = 0.01)."
    explanation: >-
      Within the Sotos sample, lower IQ was associated with higher ASD symptom levels (ANOVA p = 0.01). This is a cognitive-severity association, not evidence that lower IQ causes autistic behavior.
  - reference: PMID:38673476
    reference_title: "Neuropsychiatric Aspects of Sotos Syndrome: Explorative Review Building Multidisciplinary Bridges in Clinical Practice."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Children express autistic behavior, ADHD, anxiety based on phobias, and early bedtime-wake times."
    explanation: >-
      This narrative review synthesizes reported autistic behavior among the neuropsychiatric features of Sotos syndrome. It contributes clinical context rather than a new cohort count or prevalence estimate.


- category: Neurologic
  name: Seizures
  description: >-
    Seizures are listed among the major features of Sotos syndrome and warrant
    specialist referral when present.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:17825104
    reference_title: "Sotos syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other inconstant clinical abnormalities include scoliosis, cardiac and genitourinary anomalies, seizures and brisk deep tendon reflexes."
    explanation: >-
      Records seizures as an established but inconstant feature - which is why no
      frequency band is set here.

- category: Neurologic
  name: Ventriculomegaly
  description: >-
    Ventricular enlargement, particularly involving the trigones and occipital horns, is a characteristic structural brain finding. It does not by itself establish raised intracranial pressure.
  phenotype_term:
    preferred_term: Ventriculomegaly
    term:
      id: HP:0002119
      label: Ventriculomegaly
  evidence:
  - reference: PMID:39147584
    reference_title: 'Sotos Syndrome: Deep Neuroimaging Phenotyping Reveals a High Prevalence of Malformations of Cortical Development.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Macrocephaly, ventriculomegaly, and corpus callosal dysmorphism are typical neuroimaging features that have been described in the medical literature.
    explanation: >-
      Supports actual structural findings, replacing a treatment recommendation as the evidence for their occurrence.
- category: Cardiovascular
  name: Congenital Heart Defects
  description: >-
    Congenital septal, ductal and valvular abnormalities occur. A tertiary-center cohort found cardiac abnormalities in 27/45 patients, including congenital malformations, aortic dilation and ventricular hypertrabeculation. That broader 60% endpoint and the center’s cardiology referral profile do not establish a general frequency of congenital malformations alone. The small deletion subgroup does not establish equivalence of genotype-specific risks.
  phenotype_term:
    preferred_term: Congenital heart defect
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  evidence:
  - reference: PMID:38535015
    reference_title: "Congenital Heart Defects in Patients with Molecularly Confirmed Sotos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prevalence of heart defects (HDs) in individuals with Sotos syndrome is estimated to be around 15-40%. Septal defects and patent ductus arteriosus are the most commonly diagnosed malformations, but complex defects have also been reported."
    explanation: Gives the literature frequency range and the commonest anatomic types.
  - reference: PMID:38535015
    reference_title: "Congenital Heart Defects in Patients with Molecularly Confirmed Sotos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of 27/45 (60.0%) of the patients had heart defects, isolated or combined with other defects, including septal defects (12 patients), aortic anomalies (9 patients), mitral valve and/or tricuspid valve dysplasia/insufficiency (1 patient), patent ductus arteriosus (3 patients), left ventricular non-compaction/hypertrabeculated left ventricle (LV) (4 patients), aortic coarctation (1 patient), aortopulmonary window (1 patient), and pulmonary valve anomalies (3 patients)."
    explanation: The single-centre figure and the anatomic breakdown quoted in the description.
  - reference: PMID:38535015
    reference_title: "Congenital Heart Defects in Patients with Molecularly Confirmed Sotos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prevalences of HD in the two subgroups (deletion versus intragenic mutation) were similar (66.7% (4/6) in the deletion group versus 58.91% (23/39) in the intragenic variant group)."
    explanation: >-
      Supports the explicit negative claim that cardiac risk does not separate the
      two molecular subtypes.

- category: Skeletal
  name: Scoliosis
  description: >-
    Scoliosis occurs with both intragenic variants and microdeletions. It was present in 26/63 consecutive clinically diagnosed patients in one series; 55 had identified NSD1 abnormalities. All ten progressive cases had microdeletions, supporting a cohort-specific severity association rather than an exclusive subtype restriction.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  frequency: FREQUENT
  evidence:
  - reference: PMID:33332788
    reference_title: "The Association of Scoliosis and NSD1 Gene Deletion in Sotos Syndrome Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Scoliosis was observed in 26 patients (41%), with a significantly higher ratio of microdeletions than mutations. The 10 patients with progressive scoliosis all had NSD1 microdeletions."
    explanation: >-
      Carries both the frequency band and the genotype association, including the
      complete concordance of progressive cases with the deletion class.

  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Present in about 30% of affected individuals, scoliosis is rarely severe enough to require bracing or surgery.
    explanation: >-
      The clinical synthesis supports a FREQUENT band independently of the selected scoliosis series. Severity varies and can be greater in deletion cohorts.
- category: Musculoskeletal
  name: Joint Hyperlaxity
  description: >-
    Joint hyperlaxity, with or without pes planus, is listed among the major
    features.
  phenotype_term:
    preferred_term: Joint hyperlaxity
    term:
      id: HP:0001382
      label: Joint hypermobility
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Joint laxity is reported in at least 20% of individuals with Sotos syndrome.
    explanation: >-
      The lower-bound estimate supports joint hypermobility but does not define a bounded frequency category.
- category: Renal
  name: Renal Anomalies
  description: >-
    Structural renal anomalies include horseshoe kidney, cystic lesions and abnormal kidney size. Vesicoureteral reflux is represented separately because reflux does not necessarily imply a renal morphological abnormality.
  phenotype_term:
    preferred_term: Renal structural anomaly
    term:
      id: HP:0012210
      label: Abnormal renal morphology
  evidence:
  - reference: PMID:39494594
    reference_title: Deciphering Growth Patterns in Korean Children With Sotos Syndrome Through the Development of a Disease-Specific Growth Chart.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Renal anomalies such as horseshoe kidney, cystic lesion, renomegaly, small kidney size, or ureteropelvic junction obstruction were observed in six (11%) patients.
    explanation: >-
      Documents renal structural findings in the molecularly confirmed Korean cohort; the aggregate also includes junction obstruction and does not quantify each lesion.
- category: Neonatal
  name: Neonatal Hypotonia
  description: >-
    Hypotonia in the newborn period is one of the neonatal complications that
    prompts diagnostic suspicion, alongside feeding difficulty.
  phenotype_term:
    preferred_term: Neonatal hypotonia
    term:
      id: HP:0001319
      label: Neonatal hypotonia
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neonates may have jaundice (~65%), hypotonia (~75%), and poor feeding (~70%). These complications tend to resolve spontaneously, but in a small minority intervention is required.
    explanation: >-
      Provides separate neonatal estimates for each named finding, replacing management recommendations and selected otolaryngologic reports as frequency evidence.
  frequency: FREQUENT
  sequelae:
  - target: Motor Delay
    description: >-
      Low muscle tone contributes to delayed motor milestones alongside large body size and poor coordination; this does not explain all developmental domains.
    causal_link_type: DIRECT
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
      reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Delay of early developmental milestones is very common, and motor skills may appear particularly delayed because of a child's large size, hypotonia, and poor coordination.
      explanation: >-
        The clinical source explicitly identifies hypotonia as a contributor to motor delay.
- category: Gastrointestinal
  name: Feeding Difficulties
  description: >-
    Poor feeding affects approximately 70% of neonates in the clinical synthesis. Sucking and swallowing difficulty may require feeding support; this neonatal estimate is not a lifetime feeding-disorder prevalence.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  frequency: FREQUENT
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neonates may have jaundice (~65%), hypotonia (~75%), and poor feeding (~70%). These complications tend to resolve spontaneously, but in a small minority intervention is required.
    explanation: >-
      Provides separate neonatal estimates for each named finding, replacing management recommendations and selected otolaryngologic reports as frequency evidence.
- category: Neonatal
  name: Neonatal Jaundice
  description: >-
    Jaundice is reported in approximately 65% of neonates. The reviewed source does not establish prolonged jaundice, so the general jaundice term is retained with neonatal timing in the description.
  phenotype_term:
    preferred_term: Neonatal jaundice
    term:
      id: HP:0000952
      label: Jaundice
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neonates may have jaundice (~65%), hypotonia (~75%), and poor feeding (~70%). These complications tend to resolve spontaneously, but in a small minority intervention is required.
    explanation: >-
      Provides separate neonatal estimates for each named finding, replacing management recommendations and selected otolaryngologic reports as frequency evidence.
  frequency: FREQUENT
- category: Craniofacial
  name: High Arched Palate
  description: >-
    A high arched palate is among the head-and-neck congenital malformations
    identified across the reported literature.
  phenotype_term:
    preferred_term: High arched palate
    term:
      id: HP:0000218
      label: High palate
  evidence:
  - reference: PMID:33640723
    reference_title: 'The otolaryngologic manifestations of Sotos syndrome 1: A systematic review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our review found multiple otolaryngologic conditions present in patients with SOTOS1, including hearing loss, otitis, hyperthyroidism, hypothyroidism, head & neck tumors, congenital malformations (high arched palate, cleft lip and palate, macroglossia), feeding difficulties, respiratory difficulties, and speech disorders.
    explanation: >-
      Explicitly includes high palate; the combined head-and-neck-malformation percentage does not quantify high palate.
  sequelae:
  - target: Sleep Disturbance
    description: High palatal anatomy is proposed as one contributor to the sleep-related breathing component of disturbed sleep. This does not explain early sleep timing or all sleep-transition problems; no patient-level palatal mediation was tested.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:38434199
      reference_title: Sleep disturbances and behavioral symptoms in pediatric Sotos syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The most commonly identified sleep problems were SBD and SWTD, both occurring in 26.3%, possibly linked to the high incidence of congenital malformations of the neck and head in this population, such as general hypotonia, including weakness in the muscles of swallowing, macroglossia, high arched palates, alveolar cleft and cleft lip, and palate, which could contribute to respiratory and feeding difficulties (34).
      explanation: Frattale and colleagues explicitly propose head/neck anatomy, including high palate, as a contributor to sleep breathing problems. Sleep abnormalities were questionnaire based, and the study lacked a comprehensive physical examination to correlate anatomy with sleep scores; this is a provisional clinical hypothesis.
      directness: INDIRECT
- category: Otologic
  name: Hearing Impairment
  description: >-
    Hearing loss can develop in childhood or adulthood. Conductive loss from chronic otitis is represented separately; broader hearing impairment is retained because adult reports do not specify the type in every affected person.
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  evidence:
  - reference: PMID:31479583
    reference_title: 'The phenotype of Sotos syndrome in adulthood: A review of 44 individuals.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Reassuringly, adults with Sotos syndrome are generally healthy with few new medical issues; however, lymphedema, poor dentition, hearing loss, contractures and tremor have developed in a small number of individuals.
    explanation: >-
      Documents hearing loss in molecularly confirmed adults. The otolaryngologic review’s 14% covers all otologic conditions and is not a hearing-loss frequency.
- category: Neoplastic
  name: Neoplasia
  description: >-
    Tumors are uncommon and heterogeneous. Historical reviews estimate a tumor frequency below 5%; contemporary GeneReviews estimates approximately 3%. Reported benign tumors and hamartomas must not be described collectively as malignancies. The germline tumor-susceptibility mechanism remains provisional.
  phenotype_term:
    preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
  frequency: VERY_RARE
  evidence:
  - reference: PMID:17825104
    reference_title: Sotos syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cohen reviewed the reported neoplasias critically and suggested a tumor frequency in patients with Sotos syndrome of about 3.9% (more than in the general population) [29].
    explanation: >-
      A historical clinical synthesis supports a frequency below 5%, with limitations of reported-case ascertainment.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tumors occur in approximately 3% of persons with Sotos syndrome.
    explanation: >-
      The current clinical synthesis supports the low overall tumor frequency; it does not establish specific risks for every reported tumor.
- category: Behavioral
  name: Attention Deficit Hyperactivity Disorder
  description: >-
    ADHD was diagnosed in 8/57 (14%) molecularly confirmed children during follow-up in the Korean tertiary-center series, supporting a cohort-based OCCASIONAL band. Diagnostic ascertainment and the young age distribution limit inference about lifetime prevalence.
  phenotype_term:
    preferred_term: Attention deficit hyperactivity disorder
    term:
      id: HP:0007018
      label: Attention deficit hyperactivity disorder
  evidence:
  - reference: PMID:39494594
    reference_title: Deciphering Growth Patterns in Korean Children With Sotos Syndrome Through the Development of a Disease-Specific Growth Chart.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two (4%) patients were diagnosed with autism spectrum disorder, and eight (14%) were diagnosed with attention deficit hyperactivity disorder.
    explanation: >-
      Eight ADHD diagnoses among 57 molecularly confirmed NSD1-related patients (14%) support OCCASIONAL (5–29%) in this retrospective Korean series. Diagnoses were recorded during follow-up, with last-visit mean age 8.1 years; this is not standardized lifetime ascertainment or a mixed NSD1–NFIX denominator.
  frequency: OCCASIONAL
- category: Behavioral
  name: Anxiety
  description: >-
    Anxiety, phobias and difficulty with new social situations are reported. Available studies use heterogeneous assessments and do not establish a general frequency.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:38673476
    reference_title: 'Neuropsychiatric Aspects of Sotos Syndrome: Explorative Review Building Multidisciplinary Bridges in Clinical Practice.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Children express autistic behavior, ADHD, anxiety based on phobias, and early bedtime-wake times.
    explanation: >-
      Supports anxiety as a reported feature; the former 35.5% combined impulsivity/anxiety endpoint in a mixed NSD1–NFIX cohort does not quantify anxiety alone.
- category: Ophthalmological
  name: Ophthalmological Abnormalities
  description: >-
    Ocular abnormalities include strabismus and refractive errors such as hypermetropia and astigmatism, represented separately. Broader ocular findings were reported in 29/77 individuals in a molecularly confirmed MRI-selected cohort. The selected denominator does not establish the frequency of individual eye findings. Correctable visual problems warrant specific assessment rather than being attributed to developmental disability alone.
  phenotype_term:
    preferred_term: Ophthalmological abnormality
    term:
      id: HP:0000478
      label: Abnormality of the eye
  evidence:
  - reference: url:https://repository.uantwerpen.be/docstore/d%3Airua%3A25028
    reference_title: https://repository.uantwerpen.be/docstore/d%3Airua%3A25028
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Ophthalmological findings were present in 37.6%.
    explanation: >-
      This author manuscript and PMID:39147584 are the same AJNR study (DOI:10.3174/ajnr.A8364), not independent cohorts. The full paper reports ocular findings in the genetically confirmed 77-person MRI-selected cohort (29/77, rounded to 37.7% in its table). It does not support assigning the 71% mixed NSD1/NFIX cohort estimate to Sotos syndrome alone.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      The following features are seen in ≥2% and <15% of individuals with Sotos syndrome ...:
      • Ocular. Astigmatism, cataracts, myopia, strabismus, nystagmus, hypermetropia
    explanation: >-
      The full introductory proposition and ocular list identify these findings in Sotos syndrome. The reported interval crosses repository frequency-band boundaries, so no individual band is assigned.
- name: Broad Forehead
  category: Head and Neck
  description: >-
    Increased forehead width is a component of the characteristic facial appearance.
  phenotype_term:
    preferred_term: Broad forehead
    term:
      id: HP:0000337
      label: Broad forehead
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The head is dolichocephalic and the forehead broad and prominent. Often the hair in the frontotemporal region is sparse. The palpebral fissures are usually downslanting.
    explanation: >-
      Describes the individual craniofacial observations; the frequency of the complete gestalt cannot be assigned to each finding.
- name: Dolichocephaly
  category: Head and Neck
  description: >-
    An elongated head shape is distinct from increased head circumference.
  phenotype_term:
    preferred_term: Dolichocephaly
    term:
      id: HP:0000268
      label: Dolichocephaly
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The head is dolichocephalic and the forehead broad and prominent. Often the hair in the frontotemporal region is sparse. The palpebral fissures are usually downslanting.
    explanation: >-
      Describes the individual craniofacial observations; the frequency of the complete gestalt cannot be assigned to each finding.
- name: Long Face
  category: Head and Neck
  description: >-
    The face becomes long and narrow with age; length and width are separate dimensions.
  phenotype_term:
    preferred_term: Long face
    term:
      id: HP:0000276
      label: Long face
  evidence:
  - reference: PMID:20301652
    reference_title: Sotos Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sotos syndrome is characterized by a distinctive facial appearance (broad, prominent forehead with a dolichocephalic head shape, sparse frontotemporal hair, downslanting palpebral fissures, malar flushing, long and narrow face, tall chin); learning disability (early developmental delay, mild-to-severe intellectual impairment); and overgrowth (height and/or head circumference ≥2 SD above the mean).
    explanation: >-
      The complete clinical-characteristics sentence identifies the facial finding in Sotos syndrome without transferring the overall gestalt frequency to an individual component.
- name: Tall Chin
  category: Head and Neck
  description: >-
    Increased chin height is characteristic, with broadening of the chin in adulthood.
  phenotype_term:
    preferred_term: Tall chin
    term:
      id: HP:0400000
      label: Tall chin
  evidence:
  - reference: PMID:20301652
    reference_title: Sotos Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sotos syndrome is characterized by a distinctive facial appearance (broad, prominent forehead with a dolichocephalic head shape, sparse frontotemporal hair, downslanting palpebral fissures, malar flushing, long and narrow face, tall chin); learning disability (early developmental delay, mild-to-severe intellectual impairment); and overgrowth (height and/or head circumference ≥2 SD above the mean).
    explanation: >-
      The complete clinical-characteristics sentence identifies the facial finding in Sotos syndrome without transferring the overall gestalt frequency to an individual component.
  - reference: PMID:31479583
    reference_title: "The phenotype of Sotos syndrome in adulthood: A review of 44 individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is a distinctive facial appearance in adults with a tall, square, prominent chin."
    explanation: Establishes that the gestalt persists into adulthood in a recognisable, altered form.

- name: Tall Stature
  category: Growth
  description: >-
    Tall stature is particularly prominent during childhood. It occurred in 23/57 patients at the last visit in the Korean cohort; height can normalize in adulthood.
  phenotype_term:
    preferred_term: Tall stature
    term:
      id: HP:0000098
      label: Tall stature
  evidence:
  - reference: PMID:39494594
    reference_title: Deciphering Growth Patterns in Korean Children With Sotos Syndrome Through the Development of a Disease-Specific Growth Chart.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At their last visit (8.1 ± 5.6 years), tall stature and macrocephaly were observed in 23 (40%), and 51 (89%) patients, respectively.
    explanation: >-
      These separate endpoints were recorded in 57 molecularly confirmed Korean patients at their last visit; the age distribution and tertiary-center ascertainment limit generalization.
  - reference: PMID:31479583
    reference_title: 'The phenotype of Sotos syndrome in adulthood: A review of 44 individuals.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In our cohort, median height in adult women is +1.9 SD and men +0.5 SD.
    explanation: >-
      Median adult heights in the 44-person NSD1 cohort do not establish that all adults have normal height.
- name: Global Developmental Delay
  category: Neurologic
  description: >-
    Early delay affects multiple developmental domains and may precede a later diagnosis of intellectual disability.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:35094088
    reference_title: NSD1 mutations deregulate transcription and DNA methylation of bivalent developmental genes in Sotos syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinically, SS is primarily characterized by generalized overgrowth including tall stature and macrocephaly, global developmental delay often culminating in intellectual disability, distinct facial features, as well supranuclear hypotonia (7).
    explanation: >-
      Explicitly distinguishes early global developmental delay from later intellectual disability in NSD1-related Sotos syndrome.
- name: Motor Delay
  category: Neurologic
  description: >-
    Motor milestones are delayed, with large body size, hypotonia and poor coordination contributing.
  phenotype_term:
    preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Delay of early developmental milestones is very common, and motor skills may appear particularly delayed because of a child's large size, hypotonia, and poor coordination.
    explanation: >-
      The clinical synthesis identifies contributors to delayed motor milestones; it does not attribute all cognitive or language delay to hypotonia.
- name: Delayed Speech and Language Development
  category: Neurologic
  description: >-
    Expressive language development is often delayed. This does not imply that language impairment is disproportionately severe relative to general intellectual functioning.
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:17825104
    reference_title: Sotos syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Delay in expressive language and motor development during the infancy is particularly common.
    explanation: >-
      Documents delayed expressive language and motor development in the clinical review.
- name: Dysgyria
  category: Neurologic
  description: >-
    Abnormal cortical gyration was frequent in a selected MRI cohort; the anatomical distribution varied.
  phenotype_term:
    preferred_term: Dysgyria
    term:
      id: HP:0032398
      label: Dysgyria
  evidence:
  - reference: PMID:39147584
    reference_title: 'Sotos Syndrome: Deep Neuroimaging Phenotyping Reveals a High Prevalence of Malformations of Cortical Development.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In addition to previously described features, malformations of cortical development were identified in most patients (95.0%), typically dysgyria (92.2%) and polymicrogyria (22.1%), varying in location and distribution.
    explanation: >-
      These proportions describe 77 genetically diagnosed individuals selected for retrospective MRI review; they are not assigned as population frequencies.
  sequelae:
  - target: Hippocampal Malrotation
    description: >-
      Regional temporal cortical dysgyria may alter adjacent hippocampal folding, as proposed by the imaging study. This remains a developmental hypothesis rather than a demonstrated causal relation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39147584
      reference_title: 'Sotos Syndrome: Deep Neuroimaging Phenotyping Reveals a High Prevalence of Malformations of Cortical Development.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Incomplete rotation of the hippocampus was observed in 50.6% of patients and was associated with other imaging findings, in particular with dysgyria (100% versus 84.2%, P = .012).
      explanation: >-
        The abstract reports the dysgyria association in the same 77-person study. This is observational support only; the separate full-text item supplies the authors' developmental hypothesis.
      directness: INDIRECT
    - reference: url:https://repository.uantwerpen.be/docstore/d%3Airua%3A25028
      reference_title: https://repository.uantwerpen.be/docstore/d%3Airua%3A25028
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        suggesting that it may be secondary to regional temporal dysgyria from abnormal cortical folding.
      explanation: >-
        This author manuscript and PMID:39147584 are the same AJNR study (DOI:10.3174/ajnr.A8364), not independent cohorts. In this sentence, “it” refers to incomplete hippocampal rotation. This full-text clause explicitly proposes the regional temporal-dysgyria hypothesis; the association alone does not establish causation, and incomplete rotation can be a normal variant.
      directness: INDIRECT
- name: Polymicrogyria
  category: Neurologic
  description: >-
    Polymicrogyria was identified in 22.1% of the selected 77-person MRI cohort.
  phenotype_term:
    preferred_term: Polymicrogyria
    term:
      id: HP:0002126
      label: Polymicrogyria
  evidence:
  - reference: PMID:39147584
    reference_title: 'Sotos Syndrome: Deep Neuroimaging Phenotyping Reveals a High Prevalence of Malformations of Cortical Development.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In addition to previously described features, malformations of cortical development were identified in most patients (95.0%), typically dysgyria (92.2%) and polymicrogyria (22.1%), varying in location and distribution.
    explanation: >-
      These proportions describe 77 genetically diagnosed individuals selected for retrospective MRI review; they are not assigned as population frequencies.
- name: Recurrent Otitis Media
  category: Ear
  description: >-
    Recurrent middle-ear inflammation can impair sound conduction.
  phenotype_term:
    preferred_term: Recurrent otitis media
    term:
      id: HP:0000403
      label: Recurrent otitis media
  evidence:
  - reference: PMID:17825104
    reference_title: Sotos syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Recurrent upper respiratory infections and otitis media are frequent, leading to some degree of conductive hearing loss.
    explanation: >-
      The clinical review explicitly connects recurrent otitis media to conductive hearing loss.
  sequelae:
  - target: Conductive Hearing Impairment
    description: >-
      Middle-ear disease impairs transmission of sound, producing conductive hearing loss.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:17825104
      reference_title: Sotos syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Recurrent upper respiratory infections and otitis media are frequent, leading to some degree of conductive hearing loss.
      explanation: >-
        The clinical review explicitly connects recurrent otitis media to conductive hearing loss.
  - target: Hearing Impairment
    description: >-
      Chronic otitis media can cause the conductive component of hearing impairment. This relation does not explain unspecified adult-onset or sensorineural hearing loss.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:17825104
      reference_title: Sotos syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Recurrent upper respiratory infections and otitis media are frequent, leading to some degree of conductive hearing loss.
      explanation: >-
        The clinical review explicitly connects recurrent otitis media to conductive hearing loss.
- name: Conductive Hearing Impairment
  category: Ear
  description: >-
    Conductive hearing loss may result from recurrent or chronic otitis media.
  phenotype_term:
    preferred_term: Conductive hearing impairment
    term:
      id: HP:0000405
      label: Conductive hearing impairment
  evidence:
  - reference: PMID:17825104
    reference_title: Sotos syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Recurrent upper respiratory infections and otitis media are frequent, leading to some degree of conductive hearing loss.
    explanation: >-
      The clinical review explicitly connects recurrent otitis media to conductive hearing loss.
- name: Constipation
  category: Gastrointestinal
  description: >-
    Constipation is a commonly reported associated feature.
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Some associated features, such as constipation and hearing problems caused by chronic otitis media, are common.
    explanation: >-
      The clinical synthesis establishes constipation and separately identifies an otitis-related hearing mechanism.
- name: Gastroesophageal Reflux
  category: Gastrointestinal
  description: >-
    Reflux can complicate feeding and cause esophageal or respiratory symptoms.
  phenotype_term:
    preferred_term: Gastroesophageal reflux
    term:
      id: HP:0002020
      label: Gastroesophageal reflux
  evidence:
  - reference: PMID:17825104
    reference_title: Sotos syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      Another common problem is gastro-
      esophageal reflux which causes heartburn, vomiting,
      esophageal irritation and respiratory problems.
    explanation: >-
      The review explicitly describes gastroesophageal reflux and its consequences. The PDF line-break hyphen is preserved verbatim.
- name: Vesicoureteral Reflux
  category: Genitourinary
  description: >-
    Vesicoureteral reflux is a recurrent urinary manifestation and may remain clinically silent until renal impairment develops.
  phenotype_term:
    preferred_term: Vesicoureteral reflux
    term:
      id: HP:0000076
      label: Vesicoureteral reflux
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Some individuals may have quiescent vesicoureteral reflux and may present in adulthood with renal impairment.
    explanation: >-
      Describes occurrence and possible later renal complications; it does not quantify reflux specifically.
- name: Pes Planus
  category: Musculoskeletal
  description: >-
    Flat feet can accompany joint hyperlaxity.
  phenotype_term:
    preferred_term: Pes planus
    term:
      id: HP:0001763
      label: Pes planus
  evidence:
  - reference: PMID:20301652
    reference_title: Sotos Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Major features of Sotos syndrome include behavioral findings (most notably autism spectrum disorder), advanced bone age, cardiac anomalies, cranial MRI/CT abnormalities, joint hyperlaxity with or without pes planus, maternal preeclampsia, neonatal complications, renal anomalies, scoliosis, and seizures.
    explanation: >-
      Explicitly includes pes planus in the clinical feature spectrum; this co-occurrence does not by itself establish a causal hypermobility-to-flatfoot edge.
- name: Prominent Forehead
  category: Head and Neck
  description: >-
    Anterior prominence of the forehead is distinct from increased forehead width.
  phenotype_term:
    preferred_term: Prominent forehead
    term:
      id: HP:0011220
      label: Prominent forehead
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The head is dolichocephalic and the forehead broad and prominent. Often the hair in the frontotemporal region is sparse. The palpebral fissures are usually downslanting.
    explanation: >-
      Describes the individual craniofacial observations; the frequency of the complete gestalt cannot be assigned to each finding.
- name: Atrial Septal Defect
  category: Cardiovascular
  description: >-
    A congenital septal defect reported in NSD1-related Sotos syndrome; the broad cardiac-development hypothesis does not yet localize the anatomical defect.
  phenotype_term:
    preferred_term: Atrial septal defect
    term:
      id: HP:0001631
      label: Atrial septal defect
  evidence:
  - reference: PMID:38535015
    reference_title: Congenital Heart Defects in Patients with Molecularly Confirmed Sotos Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The predominant cardiac anomalies observed in the current study are septal defects, encompassing both atrial ostium secundum (ASDos) and ventricular (VSD) variations.
    explanation: >-
      Both atrial and ventricular septal defects were observed in the molecularly confirmed 45-person cardiology cohort; no population frequency is assigned.
- name: Ventricular Septal Defect
  category: Cardiovascular
  description: >-
    A congenital septal defect reported in NSD1-related Sotos syndrome; the broad cardiac-development hypothesis does not yet localize the anatomical defect.
  phenotype_term:
    preferred_term: Ventricular septal defect
    term:
      id: HP:0001629
      label: Ventricular septal defect
  evidence:
  - reference: PMID:38535015
    reference_title: Congenital Heart Defects in Patients with Molecularly Confirmed Sotos Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The predominant cardiac anomalies observed in the current study are septal defects, encompassing both atrial ostium secundum (ASDos) and ventricular (VSD) variations.
    explanation: >-
      Both atrial and ventricular septal defects were observed in the molecularly confirmed 45-person cardiology cohort; no population frequency is assigned.
- name: Patent Ductus Arteriosus
  category: Cardiovascular
  description: >-
    Persistent ductal patency was observed in three of 45 individuals in a selected cardiology cohort.
  phenotype_term:
    preferred_term: Patent ductus arteriosus
    term:
      id: HP:0001643
      label: Patent ductus arteriosus
  evidence:
  - reference: PMID:38535015
    reference_title: Congenital Heart Defects in Patients with Molecularly Confirmed Sotos Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Three patients exhibited a patent ductus arteriosus.
    explanation: >-
      The denominator is the 45-person NSD1-confirmed cohort; this observation is not a population frequency estimate.
- name: Hippocampal Malrotation
  category: Neurologic
  description: >-
    Incomplete hippocampal rotation was frequent in the MRI-selected cohort and often bilateral; unilateral incomplete rotation can also be a normal variant.
  phenotype_term:
    preferred_term: Hippocampal malrotation
    term:
      id: HP:0034396
      label: Hippocampal malrotation
  evidence:
  - reference: PMID:39147584
    reference_title: 'Sotos Syndrome: Deep Neuroimaging Phenotyping Reveals a High Prevalence of Malformations of Cortical Development.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Incomplete rotation of the hippocampus was observed in 50.6% of patients and was associated with other imaging findings, in particular with dysgyria (100% versus 84.2%, P = .012).
    explanation: >-
      Incomplete hippocampal rotation was identified in 39/77 MRI-selected, molecularly confirmed individuals. The selected denominator and possible normal variation preclude assigning a population frequency.
- name: Abnormal Corpus Callosum Morphology
  category: Neurologic
  description: >-
    Callosal dysmorphism, commonly thinning, occurs in the neuroimaging phenotype; the responsible regional developmental mechanism remains unresolved.
  phenotype_term:
    preferred_term: Abnormal corpus callosum morphology
    term:
      id: HP:0001273
      label: Abnormal corpus callosum morphology
  evidence:
  - reference: url:https://repository.uantwerpen.be/docstore/d%3Airua%3A25028
    reference_title: https://repository.uantwerpen.be/docstore/d%3Airua%3A25028
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Structural anomalies were noted in most of the patients including ... corpus callosum abnormality (68.8%), ... and hypertelorism (58.4%).
    explanation: >-
      This author manuscript and PMID:39147584 are the same AJNR study (DOI:10.3174/ajnr.A8364), not independent cohorts. The full-text result gives the callosal proportion in the genetically confirmed MRI-selected cohort. Explicit ellipses omit other findings and intervening PDF gutter numbers; this is not a population frequency.
- name: Strabismus
  category: Ophthalmological
  description: >-
    An ocular finding reported in Sotos syndrome; the selected mixed NSD1/NFIX cohort counts are not used as disease-specific frequencies.
  phenotype_term:
    preferred_term: Strabismus
    term:
      id: HP:0000486
      label: Strabismus
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      The following features are seen in ≥2% and <15% of individuals with Sotos syndrome ...:
      • Ocular. Astigmatism, cataracts, myopia, strabismus, nystagmus, hypermetropia
    explanation: >-
      The full introductory proposition and ocular list identify these findings in Sotos syndrome. The reported interval crosses repository frequency-band boundaries, so no individual band is assigned.
- name: Hypermetropia
  category: Ophthalmological
  description: >-
    An ocular finding reported in Sotos syndrome; the selected mixed NSD1/NFIX cohort counts are not used as disease-specific frequencies.
  phenotype_term:
    preferred_term: Hypermetropia
    term:
      id: HP:0000540
      label: Hypermetropia
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      The following features are seen in ≥2% and <15% of individuals with Sotos syndrome ...:
      • Ocular. Astigmatism, cataracts, myopia, strabismus, nystagmus, hypermetropia
    explanation: >-
      The full introductory proposition and ocular list identify these findings in Sotos syndrome. The reported interval crosses repository frequency-band boundaries, so no individual band is assigned.
- name: Astigmatism
  category: Ophthalmological
  description: >-
    An ocular finding reported in Sotos syndrome; the selected mixed NSD1/NFIX cohort counts are not used as disease-specific frequencies.
  phenotype_term:
    preferred_term: Astigmatism
    term:
      id: HP:0000483
      label: Astigmatism
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      The following features are seen in ≥2% and <15% of individuals with Sotos syndrome ...:
      • Ocular. Astigmatism, cataracts, myopia, strabismus, nystagmus, hypermetropia
    explanation: >-
      The full introductory proposition and ocular list identify these findings in Sotos syndrome. The reported interval crosses repository frequency-band boundaries, so no individual band is assigned.
- name: Sleep Disturbance
  category: Neurologic
  description: Disturbed sleep includes altered sleep timing and sleep-related breathing or transition problems. Early bed and rise times do not by themselves establish insomnia or an advanced sleep-phase disorder. In a pediatric survey, 27/38 had a positive SDSC screen, while only two had a prior sleep-disorder diagnosis. The sleep-breathing subscale was positive in 10/38 (26.3%), which does not establish polysomnography-confirmed obstructive sleep apnea. The 60% questionnaire response rate and referral ascertainment preclude treating 71.1% as population prevalence; no frequency band is assigned.
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Behavioral findings. A wide range of behavioral findings are common at all ages. Autism spectrum disorder, phobias, sleep disturbances, hyperactivity, and aggression have been described
    explanation: The clinical-description section establishes occurrence of sleep disturbance; the broad behavioral-feature frequency is not a sleep-specific estimate.
  - reference: PMID:33893755
    reference_title: Characterization of sleep habits of children with Sotos syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Subjects with SS showed more sleep disturbance than typically developing individuals (TD), although their sleep onset was less likely to be delayed and their sleep duration was longer.
    explanation: The cross-sectional questionnaire study included definite, probable and possible Sotos diagnoses and used historical comparators. It supports disturbed sleep without equating early waking with reduced sleep duration.
  - reference: PMID:33893755
    reference_title: Characterization of sleep habits of children with Sotos syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Individuals with SS exhibited early bed and rise times, frequently used transitional objects, displayed repetitive motion at sleep onset, and did not show a decrease in sleep duration with age.
    explanation: This identifies the sleep-timing pattern. It does not establish terminal insomnia or a diagnosed circadian-rhythm disorder; the broader sleep-disturbance binding retains that distinction.
  - reference: PMID:38434199
    reference_title: Sleep disturbances and behavioral symptoms in pediatric Sotos syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Although only two had a prior SD diagnosis, 71.1% (N = 27) exhibited pathological scores on SDSC.
    explanation: Among 38 respondents (mean age 11.1 years), 27 had positive screening scores. The source reports 12 NSD1 deletions, 24 intragenic variants and two with unavailable genetic data; 38 of 64 invited families responded. Questionnaire positivity is distinct from a prior clinical diagnosis and may be enriched by response bias.
  - reference: PMID:38434199
    reference_title: Sleep disturbances and behavioral symptoms in pediatric Sotos syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      As for the subscales, 6 (15.8%) patients in the DIMS scale, 10 (26.3%) in SBD, 4 (10.5%) in DA, 10 (26.3%) in SWTD, 2 (5.2%) in DOES, and 7 (18.4%) in SHY obtained a score above the cutoff (Supplementary Figure 1).
    explanation: >-
      Ten of 38 respondents screened positive for sleep breathing disorders (SBD). This anchors the respiratory component addressed by the provisional palatal-anatomy hypothesis; subscale positivity does not establish obstructive sleep apnea or that anatomy explains all positive total SDSC screens.
- name: Aggressive Behavior
  category: Behavioral
  description: Physical aggression is reported by parents and carers. A standardized questionnaire study compared 38 clinically diagnosed Sotos participants with matched syndrome groups; NSD1 status was unavailable. These are human clinical reports, but recruitment, retrospective reporting and comparator choice limit generalization. No individual aggression frequency is inferred from the later review’s combined behavioral summary.
  phenotype_term:
    preferred_term: Aggressive behavior
    term:
      id: HP:0000718
      label: Aggressive behavior
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Behavioral findings. A wide range of behavioral findings are common at all ages. Autism spectrum disorder, phobias, sleep disturbances, hyperactivity, and aggression have been described
    explanation: GeneReviews lists aggression in the clinical description, independently of its separate management recommendation.
  - reference: PMID:26418839
    reference_title: The behavioral characteristics of Sotos syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Individuals with Sotos syndrome showed an increased risk of self-injurious behavior, physical aggression, and destruction of property relative to the Down syndrome group but not a greater risk of stereotyped behavior.
    explanation: Sheth and colleagues report physical aggression from parent/carer questionnaires. The clinical observation is valid human evidence; the comparison does not establish a population frequency or a molecular mechanism.
  - reference: url:https://pure-oai.bham.ac.uk/ws/files/27013518/Sheth_et_cl_in_press_the_behavioral_characteristics_of_sotos_syndrome_AJMG.pdf
    reference_title: https://pure-oai.bham.ac.uk/ws/files/27013518/Sheth_et_cl_in_press_the_behavioral_characteristics_of_sotos_syndrome_AJMG.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Although NSD1 gene status was not av ailable, all participants had a confirmed diagnosis of Sotos syndrome by a clinical geneticist or pediatrician .
    explanation: The author manuscript of PMID:26418839 explicitly states clinical confirmation with unavailable NSD1 status. This is the same study, not an independent cohort; its diagnostic scope is preserved.
- name: Self-Injurious Behavior
  category: Behavioral
  description: Self-injurious behavior was reported by parents and carers in a clinically diagnosed Sotos cohort. The source does not require mutilating injury or suicidal intent, so the general self-injurious-behavior term is used. A later review’s combined summary of self-injury, stereotypy and destruction does not supply a frequency for self-injury alone.
  phenotype_term:
    preferred_term: Self-injurious behavior
    term:
      id: HP:0100716
      label: Self-injurious behavior
  evidence:
  - reference: PMID:26418839
    reference_title: The behavioral characteristics of Sotos syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Individuals with Sotos syndrome showed an increased risk of self-injurious behavior, physical aggression, and destruction of property relative to the Down syndrome group but not a greater risk of stereotyped behavior.
    explanation: Sheth and colleagues report self-injury from parent/carer questionnaires. The clinical observation is valid human evidence; the comparison does not establish a population frequency or a molecular mechanism.
  - reference: url:https://pure-oai.bham.ac.uk/ws/files/27013518/Sheth_et_cl_in_press_the_behavioral_characteristics_of_sotos_syndrome_AJMG.pdf
    reference_title: https://pure-oai.bham.ac.uk/ws/files/27013518/Sheth_et_cl_in_press_the_behavioral_characteristics_of_sotos_syndrome_AJMG.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Although NSD1 gene status was not av ailable, all participants had a confirmed diagnosis of Sotos syndrome by a clinical geneticist or pediatrician .
    explanation: The author manuscript of PMID:26418839 explicitly states clinical confirmation with unavailable NSD1 status. This is the same study, not an independent cohort; its diagnostic scope is preserved.
- name: Hypodontia
  category: Dental
  description: Congenital absence of teeth, particularly premolars, is reported. In a dental series, 9/13 children and adolescents lacked one or more premolars; 12/13 had an identified NSD1 mutation, including all nine with hypodontia. This small dental sample is not a population estimate. GeneReviews lists hypodontia among associated findings in the ≥2% to <15% interval; differing ascertainment and that interval’s overlap of frequency bands preclude a single category. Poor adult dentition is not evidence of congenital tooth absence.
  phenotype_term:
    preferred_term: Hypodontia
    term:
      id: HP:0000668
      label: Hypodontia
  evidence:
  - reference: PMID:19876911
    reference_title: Premolar hypodontia is a common feature in Sotos syndrome with a mutation in the NSD1 gene.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We investigated the dental manifestations of this disorder and found one or several premolar teeth were absent in 9 out of 13 (69%) affected children and adolescents. A heterozygous mutation in the NSD1 gene was identified in 12 patients, including all patients with hypodontia.
    explanation: This primary dental investigation establishes premolar agenesis in NSD1-positive patients. The observed 9/13 proportion is retained with its selected clinical sample and molecularly characterized subset, rather than generalized to all Sotos syndrome.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'The following features are seen in ≥2% and <15% of individuals with Sotos syndrome ...:

      • Nail and tooth anomalies. Hypoplastic nails, hypodontia'
    explanation: The complete introductory proposition and tooth-anomaly list support clinical occurrence. The range is preserved in the description without forcing a frequency category or substituting poor dentition for hypodontia.
animal_models:
- name: Nsd1 heterozygous mouse (CRISPR exon 3)
  species: Mouse
  genotype: Nsd1 heterozygous loss-of-function (CRISPR-targeted)
  description: >-
    The only reported constitutive heterozygous mouse for the Sotos gene, made
    to ask whether Nsd1 haploinsufficiency reproduces the human syndrome. Nsd1
    expression in the mouse brain is predominantly neuronal, and the
    heterozygotes show behavioural changes reminiscent of some of the human
    deficits. Homozygous loss is embryonic lethal, so heterozygosity is the only
    postnatal window on this gene.
  publication: PMID:31909872
  genes:
  - preferred_term: NSD1
    term:
      id: hgnc:14234
      label: NSD1
  modeled_mechanisms:
  - target: Dysregulated Developmental Transcriptional Program
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    model_scale: ORGANISM
    description: >-
      Halving Nsd1 dose in the mouse produces behavioural change but, on the
      published account, only a partial resemblance to the human phenotype. The
      model therefore supports the transcriptional-program node as
      dose-sensitive without establishing that the human syndrome follows from
      it in full.
    limitations: >-
      The published abstract claims only "behavioral characteristics reminiscent
      of some of the deficits" and reports no overgrowth or macrocephaly, which
      are two of the three cardinal human features the same abstract names. The
      more specific negative results attributed to this model in secondary
      summaries - absent overgrowth and macrocephaly, absent gross cortical
      enlargement, reduced SATB2-positive upper-layer neurons - come from full
      text that is not in the reference cache, so they are deliberately not
      curated here and the relationship is recorded as partial rather than as an
      outright failure to recapitulate.
    evidence:
    - reference: PMID:31909872
      reference_title: "Investigating cortical features of Sotos syndrome using mice heterozygous for Nsd1."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We also generated a mouse strain lacking one allele of Nsd1 and analyzed morphological and behavioral characteristics in these mice, showing behavioral characteristics reminiscent of some of the deficits seen in Sotos syndrome patients."
      explanation: >-
        The authors' own summary claim, whose hedging ("some of the deficits")
        is what fixes this as a partial rather than a full recapitulation.
    - reference: PMID:31909872
      reference_title: "Investigating cortical features of Sotos syndrome using mice heterozygous for Nsd1."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "we assessed the expression of Nsd1 within the mouse brain, and showed a predominantly neuronal pattern of expression for this histone-modifying factor"
      explanation: >-
        Establishes that the gene is expressed where the model's behavioural
        readout would have to arise, which is what makes the neural arm of the
        transcriptional node testable in this species.
  evidence:
  - reference: PMID:31909872
    reference_title: "Investigating cortical features of Sotos syndrome using mice heterozygous for Nsd1."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In children, the three cardinal features of Sotos syndrome are a characteristic facial appearance, learning disability and overgrowth (height and/or head circumference > 2 SDs above average)."
    explanation: >-
      The paper's own statement of the three features a faithful model would
      have to reproduce, which is the yardstick the reported behavioural-only
      result is measured against.

genetic:
- name: NSD1
  gene_term:
    preferred_term: NSD1
    term:
      id: hgnc:14234
      label: NSD1
  association: Haploinsufficiency (loss-of-function variants and whole-gene deletion)
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  frequency: identified in about 93% of individuals with a clinical diagnosis of Sotos syndrome
  notes: >-
    NSD1 (5q35) encodes a SET-domain lysine methyltransferase that writes H3K36
    mono- and dimethylation. Two lesion classes account for the disease: intragenic
    loss-of-function variants (truncating throughout the gene, missense only within
    functional domains) and the recurrent whole-gene 5q35 microdeletion. Detection
    rates differ by ancestry because the deletion class does. Confirmed pathogenic
    NSD1 variants generate a specific blood DNA-methylation episignature, which is
    used to reclassify variants of uncertain significance. Note also that molecular
    yield is cohort-dependent: a Brazilian series identified NSD1 abnormalities in
    only 32% of clinically diagnosed patients, which the authors read as evidence
    for genetic heterogeneity in that population rather than as contradicting the
    higher published yields.
  evidence:
  - reference: PMID:11896389
    reference_title: "Haploinsufficiency of NSD1 causes Sotos syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We isolated NSD1 from the 5q35 breakpoint in an individual with Sotos syndrome harboring a chromosomal translocation."
    explanation: Records how the gene was mapped to the disease, via a translocation breakpoint.
  - reference: PMID:15942875
    reference_title: "Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Furthermore, our data suggest that 93% of patients who have been clinically diagnosed with Sotos syndrome have identifiable NSD1 abnormalities, of which 83% are intragenic mutations and 10% are 5q35 microdeletions."
    explanation: Supports the detection rate quoted in `frequency` and the split between lesion classes.
  - reference: PMID:23190751
    reference_title: "Clinical and genetic spectrum of 18 unrelated Korean patients with Sotos syndrome: frequent 5q35 microdeletion and identification of four novel NSD1 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NSD1 abnormalities were identified in 15 (83%) patients. Among them, eight patients (53%) had 5q35 microdeletions and the other seven patients (47%) had seven different NSD1 intragenic mutations including four novel mutations."
    explanation: >-
      An East Asian cohort showing the inverted lesion-class ratio relative to
      European series - independent replication of the ancestry effect.
  - reference: PMID:27834868
    reference_title: "Steric Clash in the SET Domain of Histone Methyltransferase NSD1 as a Cause of Sotos Syndrome and Its Genetic Heterogeneity in a Brazilian Cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NSD1 mutations were identified in only 32% of the Brazilian Sotos patients in our study cohort suggesting other genes (including unknown disease genes) underlie the molecular etiology for the majority of these patients."
    explanation: >-
      The cohort-dependent yield noted above, quoted with the authors' own
      heterogeneity interpretation.
  - reference: PMID:34575025
    reference_title: "NSD1: A Lysine Methyltransferase between Developmental Disorders and Cancer."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Several studies have shown that NSD1 controls gene expression by methylation of lysine 36 of histone 3 (H3K36me1/2) in a complex crosstalk with de novo DNA methylation."
    explanation: >-
      Review-level statement of the gene's molecular function and its coupling to
      DNA methylation, which is the basis of the mechanism curated above.

diagnosis:
- name: Molecular Genetic Confirmation
  description: >-
    The diagnosis is established by identifying a heterozygous NSD1 pathogenic
    variant or a deletion encompassing NSD1. Because the two lesion classes need
    different assays, testing has to cover both sequence variants and copy number -
    sequencing alone will miss the deletion class, which is the majority class in
    Japanese and Korean patients.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C19770
      label: Molecular Analysis
  results: >-
    Detection of a heterozygous NSD1 pathogenic variant, or of a 5q35 deletion
    encompassing NSD1, establishes the diagnosis.
  evidence:
  - reference: PMID:20301652
    reference_title: "Sotos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of Sotos syndrome is established in a proband with a heterozygous NSD1 pathogenic variant or a deletion encompassing NSD1 identified by molecular genetic testing."
    explanation: The GeneReviews diagnostic criterion, naming both lesion classes.
  - reference: PMID:17825104
    reference_title: "Sotos syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "FISH analysis, MLPA or multiplex quantitative PCR allow the detection of total/partial NSD1 deletions, and direct sequencing allows detection of NSD1 mutations."
    explanation: >-
      Spells out the two assay classes, which is the point the description makes
      about sequencing alone being insufficient.
  - reference: PMID:42618064
    reference_title: "Sotos and Malan Syndromes in Childhood: Molecular and Clinical Findings From a Nationwide Cohort of 48 Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Molecular analyses included whole-exome sequencing, clinical exome sequencing, targeted gene panels, multiplex ligation-dependent probe amplification, and chromosomal microarray analysis."
    explanation: Shows the contemporary assay combination used to cover both lesion classes.

- name: NSD1 DNA Methylation Episignature Analysis
  description: >-
    Genome-wide DNA methylation profiling of peripheral blood detects a
    NSD1-specific signature of 7,085 CpG sites, almost all hypomethylated. In the
    defining study the signature classified every sample in independent validation
    cohorts correctly, distinguished Sotos syndrome from benign NSD1 variants and
    from the clinically overlapping Weaver syndrome, and reclassified NSD1 missense
    variants of uncertain significance in agreement with blinded expert clinical
    review. It remains an adjunct to variant interpretation, not a replacement for
    the molecular diagnostic criterion above. Long-read nanopore sequencing has
    since been shown to recover an equivalent signature, and even a single-locus
    mark at the NSD1 CpG island, which would let genotype and methylation be
    assessed in one assay.
  diagnosis_term:
    preferred_term: DNA methylation episignature analysis
    term:
      id: NCIT:C63328
      label: DNA Methylation Analysis
  results: >-
    A positive Sotos score supports pathogenicity of an NSD1 sequence variant and
    argues against clinically overlapping overgrowth syndromes.
  evidence:
  - reference: PMID:26690673
    reference_title: "NSD1 mutations generate a genome-wide DNA methylation signature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "By interrogating DNAm in SS patients, we identify a genome-wide, highly significant NSD1(+/-)-specific signature that differentiates pathogenic NSD1 mutations from controls, benign NSD1 variants and the clinically overlapping Weaver syndrome."
    explanation: States exactly what the signature discriminates, which is the diagnostic claim here.
  - reference: PMID:26690673
    reference_title: "NSD1 mutations generate a genome-wide DNA methylation signature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Validation studies of independent cohorts of SS and controls assigned 100% of these samples correctly."
    explanation: The validation performance quoted in the description.
  - reference: PMID:26690673
    reference_title: "NSD1 mutations generate a genome-wide DNA methylation signature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "As shown in Fig. 2, the NSD1+/−-specific signature allowed clear classification of VOUS as pathogenic or benign; 9/16 samples received positive SS scores clustering with the NSD1+/− pathogenic variants; these mutations were classified as pathogenic."
    explanation: Supports the variant-reclassification use, with the actual counts.
  - reference: PMID:39966947
    reference_title: "Diagnostic utility of single-locus DNA methylation mark in Sotos syndrome developed by nanopore sequencing-based episignature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Long-read sequencing enabled the successful extraction of two sets of differential methylation marks unique to each of Sotos syndrome and ATR-X syndrome, referred to as long-read-based DNA methylation signatures (LR-DNAm signatures), as alternatives to reported DNA methylation signatures"
    explanation: Supports the nanopore alternative described at the end of this entry.
  - reference: PMID:37889307
    reference_title: "Comprehensive evaluation of the implementation of episignatures for diagnosis of neurodevelopmental disorders (NDDs)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this setting, we show that Illumina, Noob or Funnorm normalization methods achieved higher classification performances on the testing sets compared to Quantile, Raw and Swan normalization methods."
    explanation: >-
      A caution rather than a capability claim: episignature performance for Sotos
      syndrome depends on preprocessing choices, so a negative result is
      interpretable only in the context of the pipeline that produced it.

definitions:
- name: Cardinal Clinical Triad of Sotos Syndrome
  definition_type: DIAGNOSTIC_CRITERIA
  derivation_basis: ESTABLISHED_CRITERIA
  description: >-
    GeneReviews treats three features together as cardinal: the distinctive facial
    appearance, learning disability, and overgrowth of height and/or head
    circumference at or above 2 SD. The triad is a clinical-recognition construct
    that prompts molecular testing; it is not the diagnostic criterion, which is
    molecular. It is also not fully sensitive - a tenth of NSD1-positive
    individuals have normal height and head circumference.
  scope: Clinical recognition prompting NSD1 molecular testing
  inclusion_criteria:
  - preferred_term: Distinctive facial appearance
    description: >-
      Broad prominent forehead with dolichocephaly, sparse frontotemporal hair,
      downslanting palpebral fissures, malar flushing, long narrow face, tall chin.
    term:
      id: HP:0001999
      label: Abnormal facial shape
  - preferred_term: Learning disability
    description: >-
      From early developmental delay to mild-to-severe intellectual impairment. This clinical-recognition criterion deliberately retains the source's composite scope: binding it only to Intellectual disability would exclude developmental delay. The component phenotypes have separate HPO bindings; this is a composite-criterion modeling decision, not a claim that HPO lacks these terms.
  - preferred_term: Overgrowth
    description: Height and/or head circumference at or above 2 SD above the mean.
    term:
      id: HP:0001548
      label: Overgrowth
  evidence:
  - reference: PMID:20301652
    reference_title: "Sotos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These three clinical features (distinctive facial features, learning disability, and overgrowth) are considered the cardinal features of Sotos syndrome."
    explanation: States the triad exactly as this definition records it.
  - reference: PMID:15942875
    reference_title: "Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Facial dysmorphism, learning disability, and childhood overgrowth were present in 90% of the individuals."
    explanation: >-
      Quantifies the triad's sensitivity in molecularly confirmed cases, which is
      the basis for the caveat in the description.

progression:
- phase: Childhood
  age_range: Early childhood through mid adolescence
  notes: >-
    Height excess tends to attenuate with age. The Korean growth-chart estimates differed by age, sex and measure, and were based largely on childhood follow-up; their age-specific significance thresholds do not establish that overgrowth or macrocephaly ends at a fixed age in every patient.
  evidence:
  - reference: PMID:39494594
    reference_title: "Deciphering Growth Patterns in Korean Children With Sotos Syndrome Through the Development of a Disease-Specific Growth Chart."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Males with SS demonstrated higher height before the age of 12.0, greater weight before 10.0, and larger head circumference before 15.5 compared to age- and sex-matched controls."
    explanation: >-
      Reports age-specific comparisons within this Korean cohort; lack of a significant difference at later ages does not define a universal clinical endpoint.
- phase: Adulthood
  age_range: Adults
  notes: >-
    Adults are generally healthy with few new medical problems, and the height
    excess is modest by adulthood (median +1.9 SD in women, +0.5 SD in men).
    Reproductive rates are low. A minority develop new problems - lymphoedema, poor
    dentition, hearing loss, contractures, tremor.
  evidence:
  - reference: PMID:31479583
    reference_title: "The phenotype of Sotos syndrome in adulthood: A review of 44 individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In our cohort, median height in adult women is +1.9 SD and men +0.5 SD."
    explanation: The adult stature figures quoted here.
  - reference: PMID:31479583
    reference_title: "The phenotype of Sotos syndrome in adulthood: A review of 44 individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Reassuringly, adults with Sotos syndrome are generally healthy with few new medical issues; however, lymphedema, poor dentition, hearing loss, contractures and tremor have developed in a small number of individuals."
    explanation: Supports both the reassuring general statement and the specific minority complications.

epidemiology:
- name: Ancestry-Dependent Lesion-Class Distribution
  description: >-
    The proportion of Sotos syndrome caused by the 5q35 microdeletion rather than
    an intragenic variant differs markedly by population. In the Japanese referral
    series 52% of patients had a microdeletion against 6% of non-Japanese patients,
    and a Korean series found 53% of NSD1-positive patients had a deletion. This
    matters operationally: a diagnostic strategy that sequences NSD1 without a
    copy-number assay will miss most cases in these populations. The authors of the
    Japanese series were careful to note that patient-selection bias may contribute,
    since the flanking low-copy repeats mediating the deletion are present in
    different populations.
  evidence:
  - reference: PMID:14517949
    reference_title: "Fifty microdeletions among 112 cases of Sotos syndrome: low copy repeats possibly mediate the common deletion."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A large difference in the frequency of microdeletions between Japanese and non-Japanese patients was noted: 49 (52%) of the 95 Japanese patients and only one (6%) of the 17 non-Japanese had microdeletions."
    explanation: The primary observation of the population difference.
  - reference: PMID:14517949
    reference_title: "Fifty microdeletions among 112 cases of Sotos syndrome: low copy repeats possibly mediate the common deletion."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Such LCRs seem to be present in different populations. Thus the different frequency of microdeletions between Japanese and non-Japanese cases in our study may have been caused by patient-selection bias."
    explanation: >-
      The authors' own caveat, quoted so the entry does not overstate the effect as
      a settled population-genetic fact.
  - reference: PMID:23190751
    reference_title: "Clinical and genetic spectrum of 18 unrelated Korean patients with Sotos syndrome: frequent 5q35 microdeletion and identification of four novel NSD1 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mutation spectrum of Korean patients with Sotos syndrome was similar to that of previous studies for Japanese patients."
    explanation: Independent East Asian replication of the deletion-predominant pattern.

differential_diagnoses:
- name: Malan Syndrome (NFIX-related, "Sotos syndrome 2")
  description: >-
    NFIX haploinsufficiency produces an overgrowth-intellectual disability
    phenotype historically labelled "Sotos syndrome 2" and often described as
    Sotos-like. It is a distinct MONDO concept and is curated separately in dismech
    as Malan_Syndrome; it is cross-referenced here rather than folded into this
    entry. NFIX and NSD1 lesions are routinely tested for together, and a recent
    nationwide cohort recruited both under one protocol.
  disease_term:
    preferred_term: Malan syndrome
    term:
      id: MONDO:0013885
      label: Malan overgrowth syndrome
  distinguishing_features:
  - Caused by NFIX loss of function at 19p13, not NSD1 loss at 5q35
  - The NSD1 blood episignature is Sotos-specific and does not classify NFIX cases as Sotos
  evidence:
  - reference: PMID:42618064
    reference_title: "Sotos and Malan Syndromes in Childhood: Molecular and Clinical Findings From a Nationwide Cohort of 48 Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Malan syndrome, a phenotypically overlapping condition, results from haploinsufficiency of the NFIX gene due to either heterozygous chromosomal microdeletions involving the 19p13.2 region or heterozygous loss-of-function variants."
    explanation: >-
      Establishes both the phenotypic overlap that makes this a differential and
      the distinct gene and locus that separate it.

- name: Weaver Syndrome (EZH2-related overgrowth)
  description: >-
    EZH2-related overgrowth shares childhood overgrowth, advanced bone age,
    macrocephaly and a distinctive facial gestalt with Sotos syndrome, and the two
    were long distinguished clinically with difficulty. The NSD1 methylation
    episignature separates them objectively: Weaver patients with confirmed EZH2
    variants all received strongly negative Sotos scores.
  disease_term:
    preferred_term: Weaver syndrome
    term:
      id: MONDO:0010193
      label: Weaver syndrome
  distinguishing_features:
  - EZH2/PRC2 H3K27 methyltransferase lesion rather than NSD1 H3K36 methyltransferase
  - The two disorders carry different, mutually exclusive DNA methylation episignatures
  evidence:
  - reference: PMID:26690673
    reference_title: "NSD1 mutations generate a genome-wide DNA methylation signature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All Weaver syndrome patients with EZH2+/− mutations received a strongly negative SS score (between −0.151 and −0.105) and were therefore classified confidently as ‘not SS' (Fig. 2)."
    explanation: Direct demonstration that the episignature discriminates the two overlapping overgrowth syndromes.
  - reference: PMID:26690673
    reference_title: "NSD1 mutations generate a genome-wide DNA methylation signature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Constitutional mutations in two different genes involved in regulating histone modifications, NSD1 and EZH2, have been shown to cause clinically overlapping overgrowth disorders, Sotos syndrome (SS) and Weaver syndrome, respectively."
    explanation: States the clinical overlap and the molecular distinction that motivates this differential.

- name: Tatton-Brown-Rahman Syndrome (DNMT3A-related overgrowth)
  description: >-
    DNMT3A-related overgrowth shares clinical features with Sotos syndrome, and the
    resemblance is now known to be mechanistic rather than coincidental: NSD1
    deposits the H3K36me2 mark that recruits DNMT3A, so the two genes act at
    consecutive steps of one pathway. Tatton-Brown-Rahman-derived DNMT3A missense
    mutations abolish PWWP recognition of that mark.
  disease_term:
    preferred_term: Tatton-Brown-Rahman syndrome
    term:
      id: MONDO:0014382
      label: Tatton-Brown-Rahman overgrowth syndrome
  distinguishing_features:
  - Germline DNMT3A variants rather than NSD1 loss of function
  - The shared pathway means clinical overlap is expected, so molecular testing rather than phenotyping is the discriminator
  evidence:
  - reference: PMID:31485078
    reference_title: "The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "TBRS shares clinical features with Sotos syndrome (which is caused by haploinsufficiency of NSD1, a histone methyltransferase that catalyses the dimethylation of histone H3 at K36 (H3K36me2)8,12,13), which suggests that there is a mechanistic link between these two diseases."
    explanation: States the clinical overlap and the pathway relationship that explains it.

- name: Beckwith-Wiedemann Syndrome and Other Overgrowth Differentials
  description: >-
    Beyond the chromatin overgrowth syndromes, the Orphanet review lists
    Beckwith-Wiedemann syndrome, fragile X syndrome, Simpson-Golabi-Behmel syndrome
    and 22q terminal deletion syndrome as the main differentials. These are
    mechanistically unrelated to NSD1 and are separated by targeted molecular
    testing rather than by phenotype.
  distinguishing_features:
  - Distinct molecular aetiologies - 11p15 imprinting, FMR1 repeat expansion, GPC3, 22q13 deletion
  - None carries the NSD1 blood methylation episignature
  evidence:
  - reference: PMID:17825104
    reference_title: "Sotos syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The main differential diagnoses are Weaver syndrome, Beckwith-Wiedeman syndrome, Fragile X syndrome, Simpson-Golabi-Behmel syndrome and 22qter deletion syndrome."
    explanation: The review's own list of differentials, recorded here without adding conditions it does not name.

treatments:
- name: Genetic Counseling
  description: >-
    Counseling covers autosomal dominant inheritance, the approximately 95% de novo rate, and the 50% transmission risk for children of an affected individual. Expression varies between generations, so a prenatal molecular diagnosis cannot predict severity. Prenatal and preimplantation testing are possible once the familial alteration is identified. For clinically unaffected parents, recurrence assessment includes the possibility of gonadal mosaicism even when parental blood testing is negative.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  therapeutic_modality: BEHAVIORAL
  evidence:
  - reference: PMID:20301652
    reference_title: "Sotos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Each child of an individual with Sotos syndrome has a 50% chance of inheriting the causative genetic alteration. Once the Sotos syndrome-related genetic alteration has been identified in an affected family member, prenatal and preimplantation genetic testing are possible."
    explanation: Supports both the recurrence-risk figure and the reproductive-testing options counselled about.
  - reference: PMID:36708490
    reference_title: Genetic Analysis of a Case of Sotos Syndrome with Suspected Germinal Mosaicism in Mother.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Gentling results indicated that the fetus and the patient inherited the same maternal chromosome 5. The heterozygous mutation of NSD1 gene c.4138delG is the pathogenic mutation of this Sots syndrome patient, and the mother may be germinal mosaicism.
    explanation: >-
      Recurrence of the same variant in two pregnancies despite negative parental blood testing supports suspected maternal germline mosaicism. This report supersedes the 2007 statement that germline mosaicism had never been reported; it does not estimate a population recurrence risk.
- name: Developmental and Educational Intervention
  description: >-
    Referral to appropriate specialists for learning disability and speech delay is
    the mainstay of management. There is no disease-modifying therapy; care is
    supportive, multidisciplinary and organised around the affected domains. The
    neuropsychological profile argues for targeting language, visuospatial ability
    and mathematics specifically rather than delivering generic support.
  treatment_term:
    preferred_term: Speech Language Therapy
    term:
      id: NCIT:C159273
      label: Speech Language Therapy
  therapeutic_modality: BEHAVIORAL
  target_phenotypes:
  - preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:20301652
    reference_title: "Sotos Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Treatment of manifestations: Referral to appropriate specialists for management of learning disability / speech delays, behavioral findings, cardiac abnormalities, renal anomalies, scoliosis, and seizures"
    explanation: The GeneReviews management recommendation from which this treatment entry derives.
  - reference: PMID:17825104
    reference_title: "Sotos syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "An adequate psychological and educational program with speech therapy and motor stimulation plays an important role in the global development of the patients."
    explanation: >-
      States that speech therapy, as part of a structured educational and psychological
      program, materially affects global developmental outcome — which is the claim this
      treatment entry makes. Replaces an earlier three-word quote from the same review
      ("Management is multidisciplinary.") that named no intervention and so could not
      support the entry on its own.
  - reference: PMID:38673476
    reference_title: "Neuropsychiatric Aspects of Sotos Syndrome: Explorative Review Building Multidisciplinary Bridges in Clinical Practice."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Comprehensive assistance is needed for Sotos syndrome patients in responding to areas of difficulty."
    explanation: Supports targeting intervention at identified areas of difficulty rather than generically.

- name: Multisystem Surveillance and Supportive Care
  description: >-
    Regular general paediatric review, more frequent for younger children, those
    with many medical complications and families needing more support, and less
    frequent for older children and those with fewer complications. Two specific
    points sharpen this generic recommendation: echocardiography at diagnosis with
    cardiological follow-up, given the high heart-defect rate; and spinal
    surveillance weighted towards the deletion subtype, in which progressive
    scoliosis concentrates. GeneReviews also gives an explicit non-intervention
    rule - ventricular dilatation on brain MRI without raised intracranial pressure
    should not be treated. Neuropsychiatric evaluation after 12 months includes screening for sleep, attention, anxiety and autistic symptoms. Ongoing review includes aggression and self-injury, with pediatric psychiatric input for serious aggressive or destructive behavior. These GeneReviews recommendations reflect expert clinical experience rather than a published practice guideline.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301652
    reference_title: "Sotos Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Surveillance: Regular review by a general pediatrician for younger children, individuals with many medical complications, and families requiring more support than average; less frequent review of older children / teenagers and those individuals without many medical complications."
    explanation: The GeneReviews surveillance schedule this entry records.
  - reference: PMID:38535015
    reference_title: "Congenital Heart Defects in Patients with Molecularly Confirmed Sotos Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "An accurate and detailed echocardiogram should be performed in patients with Sotos syndrome at diagnosis, and a specific cardiological follow-up program is needed."
    explanation: The cardiac-surveillance recommendation, from the cohort that found a 60% heart-defect rate.
  - reference: PMID:20301652
    reference_title: "Sotos Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "intervention is not recommended if the brain MRI shows ventricular dilatation without increased intracranial pressure"
    explanation: >-
      An explicit do-not-treat rule, curated because avoiding an unnecessary shunt
      is a management action in its own right.

  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: 'For persons age >12 mos: screening for concerns incl sleep disturbances, ADHD, anxiety, &/or findings suggestive of ASD'
    explanation: GeneReviews recommends initial neuropsychiatric screening after 12 months. This is a management recommendation, not an observation or prevalence estimate.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Assessment for anxiety, ADHD, ASD, aggression, & self-injury
    explanation: The surveillance table recommends ongoing assessment of these neurobehavioral concerns; this does not establish their frequency.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    reference_title: https://www.ncbi.nlm.nih.gov/books/NBK1479/pdf/Bookshelf_NBK1479.pdf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Concerns about serious aggressive or destructive behavior can be addressed by a pediatric psychiatrist.
    explanation: Supports specialist input for serious behavioral concerns, without inferring occurrence from treatment advice.

discussions:
- discussion_id: sotos_mouse_model_does_not_show_overgrowth
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    How faithfully does the heterozygous Nsd1 mouse reproduce growth and neurobehavioral phenotypes across ages and genetic backgrounds?
  attaches_to:
  - animal_models#Nsd1 heterozygous mouse (CRISPR exon 3)
  - phenotypes#Childhood Overgrowth
  - pathophysiology#Dysregulated Developmental Transcriptional Program
  rationale: >-
    The cached primary abstract documents behavioral abnormalities in a heterozygous Nsd1 mouse but does not supply growth measurements. Absence of a growth result from an abstract is not evidence of a tested negative result. Model findings should be interpreted at the measured phenotype level; this abstract alone cannot establish a dissociation between the human growth and neurobehavioral arms.
  notes: >-
    Deliberately framed around what the cached abstract supports. Secondary
    summaries of this paper report explicit negative findings for overgrowth and
    macrocephaly from full text that is not in the reference cache; if that text
    is later cached, this discussion and the model link should both be revisited,
    and the link may become FAILS_TO_RECAPITULATE.
- discussion_id: sotos_overgrowth_mechanism_unexplained
  prompt: >-
    Does the proposed MAPK/ERK–chondrocyte maturation pathway mediate human Sotos overgrowth, and which NSD1-dependent changes are necessary?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Dysregulated Developmental Transcriptional Program
  - phenotypes#Childhood Overgrowth
  - phenotypes#Advanced Bone Age
  rationale: >-
    A source-supported provisional growth pathway is represented: altered MAPK/ERK signaling in patient-derived fibroblasts may affect hypertrophic chondrocyte differentiation. The study did not measure affected growth plates, and kinase-significance estimates depended on outlier exclusion. Patient blood profiling additionally identifies skeletal-development genes, but neither study establishes the tissue-specific mediators of statural growth or explains macrocephaly. The remaining gap is experimental confirmation and anatomical attribution, not absence of a published growth hypothesis.
  proposed_experiments:
  - experiment_id: sotos-growth-plate-chondrocyte-model
    name: NSD1-haploinsufficient human chondrocyte and growth-plate model
    description: >-
      Differentiate isogenic NSD1+/- and corrected human iPSC lines into
      chondrocytes and cartilage organoids, and compare proliferation, hypertrophic
      transition timing, H3K36me2 distribution and intergenic DNA methylation across
      matched differentiation stages.
    readouts:
    - name: Chondrocyte proliferative and hypertrophic-transition kinetics by NSD1 genotype
      target: "phenotypes#Advanced Bone Age"
    - name: H3K36me2 and CpG-methylation state at growth-regulatory loci in chondrocytes
      target: "pathophysiology#Dysregulated Developmental Transcriptional Program"
    decision_criterion: >-
      A reproducible genotype-dependent acceleration of hypertrophic transition,
      reversed by isogenic correction and accompanied by a chromatin change at
      identifiable growth-regulatory loci, would establish a candidate skeletal
      overgrowth mechanism. Normal chondrocyte behaviour despite the expected
      chromatin defect would push the explanation towards an endocrine or systemic
      route.
  evidence:
  - reference: PMID:23155469
    reference_title: Sotos syndrome is associated with deregulation of the MAPK/ERK-signaling pathway.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In analogy, we propose that deregulation of the MAPK/ERK pathway in SoS results in altered hypertrophic differentiation of NSD1 expressing chondrocytes and may be a determining factor in statural overgrowth and accelerated skeletal maturation in SoS.
    explanation: >-
      An explicit causal hypothesis links altered signaling to growth-plate differentiation and the two clinical outcomes. Patient growth plates were not studied; normal human growth plates established NSD1 localization.
    directness: INDIRECT
  - reference: PMID:35094088
    reference_title: NSD1 mutations deregulate transcription and DNA methylation of bivalent developmental genes in Sotos syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified other transcriptionally and epigenetically deregulated genes that are known to regulate skeletal overgrowth and craniofacial anomalies, suggesting that perturbation of these genes contributes to the SS phenotypes.
    explanation: >-
      The patient blood study proposes developmental target-gene dysregulation as an explanation for growth and craniofacial findings; the specific tissue and individual facial components were not experimentally resolved.
    directness: INDIRECT
- discussion_id: sotos_episignature_causal_status
  prompt: >-
    Is the peripheral-blood DNA methylation episignature a step in the causal chain
    that produces the Sotos phenotype, or a robust biomarker of NSD1 loss measured
    in the wrong tissue?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Intergenic DNA Hypomethylation from Loss of DNMT3A Recruitment
  rationale: >-
    The intergenic hypomethylation node is curated as mechanism because the
    H3K36me2-DNMT3A dependency was established experimentally and the same
    hypomethylation is observed in patient tissue. But the diagnostic episignature
    is measured in peripheral blood, and the phenotype is generated in developing
    brain, heart and skeleton. Whether the methylation change in the relevant
    developing tissues is a cause of the transcriptional dysregulation or a parallel
    consequence of the same histone lesion is not settled by any cited study. The
    same open question is recorded at module level for the chromatinopathies
    generally; this entry inherits it rather than resolving it, and the episignature
    is therefore curated under `diagnosis` as a classifier rather than as a
    downstream pathophysiology node.
  evidence:
  - reference: PMID:26690673
    reference_title: "NSD1 mutations generate a genome-wide DNA methylation signature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "As DNAm can be tissue and cell-type specific, we tested fibroblast-derived DNA from three SS patients with truncating mutations in NSD1 in comparison to four control fibroblast samples."
    explanation: >-
      The authors themselves treat tissue specificity as the live question and
      address it only with three fibroblast samples - no developing brain, cardiac
      or skeletal tissue is examined.

- discussion_id: sotos_phenotype_causality_craniofacial
  prompt: >-
    Which NSD1-dependent developmental processes generate the individual facial, hair and palatal components of the Sotos gestalt?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Sparse Frontotemporal Hair
  - phenotypes#Downslanting Palpebral Fissures
  - phenotypes#Broad Forehead
  - phenotypes#Prominent Forehead
  - phenotypes#Dolichocephaly
  - phenotypes#Long Face
  - phenotypes#Tall Chin
  - phenotypes#High Arched Palate
  rationale: >-
    Patient transcriptional profiles support a provisional craniofacial-development hypothesis, represented for the overall gestalt. The reviewed sources do not establish which downstream genes or regional developmental processes generate each facial, hair or palatal component.
- discussion_id: sotos_phenotype_causality_brain_size
  prompt: >-
    Which NSD1-loss pathways cause head enlargement, ventricular enlargement and callosal dysmorphism, and do these findings share a regional developmental origin?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Macrocephaly
  - phenotypes#Ventriculomegaly
  - phenotypes#Abnormal Corpus Callosum Morphology
  rationale: >-
    The imaging study raises a PI3K/AKT/mTOR growth hypothesis by extrapolating from NSD1 overexpression and other megalencephaly disorders; this does not establish a forward NSD1-loss mechanism in the human brain. Regional growth, ventricular CSF-space anatomy and callosal development remain incompletely attributed. Cortical-migration hypotheses are represented for cortical folding, but do not by themselves establish the cause of these separate findings.
- discussion_id: sotos_phenotype_causality_neurobehavior
  prompt: >-
    Which neuronal mechanisms mediate seizures, ADHD, anxiety, aggression, self-injury and language delay, and what explains altered sleep timing beyond the proposed respiratory contribution?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Seizures
  - phenotypes#Attention Deficit Hyperactivity Disorder
  - phenotypes#Anxiety
  - phenotypes#Delayed Speech and Language Development
  - phenotypes#Aggressive Behavior
  - phenotypes#Self-Injurious Behavior
  - phenotypes#Sleep Disturbance
  rationale: >-
    Candidate synaptic and neuronal-migration mechanisms are represented for the broad cognitive phenotype, but the reviewed sources do not establish their mediation of seizures, ADHD, anxiety or language delay specifically. The 77-person imaging cohort found no significant seizure–cortical-malformation association; co-occurrence is therefore insufficient to add that edge. Aggression and self-injury are clinically observed, but the reviewed behavioral studies do not establish which NSD1-dependent neuronal process mediates either finding. Sleep scores correlate with behavior, but this does not establish a directed sleep-to-aggression or sleep-to-ADHD mechanism. The proposed palatal-anatomy contribution is represented for sleep breathing problems; it does not explain early sleep timing or the full sleep phenotype.
- discussion_id: sotos_phenotype_causality_musculoskeletal
  prompt: >-
    How do skeletal patterning, neighboring-gene effects and neuromuscular function contribute to scoliosis, joint laxity and flat feet?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Scoliosis
  - phenotypes#Joint Hyperlaxity
  - phenotypes#Pes Planus
  rationale: >-
    Scoliosis severity has a deletion-subtype association and joint laxity can coexist with flat feet, but the reviewed Sotos sources do not establish a tissue-specific causal chain among these observations. Neighboring-gene effects, skeletal patterning and neuromuscular contributions remain unresolved; a generic growth or hypotonia edge would exceed the evidence.
- discussion_id: sotos_phenotype_causality_cardiac_anatomy
  prompt: >-
    Which cardiac developmental defects mediate septal abnormalities and persistent ductal patency in NSD1-related Sotos syndrome?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Atrial Septal Defect
  - phenotypes#Ventricular Septal Defect
  - phenotypes#Patent Ductus Arteriosus
  rationale: >-
    Failure to activate cardiac developmental programs is represented as a provisional explanation for congenital heart defects overall. Stem-cell experiments do not resolve septal patterning or ductal closure, and the clinical series does not establish the specific intermediary causing each anatomical lesion.
- discussion_id: sotos_phenotype_causality_other_clinical
  prompt: >-
    What explains neonatal jaundice, middle-ear susceptibility, gastrointestinal dysfunction and vesicoureteral reflux in Sotos syndrome?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Neonatal Jaundice
  - phenotypes#Recurrent Otitis Media
  - phenotypes#Constipation
  - phenotypes#Gastroesophageal Reflux
  - phenotypes#Vesicoureteral Reflux
  rationale: >-
    The reviewed clinical sources document these manifestations and the otitis-to-conductive-hearing-loss consequence, but do not establish the upstream Sotos-specific causal processes. Neonatal bilirubin handling, middle-ear susceptibility, gastrointestinal motility or sphincter function and ureterovesical development remain unassigned; swallowing dysfunction cannot be assumed to cause reflux or constipation.
- discussion_id: sotos_phenotype_causality_ocular_components
  prompt: >-
    Which developmental processes cause the individual ocular findings?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Strabismus
  - phenotypes#Hypermetropia
  - phenotypes#Astigmatism
  rationale: >-
    Patient blood transcriptional data identify candidate ocular-development genes and support a provisional link to broad eye abnormalities. Neither that study nor the clinical observations establish the mechanism of ocular alignment or the specific refractive defects; those anatomical and functional attributions remain unresolved.
notes: >-
  This entry covers NSD1-related Sotos syndrome. NFIX-related Malan syndrome and biallelic APC2 disease are separate disorders. APC2 is included as a candidate downstream effector of NSD1 in cortical models, with the human disease distinction retained. Intragenic-variant and 5q35-deletion subtypes overlap clinically; deletion cohorts show quantitative differences in learning disability, overgrowth and scoliosis. Lack of correlation with deletion size does not exclude neighboring-gene contributions and does not imply a more severe dose of NSD1 loss. The molecular and neural mechanisms refine the epigenetic-machinery neurodevelopmental module; non-neural growth, mesendodermal, feeding and tumor hypotheses have distinct scopes. Falcon and asta reports were treated as navigation; claims were reassessed against their cited source context and additional clinical and mechanistic literature. Module conformance is deliberate: NSD1 dosage, H3K36me2 depletion, developmental transcription and cortical neuronal maturation align with the epigenetic-machinery module. Intergenic DNA hypomethylation, enhancer priming and the separate synaptic-development node refine its coarse steps without claiming additional one-to-one counterparts. Structural-variant formation, growth-plate/FGF-MAPK signaling, mesendodermal differentiation, feeding physiology and tumor biology extend beyond its neural scope. The module's composite phenotype output is represented by the separate clinical phenotypes. There is currently no overgrowth-syndrome grouping in kb/groupings/; existing Weaver, Malan, Tatton-Brown-Rahman, Luscan-Lumish, Marshall-Smith and CHD8-related entries provide candidates for future grouping curation. The uantwerpen author manuscript and PMID:39147584 identify one AJNR imaging study (DOI:10.3174/ajnr.A8364); URL evidence is used only for full-text details and is not independent replication. The asta report was predominantly off topic; the substantive Falcon report supplied leads whose claims were independently checked.

review_notes: >-
  All original phenotypes and added findings were reviewed for source support, HPO specificity and causal explanation. Frequency corrections separate NSD1-related disease from NFIX/Malan or mixed-genotype cohorts, symptom-screen thresholds from clinical diagnoses, and selected specialty cohorts from population estimates. The facial gestalt and combined height/head-size overgrowth endpoint retain their own frequencies, without transferring those denominators to component findings. Bone-age estimates retain their age and threshold differences; neonatal hypotonia, poor feeding and jaundice use neonatal estimates. Clinical phenotype nodes are distinguished from blood DNA-methylation assays and molecular experimental readouts, which remain in diagnosis or mechanisms. Provisional paths represent published growth-plate, synaptic, cortical-migration, developmental-transcription and tumor-suppressor hypotheses, with tissue, dosage and model-translation limits explicit. Remaining clinical causal gaps are enumerated in discussions by the specific unresolved attribution; none is left merely because a supported path was not yet modeled. Advanced-bone-age estimates remain unreconciled across age, sex, threshold and ascertainment: the cached GeneReviews chapter itself gives 75–80% before puberty, so this is no longer only a Falcon lead; the Korean primary cohort reports 8/20 males and 1/13 females among 33 assessed at last visit with a greater-than-two-year threshold. The 2005 primary series reports 76% among those measured, not all 239 clinically reviewed individuals. These observations are compatible with a substantial prepubertal frequency but do not establish one comparable lifetime rate. A reviewer with age-stratified primary radiographs, assessed denominators and thresholds should revisit the band; it remains unset. Macrocephaly and ADHD retain explicitly scoped bands from the 57-person Korean NSD1-confirmed series. The September 10 behavioral follow-up adds sleep disturbance, aggression, self-injurious behavior and hypodontia from clinical sources, with screening versus diagnosis, unavailable genotype data and selected dental/behavioral ascertainment stated explicitly. Early bed/rise timing is retained within sleep disturbance without diagnosing insomnia or a circadian phase disorder. The review’s combined behavioral percentage is not assigned to any individual phenotype. Published provisional routes are represented for palatal anatomy contributing to sleep breathing problems and GREM2/TSPEAR dysregulation contributing to hypodontia; the latter is supported clinically by premolar agenesis, not by nonspecific poor adult dentition.

📚

References & Deep Research

References

1

PMID:20301652

Sotos Syndrome.

No top-level findings curated for this source.

Deep Research

2

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Sotos Syndrome · 2026-09-05T18:31:31Z · View source

Created kb/disorders/Sotos_Syndrome.yaml (2021 lines) for MONDO:0019349, NSD1-related Sotos syndrome, closing claim issue #11086. Stub stubs/Sotos_Syndrome.yaml deleted. DEEP RESEARCH THAT ACTUALLY RAN. Two providers, both completed, no fallback used. (1) asta (`just research-disorder asta Sotos_Syndrome`, 9.6s) -> research/Sotos_Syndrome-deep-research-asta.md. It is retrieval-only and this run was poor: of 20 retrieved papers only three were about Sotos syndrome. The rest were Bartter syndrome, nasopharyngeal carcinoma, benign prostatic hyperplasia, pregnancy toxaemia in goats, and similar. Its reference_validation reported 37/37 verified with needs_review: true and two off-topic references (PMID:22169837, GEO:GSE3586). Nothing from this report is cited in the entry; it contributed only orientation (confirming NSD1/H3K36 and the APC2 link, both of which were then sourced from primary literature). (2) falcon / Edison (`just research-disorder falcon Sotos_Syndrome`, 677s) -> research/Sotos_Syndrome-deep-research-falcon.md plus one artifact (Sotos_Syndrome-deep-research-falcon_artifacts/artifact-00.md, a markdown summary table, not an image, so it is not referenced from any evidence `images:` slot). This run was substantive. reference_validation: 14/14 resolved, 0 not found, 0 off topic. Its ordered causal chain independently matches the one curated here, including its explicit statement that "The exact growth-effector pathway is unresolved; a simple GH/IGF excess mechanism has not been established" - which is the basis of the sotos_overgrowth_mechanism_unexplained knowledge-gap discussion. TERM VALIDATION FINDINGS FROM THE FALCON REPORT (none of these were bound). Its term_validation block reported needs_review: true, with GO:0016571 (obsolete histone methylation) and GO:0006306 (obsolete DNA methylation) flagged obsolete - both avoided; GO:0140954 (histone H3K36 dimethyltransferase activity) and GO:0040029 (epigenetic regulation of gene expression) were used instead. Separately, and NOT caught by the report's own validator, the report suggested HP:0001513 for "Overgrowth". HPO calls HP:0001513 "Obesity". That binding was rejected; the overgrowth phenotype is bound to HP:0000098 Tall stature. This is the exact failure mode the dismech-terms skill warns about - a resolvable CURIE naming a different concept - and it is worth recording that the report's own term validator did not flag it because the report never asserted a label for it. The dismech pre-edit validation hook also caught two MONDO IDs I had written from memory in the differential_diagnoses block: MONDO:0013994 (actually Joubert syndrome 20) for Malan syndrome and MONDO:0014508 (actually vitelliform macular dystrophy 4) for Tatton-Brown-Rahman syndrome. Both were corrected against the existing KB entries to MONDO:0013885 and MONDO:0014382 respectively before the file was written. GENEREVIEWS BASELINE (required, and present). PMID:20301652 "Sotos Syndrome." (Adam, Bick, Mirzaa et al.), tagged `GeneReviews` in the top-level `references:` block. Every phenotype named in its Clinical Characteristics section is represented in `phenotypes:` except two, both deliberate: malar flushing has no HPO term (searched HP via OLS; folded into the Distinctive Facial Appearance description instead), and maternal preeclampsia is a maternal rather than proband finding with no suitable proband-level HPO binding (noted in the entry rather than curated as a phenotype). Its Management section supplied the Developmental and Educational Intervention and Multisystem Surveillance treatments, including the explicit do-not-treat rule for ventricular dilatation without raised ICP, which is curated as evidence on both the imaging phenotype and the surveillance treatment. GeneReviews lists no Agents/Circumstances to Avoid section in the cached abstract. MECHANISM MODEL AND WHY. The pathophysiology is a nine-node causal chain, not a list: NAHR at 5q35 Sos-REP low-copy repeats -> NSD1 Haploinsufficiency NSD1 Haploinsufficiency -> Genome-Wide H3K36me2 Depletion H3K36me2 Depletion -> Intergenic DNA Hypomethylation (loss of DNMT3A recruitment) H3K36me2 Depletion -> Loss of Developmental Enhancer Priming both arms -> Dysregulated Developmental Transcriptional Program Transcriptional Program -> Impaired Cortical Neuronal Migration -> (phenotype) ID Transcriptional Program -> Impaired Mesendodermal Differentiation -> (phenotype) CHD Reduced NSD1 Tumor-Suppressor Function -> (phenotype) Neoplasia Judgement calls: - The NAHR node is placed UPSTREAM of haploinsufficiency rather than beside it, because the structural event is how one subtype reaches the dosage lesion. It carries `subtypes: [5q35 Microdeletion]` so it does not read as a claim about every case. - The two chromatin arms are separate nodes because they are separate claims evidenced in separate systems (Weinberg 2019 mouse/human intergenic methylation vs the 2025 JBC mESC enhancer-priming work). Collapsing them would have bundled two mechanisms in one node. - The episignature is deliberately NOT a pathophysiology node. It is curated under `diagnosis:` as a classifier, and the reason is recorded as an explicit KNOWLEDGE_GAP discussion (sotos_episignature_causal_status): the signature is measured in blood, the phenotype is generated in developing brain/heart/skeleton, and no cited study settles whether the methylation change in those tissues is causal or parallel. This follows the parent module's own recorded position on episignatures. - The overgrowth arm has NO curated edge, and that is the single most important modelling decision here. The entry reaches intellectual disability through APC2 (rescue-validated) and cardiac defects through mesendodermal differentiation, but nothing in the cited literature connects the chromatin lesion to a growth-plate or GH/IGF mechanism. Rather than draw an unsourced edge from the transcriptional node to Childhood Overgrowth and Advanced Bone Age, I left the gap open and recorded it as sotos_overgrowth_mechanism_unexplained with a proposed isogenic-chondrocyte experiment. The Choufani evidence item on that discussion is quoted precisely because the authors' interpretation ("reflects the cardinal features of SS (that is, overgrowth and developmental delay)") overreaches the enrichment categories they actually report. - Three edges are graded INDIRECT_UNKNOWN_INTERMEDIATES with `directness: INDIRECT` on their evidence: migration -> intellectual disability, mesendoderm -> cardiac defects, and tumour suppressor -> neoplasia. Each is an inference across a species, system or population gap and is said so in the edge description. MODULE CONFORMANCE. Five nodes conform to epigenetic_machinery_neurodevelopmental_dysregulation, including its declared key target "Dysregulated Neurodevelopmental Transcriptional Program". NSD1 is named in that module's own notes as a writer-class component, so this is the intended fit. The NAHR node and the tumour-suppressor node are deliberately unconformed: the module scopes structural-variant mechanisms out and explicitly assigns cancer biology to the cancer hallmark modules. SUBTYPE DECISION. Intragenic variant vs 5q35 microdeletion are `has_subtypes`, not separate entries. Tatton-Brown 2005 (PMID:15942875) states that every feature in deletion patients also occurs in intragenic-variant patients and that deletion size does not correlate with phenotype, so the deletion is not a contiguous-gene syndrome with its own features. The quantitative differences (less overgrowth, more severe learning disability, more progressive scoliosis) are recorded on the subtype records and on the Childhood Overgrowth, Intellectual Disability and Scoliosis phenotypes. SCOPE. NFIX-related "Sotos syndrome 2" is a separate MONDO concept, already curated as kb/disorders/Malan_Syndrome.yaml, and is cross-referenced as a differential diagnosis rather than absorbed. Biallelic APC2 loss ("Sotos syndrome 3") is likewise not curated here as a disease; APC2 appears only in its evidenced role as an NSD1 transcriptional target. GROUPING. No overgrowth-syndrome grouping exists in kb/groupings/ (checked all 101 files; nothing matches overgrowth, chromatin or epigenetic). Several KB members of that family already exist (Weaver, Malan, Tatton-Brown-Rahman, Luscan-Lumish, Marshall-Smith, CHD8-related overgrowth). An "Overgrowth-Intellectual Disability Syndromes" grouping is a sensible follow-up but NO grouping file was created or edited by this session, as instructed. REFERENCES. 29 distinct PMIDs cited across 124 evidence items; all fetched with `just fetch-reference` into references_cache/. Provenance of the reference set: the GeneReviews chapter (PMID:20301652) from the required PubMed GeneReviews search; the mechanism and cohort papers from direct PubMed E-utilities searches (asta having been useless); and two from the falcon report resolved DOI -> PMID via the PMC ID converter (PMID:35094088 Brennan 2022 human transcriptomics/methylomics, PMID:17825104 Baujat 2007 Orphanet review). No reference listed as unresolved or off-topic by either report is cited. Two references considered and NOT used: PMID:22169837 (a single dental case report, flagged off-topic by asta's own validator and adding nothing the cohorts do not cover) and PMID:20018718's background sentence on tumour risk, which was replaced on the Neoplasia phenotype by the Orphanet review's equivalent statement so a clinical claim is not carried by a cell-line paper's introduction. PMID:20018718 is still cited on the tumour-suppressor pathophysiology node, where its own IN_VITRO experiments are the point. VALIDATION RESULTS - all run to completion, output read: just validate kb/disorders/Sotos_Syndrome.yaml -> Schema: No issues found. Term validation: passed. Reference validation: passed, 124/124 snippets verified. Caches unchanged. just validate-disorders kb/disorders/Sotos_Syndrome.yaml (authoritative batched gate) -> All 1 disorder file(s) passed validation; 124/124 snippets verified. just count-verified-snippets kb/disorders/Sotos_Syndrome.yaml -> 124/124 verified. just check-entity-refs -> OK: entity references resolve in 1 KB file(s). just check-causal-targets -> OK: no new broken pathograph targets. just check-duplicate-keys -> OK: no duplicate mapping keys. just check-qualifier-terms -> OK (entry uses no `qualifiers` blocks). just compliance -> Global 96.7% (237/245), Weighted 97.1%. Remaining compliance gaps, all deliberate: `datasets:` is absent (no Sotos-specific GEO/omics dataset was verified for this entry, and `just verify-datasets` was therefore not needed); the proposed experiment inside the overgrowth knowledge-gap discussion has no `evidence:` or `datasets:` because it is a proposal, not a performed study; and the three classification assignments carry `notes:` provenance rather than `evidence:`, which matches how Weaver_Syndrome records its ISDS assignment. No git commands were run and nothing was committed, per the orchestrator's instruction.

Asta ▸

Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Sotos Syndrome. Core disease mechanisms, molecular and cellular pathways,...

Asta Scientific Corpus Retrieval 20 citations 2026-09-05T17:55:53.897864

Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Sotos Syndrome. Core disease mechanisms, molecular and cellular pathways,...

This report is retrieval-only and is generated directly from Asta results.

Papers retrieved: 20
Snippets retrieved: 20

Relevant Papers

[1] Sotos syndrome.

Authors: T. McLellan, Bryan Rotella, Stephanie Grote-Garcia, Steven L. Proctor, Daniel Patanella et al.
Year: 2011
Venue: Journal of the Indian Society of Pedodontics and Preventive Dentistry
URL: https://www.semanticscholar.org/paper/cf89215b6e9de5fc180c3ecb401d94116937c3e5
DOI: 10.4103/0970-4388.90741
PMID: 22169837
Citations: 4
Summary: A case of Sotos syndrome is presented in a 5½-year-old child with typical facial gestalt including macrodolichocephaly with frontal bossing, frontoparietal sparseness of hair, apparent hypertelorism, downslanting palpebral fissures, and facial flushing.
Evidence snippets:
Snippet 1 (score: 0.413) > Sotos syndrome.

[2] Histone Lysine Methylation and Neurodevelopmental Disorders

Authors: Jeong-Hoon Kim, J. Lee, Im-Soon Lee, Sung Bae Lee, K. Cho
Year: 2017
Venue: International Journal of Molecular Sciences
URL: https://www.semanticscholar.org/paper/89be0a35498be6fa3fb43ece6485a32a2a783a41
DOI: 10.3390/ijms18071404
PMID: 28665350
PMCID: 5535897
Citations: 60
Influential citations: 4
Summary: The latest studies that revealed the pathological implications of alterations in histone methylation status in the context of various neurodevelopmental disorders are reviewed and possible therapeutic application of epigenetic compounds regulating histonemethylation status for the treatment of these diseases are proposed.
Evidence snippets:
Snippet 1 (score: 0.400) > Recent studies demonstrated that disrupted levels or patterns of H3K36 methylation can cause a range of human diseases, including neurodevelopmental disorders. Among them, Sotos syndrome 1 (SOTOS1; OMIM 117550) represents an important human model system for studying the neurodevelopmental outcome of epigenetic dysregulation, which is caused by mutations in NSD1 [117]. SOTOS1 is an autosomal dominant disorder characterized by pre-and postnatal overgrowth, facial dysmorphism, macrocephaly, and non-progressive neurological delay [118]. Interestingly, amplified genomic events of NSD1 resulted in the opposite phenotypic outcome of SOTOS1, so that duplication in NSD1 led to reversed clinical phenotypes of SOTOS1 with microcephaly, as well as delayed bone age, indicating the importance of proper NSD1 expression during brain development [119]. In addition, it was shown that neuroblastoma and glioma may occur in human in the absence of NSD1 function [120]. Although the MAPK/ERK pathway was mapped as a downstream signaling pathway of NSD1-related overgrowth of stature in SOTOS1 [121], until recently, the molecular mechanisms how dysregulated NSD1 affects the mental retardation in SOTOS1 patients remains elusive. To date, two Sotos-like overgrowth syndromes called as Sotos syndrome 2 (SOTOS2; OMIM 614753) and 3 (SOTOS3; OMIM 617169) have been reported, which are caused by mutations in the NFIX and APC2 genes, respectively [122,123]. Among the products of the two genes, APC2, a WNT signaling pathway regulator, has recently been suggested as a crucial target of NSD1, of which defects may cause the intellectual disability associated with SOTOS [123]. In the mouse model system, Apc2 deficiency caused impaired learning and memory abilities along with an abnormal head shape.

[3] Molecular Genetics of Bartter Syndrome: Bridging Genotype–Phenotype Correlations and Precision Therapeutics

Authors: Lina Zhu, Yang Li, Yiyao Bao
Year: 2026
Venue: Current Issues in Molecular Biology
URL: https://www.semanticscholar.org/paper/a5e1ddccfa7d333834c4d32be123c71bfd573f83
DOI: 10.3390/cimb48040422
PMID: 42042082
PMCID: 13114623
Summary: A comprehensive framework to provide a comprehensive framework to facilitate precise diagnosis and individualized treatment strategies, ultimately advancing precision medicine in the management of Bartter syndrome is provided.
Evidence snippets:
Snippet 1 (score: 0.391) > Molecular genetic research on Bartter syndrome has made remarkable strides, elucidating the principal BS genes SLC12A1, KCNJ1, CLCNKB, BSND, and MAGED2 and their corresponding protein defects, thereby refining the molecular framework of disease classification while separating CaSR-associated Bartter-like disease from the core canonical BS spectrum. This progress has significantly deepened our understanding of the underlying pathophysiology and provided an essential framework for correlating genotypes with clinical phenotypes. However, the intricate relationship between genetic mutations and clinical manifestations remains complex and multifaceted, reflecting the profound heterogeneity of the syndrome. Addressing these diagnostic challenges and refining disease classification beyond traditional clinical criteria requires an integrative approach that seamlessly balances high-throughput sequencing technologies with rigorous functional studies. > The mechanisms by which these genetic mutations lead to protein dysfunction are diverse, encompassing critical defects in protein expression, impaired membrane localization, and direct functional impairments. Notably, aberrant protein folding, endoplasmic reticulum-associated degradation (ERAD), and splicing abnormalities have emerged as critical pathogenic pathways. These mechanistic insights not only enhance our fundamental understanding of the disease but also highlight highly promising therapeutic targets. While current treatments remain predominantly symptomatic, focusing primarily on managing electrolyte imbalances and associated complications, they inherently fail to address the underlying molecular defects driving the disease. > The precise identification of specific molecular defects opens innovative avenues for the development of targeted interventions aimed at correcting or compensating for specific protein abnormalities. For instance, molecular chaperones that assist in protein folding, agents that modulate aberrant splicing, and future gene-based strategies represent important experimental directions for mechanism-based therapy. Consequently, the future of Bartter syndrome management may increasingly move toward precision medicine tailored to the molecular pathology of individual patients. However, the transition from concept to clinical implementation will require substantial additional functional, translational, and trial-level evidence. Such mechanism-based strategies promise not only to alleviate clinical symptoms but to fundamentally modify disease progression, thereby drastically improving long-term prognosis and quality of life for patients.

[4] New therapeutic targets in rare genetic skeletal diseases

Authors: M. Briggs, Peter A. Bell, M. Wright, K. A. Pirog
Year: 2015
Venue: Expert Opinion on Orphan Drugs
URL: https://www.semanticscholar.org/paper/1363107f71ae6d2d60abca471cddf3da5d13644b
DOI: 10.1517/21678707.2015.1083853
PMID: 26635999
PMCID: 4643203
Citations: 39
Influential citations: 1
Summary: An overview of disease mechanisms that are shared amongst groups of different GSDs and potential therapeutic approaches that are under investigation are described to generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.
Evidence snippets:
Snippet 1 (score: 0.375) > However, emerging knowledge suggests that the primary genetic defect may be less important than the cells' response to the expression of the mutant gene product [107]. Moreover, the largely overlooked response of a cell (i.e. chondrocyte) to the abnormal extracellular environment is also important for disease progression as illustrated by several GSDs discussed in this review. > It is important that 'omics'-based approaches and technologies are systematically applied to the study of rare GSDs so that definitive reference profiles and disease signatures are generated for each phenotype. These can then be used in a Systems Biology approach to identify both common and dissimilar pathological signatures and disease mechanisms. This approach is entirely dependent upon relevant in vitro and in vivo models (and also novel 'disease-mechanism phenocopies' [107]) for testing new diagnostic and prognostic tools and for determining the molecular mechanisms that underpin the pathophysiology so that effective therapeutic treatments can be developed and validated. This approach will eventually lead to personalized treatments and care strategies centred on shared disease mechanisms with the use of relevant biomarkers to monitor the efficacy of treatment and disease progression. > It is vital that all relevant stakeholders are involved from the outset in defining the appropriate outcomes of any potential therapeutic regime. The perceptions of a successful therapy can differ widely between the clinical academic community and the relevant patient-support groups and it is vital that there is engagement on all these issues. > In summary, the identification of causative genes and mutations for GSDs over the last 20 years, coupled with the generation and in-depth analysis of a plethora of relevant cell and mouse models, has derived new knowledge on disease mechanisms and suggested potential therapeutic targets. The fast-evolving hypothesis that clinically disparate diseases can share common disease mechanisms is a powerful concept that will generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.

[5] Nasopharyngeal Carcinoma Signaling Pathway: An Update on Molecular Biomarkers

Authors: W. Tulalamba, T. Janvilisri
Year: 2012
Venue: International Journal of Cell Biology
URL: https://www.semanticscholar.org/paper/307cb9186444d9dad6e2e3b53763be0de76de186
DOI: 10.1155/2012/594681
PMID: 22500174
PMCID: 3303613
Citations: 96
Influential citations: 5
Summary: The molecular signaling pathways in the NPC are discussed for the holistic view of NPC development and progression and the important insights toward NPC pathogenesis may offer strategies for identification of novel biomarkers for diagnosis and prognosis.
Evidence snippets:
Snippet 1 (score: 0.367) > In the pregenomic eras, highly integrated and complex circuitry of molecular signaling in NPC pathogenesis was only partially understood. Over the past decade, the knowledge of the molecular mechanisms in NPC carcinogenesis has been rapidly accumulated. Dysregulation and abnormal protein expression of molecules in certain signaling pathways involved in cellular functions including proliferation, adhesion, survival, and apoptosis has been demonstrated in the NPC cells. Detailed information on the complex network in signaling pathway leading to a coordinated pattern of gene expression and regulation in NPC will undoubtedly provide important clues to develop novel prognostic and therapeutic strategies for this cancer. Refining molecular markers into clinically relevant assays may assist in the detection of NPC in asymptomatic patients, as well as stage classification and monitoring disease progression and treatments. Furthermore, selective regulation of particular proteins targeting cancer cell proliferation, invasion, and apoptosis is a hopeful prospect for future anticancer therapy that slow disease progression and improve survival.

[6] Phenotypic categorization of genetic skin diseases reveals new relations between phenotypes, genes and pathways

Authors: R. Sadreyev, J. Feramisco, H. Tsao, N. Grishin
Year: 2009
Venue: Bioinformatics
URL: https://www.semanticscholar.org/paper/c53babf10fe6c28338852adee48cf41949958e14
DOI: 10.1093/bioinformatics/btp538
PMID: 19744994
PMCID: 2773259
Citations: 7
Summary: Analysis of genetic skin disorders and a manually designed set of elementary phenotypes whose combinations define diseases as points in a multidimensional space reveals new patterns that suggest previously unknown functional links between proteins, signaling pathways and disease phenotypes.
Evidence snippets:
Snippet 1 (score: 0.363) > Rigorous quantitative analysis of disease phenotypes is a key problem on our way to understanding systemic effects of human gene mutations. Such understanding would enable statistical prediction of clinical manifestations for genome abnormalities, inference of causative genes from complex disease phenotypes, as well as deeper insights into molecular mechanisms of pathophysiology. This tremendous task requires the development of new approaches to link the rapidly growing dataset of gene-disease associations with the many complex and overlapping phenotypes of human disease. > Previously reported approaches to this problem ranged from considering diseases as individual entities connected through shared causative genes (Goh et al., 2007) or co-occurrence in the same patient (Rzhetsky et al., 2007), to more detailed classifications involving the comparison of disease phenotypes, usually based on ontologies of phenotypic terms derived from natural-language phenotype descriptions through automated or semi-automated text analysis (Robinson et al., 2008;van Driel et al., 2006). These analyses may include additional high-throughput data on protein associations (Lage et al., 2007;Wu et al., 2008), improving prediction of new connections between diseases and proteins involved. Here we suggest a different approach to quantitative gene-phenotype analysis. By focusing on the set of genetic skin disorders, we are able to manually analyze the corresponding descriptions of phenotypic manifestations and design a set of elementary phenotypic features whose combinations define any given disease as a point in a multidimensional space. Placing the known gene-disease associations in the context of this space reveals new patterns that suggest previously unknown functional links between disease phenotypes, proteins and signaling pathways. In particular, analysis of telangiectasias (spider vein diseases), reveals a previously unrecognized interplay between the TGF-β signaling cascade and pentose phosphate pathway (PPP), which may mediate glucose-dependent regulation of TGF-β signaling in diabetes.

[7] Clinical Manifestations of Sotos Syndrome

Authors: J. Millichap
Year: 2009
Venue: Pediatric Neurology Briefs
URL: https://www.semanticscholar.org/paper/faa8082caac14db3f99d6ee4d94e2baee0a0a214
DOI: 10.15844/PEDNEURBRIEFS-23-6-1
Summary: The major clinical criteria for the diagnosis of Sotos syndrome were evaluated by geneticists in a retrospective analysis of patients examined at the Children’s Hospital, Goudi, Athens, Greece.
Evidence snippets:
Snippet 1 (score: 0.361) > Clinical Manifestations of Sotos Syndrome

[8] Human Dermal Fibroblast: A Promising Cellular Model to Study Biological Mechanisms of Major Depression and Antidepressant Drug Response

Authors: P. Mesdom, R. Colle, É. Lebigot, S. Trabado, Eric Deflesselle et al.
Year: 2020
Venue: Current Neuropharmacology
URL: https://www.semanticscholar.org/paper/79368e365458486de96794333613c12a6063bf54
DOI: 10.2174/1570159X17666191021141057
PMID: 31631822
PMCID: 7327943
Citations: 16
Summary: This review highlights the great and still underused potential of HDF, which stands out as a very promising tool in the understanding of MDD and AD mechanisms of action.
Evidence snippets:
Snippet 1 (score: 0.360) > Background: Human dermal fibroblasts (HDF) can be used as a cellular model relatively easily and without genetic engineering. Therefore, HDF represent an interesting tool to study several human diseases including psychiatric disorders. Despite major depressive disorder (MDD) being the second cause of disability in the world, the efficacy of antidepressant drug (AD) treatment is not sufficient and the underlying mechanisms of MDD and the mechanisms of action of AD are poorly understood. Objective The aim of this review is to highlight the potential of HDF in the study of cellular mechanisms involved in MDD pathophysiology and in the action of AD response. Methods The first part is a systematic review following PRISMA guidelines on the use of HDF in MDD research. The second part reports the mechanisms and molecules both present in HDF and relevant regarding MDD pathophysiology and AD mechanisms of action. Results HDFs from MDD patients have been investigated in a relatively small number of works and most of them focused on the adrenergic pathway and metabolism-related gene expression as compared to HDF from healthy controls. The second part listed an important number of papers demonstrating the presence of many molecular processes in HDF, involved in MDD and AD mechanisms of action. Conclusion The imbalance in the number of papers between the two parts highlights the great and still underused potential of HDF, which stands out as a very promising tool in our understanding of MDD and AD mechanisms of action

[9] Precision Therapeutics in Lennox–Gastaut Syndrome: Targeting Molecular Pathophysiology in a Developmental and Epileptic Encephalopathy

Authors: Debopam Samanta
Year: 2025
Venue: Children
URL: https://www.semanticscholar.org/paper/455479c1bfbea7b90b73c109228f67c813d13888
DOI: 10.3390/children12040481
PMID: 40310132
PMCID: 12025602
Citations: 23
Influential citations: 1
Summary: A narrative review explores precision therapeutic strategies for LGS based on molecular pathophysiology, including channelopathies, receptor and ligand dysfunction, receptor and ligand dysfunction, cell signaling abnormalities, cell signaling abnormalities, synaptopathies, and the repurposing of existing medications with mechanism-specific effects.
Evidence snippets:
Snippet 1 (score: 0.358) > Lennox–Gastaut syndrome (LGS) is a severe childhood-onset developmental and epileptic encephalopathy characterized by multiple drug-resistant seizure types, cognitive impairment, and distinctive electroencephalographic patterns. Current treatments primarily focus on symptom management through antiseizure medications (ASMs), dietary therapy, epilepsy surgery, and neuromodulation, but often fail to address the underlying pathophysiology or improve cognitive outcomes. As genetic causes are identified in 30–40% of LGS cases, precision therapeutics targeting specific molecular mechanisms are emerging as promising disease-modifying approaches. This narrative review explores precision therapeutic strategies for LGS based on molecular pathophysiology, including channelopathies (SCN2A, SCN8A, KCNQ2, KCNA2, KCNT1, CACNA1A), receptor and ligand dysfunction (GABA/glutamate systems), cell signaling abnormalities (mTOR pathway), synaptopathies (STXBP1, IQSEC2, DNM1), epigenetic dysregulation (CHD2), and CDKL5 deficiency disorder. Treatment modalities discussed include traditional ASMs, dietary therapy, targeted pharmacotherapy, antisense oligonucleotides, gene therapy, and the repurposing of existing medications with mechanism-specific effects. Early intervention with precision therapeutics may not only improve seizure control but could also potentially prevent progression to LGS in susceptible populations. Future directions include developing computable phenotypes for accurate diagnosis, refining molecular subgrouping, enhancing drug development, advancing gene-based therapies, personalizing neuromodulation, implementing adaptive clinical trial designs, and ensuring equitable access to precision therapeutic approaches. While significant challenges remain, integrating biological insights with innovative clinical strategies offers new hope for transforming LGS treatment from symptomatic management to targeted disease modification.

[10] Changes in Serum Proteomic Profiles at Different Stages of Pregnancy Toxemia in Goats

Authors: M. Uzti̇mür, C. N. Ünal, Gurler Akpinar
Year: 2025
Venue: Journal of Veterinary Internal Medicine
URL: https://www.semanticscholar.org/paper/4b9c488b5dbd65d7b26fd2ad9aed70e8c4b59942
DOI: 10.1111/jvim.70139
PMID: 40492724
PMCID: 12150350
Citations: 2
Summary: Understanding the serum proteome profiles of goats with pregnancy toxemia might help identify the proteomes and pathways responsible for the development of this disease and improve diagnosis and treatment.
Evidence snippets:
Snippet 1 (score: 0.357) > The pathophysiology and progression of this disease are not fully understood. > Traditional biomedical research has focused on the analysis of single genes, proteins, metabolites, or metabolic pathways in diseases. This molecular reductionist approach is based on the assumption that identifying genetic variations and molecular components will lead to new treatments for diseases [13][14][15][16]. However, many diseases are complex and multifactorial, and in order to determine the phenotype of such diseases, it is necessary to understand the changes that occur in more than one gene, pathway, protein, or metabolite at the cellular, tissue, and organismal levels [17][18][19]. Therefore, in recent years, proteomics, as one field of multi-omics technologies, has helped in evaluating the complex pathogenetic mechanisms of different diseases from a broad perspective and has made substantial contributions [20,21]. In veterinary medicine, proteomic analysis of metabolic diseases such as ketosis [16], hypocalcemia [22], and fatty liver [23] in dairy cows has contributed valuable insights for the definition of new pathophysiological pathways and new diagnosis and treatment protocols for these diseases. The proteomic approach can contribute importantly to a broad and detailed understanding of the changes that occur at the organismal level associated with the increase in BHBA concentration in goats with pregnancy toxemia. Our aim was to evaluate the serum protein profiles of goats with SPT or CPT using proteomic techniques to determine the proteomic profiles of these animals and to identify the relevant pathophysiological mechanisms.

[11] Investigating the role of NPR1 in dilated cardiomyopathy and its potential as a therapeutic target for glucocorticoid therapy

Authors: Yaomeng Huang, Tongxin Li, Shichao Gao, Shuyu Li, Xiaoran Zhu et al.
Year: 2023
Venue: Frontiers in Pharmacology
URL: https://www.semanticscholar.org/paper/be229f6f2059faab4c97ec0a04bd055adab9dfe1
DOI: 10.3389/fphar.2023.1290253
PMID: 38026943
PMCID: 10662320
Citations: 4
Summary: Natriuretic peptide receptor 1 (NPR1) was identified as a core gene associated with DCM through bioinformatics analysis and led to substantial improvements in cardiac and renal function, accompanied by an upregulation of NPR1 expression.
Evidence snippets:
Snippet 1 (score: 0.352) > Multiple pathways and molecules are involved in this process; however, the detailed underlying mechanisms remain unclear. In recent years, with the development of high-throughput sequencing and gene chip technologies, the use of bioinformatics technology to explore the occurrence, development, and prognosis of diseases has become a hot topic for scholars worldwide (Hwang et al., 2018;Nayor et al., 2019;Rinschen et al., 2019;Sturm et al., 2019;Montaner et al., 2020). > The present study aimed to use bioinformatics technology to screen for DCM-related genes and investigate their mechanisms, with the purpose of revealing the pathogenesis of DCM and seeking treatment methods. The GSE3586 dataset, containing expression profiles related to DCM, was selected from the Gene Expression Omnibus (GEO) database. This study aimed to predict the core genes that may play crucial roles in disease progression at the molecular level through the enrichment of relevant molecular pathways associated with DCM. Furthermore, the phenotype of the core genes was validated to further support the results of the bioinformatics analysis through basic and clinical experiments. Additionally, the role of glucocorticoids in DCM treatment is discussed in this article with the purpose of providing a theoretical and experimental basis for exploring the pathogenesis of DCM and elucidating therapeutic methods. This study also provides a theoretical reference for the interpretation, early diagnosis, and treatment of DCM.

[12] Modeling psychiatric disorders: from genomic findings to cellular phenotypes

Authors: Anna Falk, Vivi M. Heine, A. Harwood, Patrick F. Sullivan, M. Peitz et al.
Year: 2016
Venue: Molecular Psychiatry
URL: https://www.semanticscholar.org/paper/235b41240d78140de7ab06a3ad8a7d0b1bdff1a5
DOI: 10.1038/mp.2016.89
PMID: 27240529
PMCID: 4995546
Citations: 83
Influential citations: 2
Summary: The challenges for modeling of psychiatric disorders, potential solutions and how iPSC technology can be used to develop an analytical framework for the evaluation and therapeutic manipulation of fundamental disease processes are critically reviewed.
Evidence snippets:
Snippet 1 (score: 0.352) > The key challenge for iPSC-based disease modeling is to identify one or more relevant cellular phenotypes that accurately represent the disease pathophysiology. Increasing numbers of reports have demonstrated that for many diseases specific pathophysiology can be captured in human iPSC-based disease models. These range from cardiovascular disease, 44,45 cancer, 46,47 ocular disease, 48,49 diabetes mellitus 50,51 and neurological disorders of the brain. 52,53 Can the same approach be applied to complex psychiatric disorders? > The problem is that almost all psychiatric disorders are characterized by clinical signs and symptoms, but lack independent verification from objective biomarkers. Thus, how might these clinical phenotypes manifest themselves in terms of cell behavior? The identity of robust cellular 'readouts', which typify any psychiatric disorder, is a crucial unsolved problem and an area of intense study 54 (Table 2). When satisfactorily answered, this will herald a new degree of biological objectivity and quantification for the study of psychiatric disorders. > The aim is to find a single or small number of cell phenotypes or parameters that strongly associate with psychiatric disorders, and establish a cellular profile characteristic of cells derived from the general patient population. Although a consensus set of cellular phenotypes for psychiatric disorder is yet to be established, we can define some of their desired characteristics. First, cellular phenotypes have to relate to the biological pathways identified by genetics. Second, although there are many risk genes in disparate biological pathways, at some level, phenotypes should converge onto a much smaller grouping. Third, phenotypes need to be quantifiable. Finally, to be useful for drug development cellular phenotypes should be reversed by pharmacological treatment, although not necessarily by drugs in current use. > Although human iPSC-based approaches underrepresent the complexity of the human central nervous system, cellular phenotypes are likely to lie more proximal to molecular disease mechanisms than phenotypes seen at the level of a tissue or organism, 55 and thus may bypass compensatory homeostatic (2) Gene expression profiles of SCZ human iPSC neurons identified altered expression of many components of the cyclic AMP and WNT signaling pathways.

[13] Modelling Mitochondrial Disease in Human Pluripotent Stem Cells: What Have We Learned?

Authors: Cameron L. McKnight, Y. C. Low, D. Elliott, D. Thorburn, A. E. Frazier
Year: 2021
Venue: International Journal of Molecular Sciences
URL: https://www.semanticscholar.org/paper/bf41f9d980522896fcd2284bd630fbb418e55941
DOI: 10.3390/ijms22147730
PMID: 34299348
PMCID: 8306397
Citations: 21
Summary: Mitochondrial diseases disrupt cellular energy production and are among the most complex group of inherited genetic disorders. Affecting approximately 1 in 5000 live births, they are both clinically and genetically heterogeneous, and can be highly tissue specific, but most often affect cell types with high energy demands in the brain, heart, and kidneys. There are currently no clinically validated treatment options available, despite several agents showing therapeutic promise. However, modell...
Evidence snippets:
Snippet 1 (score: 0.349) > Mitochondrial disease hPSC models provide a system to study disease gene-or mutation-related pathomechanisms in tissues relevant to the clinical phenotype. Ultimately, the long-term goal of these models would be to identify a phenotype in a clinically relevant cell type that could be used to validate efficacy of targeted treatments, or for use in highthroughput treatment trials [94][95][96] (Figure 2). > There are now a wide range of endpoints that have been validated in terminally differentiated cell types to investigate the underlying cellular mechanisms of disease and efficiently identify targetable pathways. Many of these approaches can also be adapted to suit different cell types and even organoids at scale. The tissue specific nature of mitochondrial diseases means that mitochondrial function post-differentiation can be distinct to that from the undifferentiated stem cells or original fibroblast line, often greatly exaggerating any underlying defects [97]. Additionally, detailed transcriptomic and proteomic analyses can elucidate cellular compensation mechanisms and potential target pathways to inform downstream treatment studies [98,99]. Other approaches include microscopic visualization of key cellular features to determine a mutation's impact on cell structure or function [100]. For cardiomyocytes and neurons, electrophysiology can provide highly sensitive data to identify even subtle functional changes [101]. Calcium imaging can be particularly informative in the context of mitochondrial diseases, since calcium handling is a key role of mitochondria [102,103].

[14] Investigating the impact of gut microbiota-derived metabolites on benign prostatic hyperplasia using network pharmacology approaches

Authors: Yuanzhao Xu, Lingyue An, Jiling Xie, Chenggong Luo, Heng Zhang et al.
Year: 2026
Venue: BMC Pharmacology & Toxicology
URL: https://www.semanticscholar.org/paper/197e46477cdeb6884c734497d818f92cac74e67f
DOI: 10.1186/s40360-025-01059-y
PMID: 41535879
PMCID: 12888338
Citations: 1
Summary: A network pharmacology approach is employed to elucidate the intricate “Microbiota-Substrate-Metabolite-Target” (M-S-M-T) network in Benign Prostatic Hyperplasia (BPH), identifying key hub genes (AKT1, IL-6, IL-1B), signaling pathways, and gut microbiota-derived metabolites (butyrate, propionate, TMAO) as central regulators.
Evidence snippets:
Snippet 1 (score: 0.346) > KEGG analysis serves as a powerful tool for delineating well-characterized biological pathways and predicting the functions of currently uncharacterized genes or proteins. This methodology provides critical insights into the regulatory mechanisms governing biological processes, thereby enhancing our comprehensive understanding of them. The results of the KEGG enrichment analysis could be systematically categorized into three major groups (Fig. 5A, 5B, and 5C): 1) Human Diseases, such as "Pathways in cancer" and "Inflammatory bowel disease". This does not imply that BPH is a type of cancer or intestinal disease, but rather reveals that BPH shares many key regulatory mechanisms of cell proliferation and inflammation with these diseases. Gut microbial metabolites influence the development and progression of both BPH and its comorbidities (e.g., diabetes, cardiovascular diseases) by regulating these pathways. 2) Organismal Systems, which are primarily enriched in the "Immune system". This again highlights the central role of immune dysregulation in BPH, and the intervention effect of gut microbial metabolites on BPH through regulating immune-related pathways. 3) Signal Transduction, which is the focus of our attention. Among these, the five major pathways-AGE-RAGE, Toll-like receptor, HIF-1, C-type lectin receptor, and PI3K/Akt-serve as critical bridges linking GM metabolites, core targets, and BPH pathophysiology. Figure 5D presents the pathway-target

[15] DNA-damage-associated protein co-expression network in cardiomyocytes informs on tolerance to genetic variation and disease

Authors: Omar D. Johnson, Sayan Paul, Jose A. Gutierrez, William K. Russell, M. C. Ward
Year: 2025
Venue: iScience
URL: https://www.semanticscholar.org/paper/c060d4fbd3241deb2252e8d80ec52a5a539fd99b
DOI: 10.1016/j.isci.2025.112474
PMID: 40469117
PMCID: 12135479
Citations: 1
Summary: It is demonstrated that protein connectivity in DNA-damage-associated modules influences the tolerance to genetic variation and supports the use of dynamic networks to explore complex traits.
Evidence snippets:
Snippet 1 (score: 0.345) > While DOX can lead to cellular effects through mechanisms including the generation of ROS, at clinically tolerated sub-micromolar doses, DSBs induced through interactions with TOP2B are the main contributors to DOXinduced cardiotoxicity. 10 Clinically, DOX-induced cardiac dysfunction is not a unique pathology but shares characteristics of multiple CVDs. 6 For example, 9% of individuals receiving DOX exhibit reductions in their left ventricular ejection fractions within values that would constitute heart failure. 11,12 Similarly, treatment with DOX increases the risk for electrophysiologic dysfunction and atrial fibrillation by 10-fold and is associated with other related clinically measurable phenotypes, such as an increased QT-interval. 13,14 These pathologies overlap with those influenced by DNA damage and are impacted by genetic risk. 4,15 enome-wide association studies (GWASs) have identified hundreds of risk loci associated with complex CVDs including ll OPEN ACCESS atrial fibrillation, heart failure, and clinical cardiovascular phenotypes, highlighting the genetic component of CVD. 15 Although GWASs identify genetic risk loci that can be mapped to genes that implicate putative regulatory effects, they do not explain the molecular mechanisms of the diseases that they associate with. 16,17 This ultimately impedes our understanding of the effect of genetic variation on CVD and its applicability to identify potential drug targets. 17 ne approach to understand a complex disease phenotype is to construct networks based on molecular phenotypes such as global mRNA or protein expression levels. 0][21] Targeted studies investigating the protein interactomes of proteins encoded in GWAS loci have identified convergent points in the interaction network for autism spectrum disorder and coronary artery disease, highlighting disease-relevant biology. 22,23 Complex disease networks are likely to exert tissue-and cell-typespecific effects. Indeed, proteins relevant to late onset Alzheimer disease are localized within glial cells in the brain. 21 Similarly, the appropriate cellular context, such as cell type and state, is important for understanding the basis of CVD.

[16] Computational modelling of TNFα related pathways regulated by neuroinflammation, oxidative stress and insulin resistance in neurodegeneration

Authors: Hemalatha Sasidharakurup, Shyam Diwakar
Year: 2020
Venue: Applied Network Science
URL: https://www.semanticscholar.org/paper/aea95bfe3c4303f1361a8ea72828d2926ea0d03e
DOI: 10.1007/s41109-020-00307-w
Citations: 9
Summary: Simulations suggest insulin may be an important factor identifying neurodegeneration in AD and PD, through its action along with the neuroinflammation and oxidative stress.
Evidence snippets:
Snippet 1 (score: 0.344) > Modelling complex biological pathway networks including their cellular and molecular components, and interactions (Ji et al. 2017) can help connect critical factors statistically relevant as common signaling mechanisms or phentotypic functions to both disorders. Developing computational models can aid reproducing disease pathways and predicting dynamical behaviours essential for approprite protocol design and experimental testing and to map clinical symptoms to molecular processes going through cellular and circuit functions (Conradi et al. 2007;Bartocci and Lió 2016). Using biochemical systems theory (BST), sub-cellular reactions and biochemical pathways were modeled using ordinary differential equations (ODE) for reconstructing signalling dynamics in this study (Savageau et al. 1987). All biochemical reactions involved in disease-related signalling pathways were expressed mathematically using ODE and rate equations were computed using computational tools (Bartocci and Lió 2016). > The objective of this modeling exercise was to map major genes or proteins involved in disease mechanism, the reactions affected by the mutation of these genes and the difference in reactions when compared with healthy controls, action ofpotential drugs. In literature, BST models on oxidative stress and inflammation in insulin resistance were already available for PD condition (Braatz and Coleman 2015). These models explore some of the important pathways involved in PD and the treatment options. Most of the initial conditions for the model parameters were assigned as relative values rather than real data. With the need to model crosstalk and critical networks relevant to neurodegeneration identified by more recent studies, we have incorporated the crosstalk between insulin resistance, oxidative stress and neuroinflammation related to TNFα signalling in normal, AD and PD conditions (Fallahi-Sichani et al. 2011;Sasidharakurup et al. 2020;Su and Wu 2020). The parameteric values relating to biological states and initial conditions for this model were manually extracted from literature on disease models. In a previous study, we had modelled the role of TNFα mediated glutamate excitotoxicity and neuroinflammation (Sasidharakurup et al. 2020) and the variations in TNFα levels during both healthy and diseased conditions were analyzed.

[17] Role of Transcriptomics in Precision Oncology

Authors: Ruby Srivastava
Year: 2024
Venue: Reports of Radiotherapy and Oncology
URL: https://www.semanticscholar.org/paper/0bd862558bbb7286336111d9dfd232b5f905d3d9
DOI: 10.5812/rro-142195
Citations: 5
Summary: : Transcriptome profiling is one of the most widely used approaches in the field of multiomics research. It plays a crucial role in the prognostic, diagnostic, and predictive treatment of cancer patients. Novel next-generation sequencing (NGS) technologies permit the identification of cancer biomarkers, gene signatures, and their abnormal expression, affecting oncogenic and molecular targets and novel biomarkers for cancer therapies. Multiomics studies have changed the overall understanding o...
Evidence snippets:
Snippet 1 (score: 0.341) > : Transcriptome profiling is one of the most widely used approaches in the field of multiomics research. It plays a crucial role in the prognostic, diagnostic, and predictive treatment of cancer patients. Novel next-generation sequencing (NGS) technologies permit the identification of cancer biomarkers, gene signatures, and their abnormal expression, affecting oncogenic and molecular targets and novel biomarkers for cancer therapies. Multiomics studies have changed the overall understanding of cancer and opened a precise perspective for tumor diagnostics and therapy. The use of these approaches has strengthened our understanding of disease pathophysiology and classifications at the molecular level, including specific interference with drug mechanisms of action. Still, it has limited added value in the clinical setting. The omics data on precision medicine include the application of data from genes, transcripts, and proteins for diagnosis, monitoring of diseases, risk factor determination, counseling, and development of novel therapeutics. Bioinformatics applications have expanded statistics-based analysis toward deriving molecular pathways and process models for characterizing phenotypes and drug action mechanisms. In this review, we will discuss transcriptomics and interference analysis that allows the identification of predictive biomarkers at the molecular level to test drug response and analyze the molecular process interface of disease progression-relevant pathophysiology and mechanism of action to propose predictive biomarkers.

[18] ‘Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics’

Authors: S. Mehmood, M. Faheem, Hammad Ismail, Syeda Mehpara Farhat, Mahwish Ali et al.
Year: 2022
Venue: Frontiers in Molecular Biosciences
URL: https://www.semanticscholar.org/paper/c542ec176c594aeddb3790bb3d10767598b86ae4
DOI: 10.3389/fmolb.2022.783494
PMID: 35495618
PMCID: 9048735
Citations: 21
Influential citations: 2
Summary: This review has summarized therapeutic resistance associated with BC and the techniques used for its management, and identifies the biomarkers of disease progression and treatment progress by collective characterization and quantification of pools of biological molecules within and among the cancerous cells.
Evidence snippets:
Snippet 1 (score: 0.341) > Breast cancer is a very complex and heterogeneous disorder with unique molecular and morphological features relative to a disease which involves only a single gene or protein in a simple signaling pathway contributing toward the progression of disease in an independent and autonomous manner (Organization 2019). Various studies had represented BC heterogeneity through the differential response of the same type of BC patients to treatment and risk of developing side effects. One of the major clinical complications in the treatment of breast carcinoma patients is the development of therapeutic resistance (Luque-Bolivar et al., 2020). Recently drug resistance in BC treatment is not properly addressed, rather to focus on molecular pathways deeply; an alternative strategy of using a different drug is commonly applied. In order to reduce the adverse effects of BC treatment including drug resistance, a profound understanding of the molecular mechanism of the disease and the response to the drug is needed. Multidrug resistance (MDR) and consequent relapse on therapy are prevalent issues related to breast carcinoma as our understanding is incomplete related to the molecular mechanism of breast carcinoma disease (Waks and Winer, 2019a). Therefore, elucidating the molecular mechanisms involved in drug resistance is critical. For the management of breast cancers, the treatment decision not only depends on the Treatment with exemestane alone or in combination with an mTOR inhibitor such as everolimus (Carlini et al., 2007Chin et al., 2007Geisler et al., 2008Bahrami et al. (2020) ER+/ HER2- assessment of prognosis factors but also on the evaluation of pathological and clinical factors. Integrated data assessments of these multiple factors of breast carcinoma through multiomics can provide significant insight and hope for making therapeutic decisions (Parsons and Francavilla 2020). Major BC treatment strategies rely on the tumor subtype, immunohistochemical evaluation of prognostic elements, and seek new genetic markers to improve the diagnostic strategies and to enhance treatment outcomes with minimal side effects.

[19] Mitochondrial Dysfunction in Diabetes: Shedding Light on a Widespread Oversight

Authors: F. Iheagwam, A. J. Joseph, E. D. Adedoyin, Olawumi Toyin Iheagwam, Samuel Akpoyowvare Ejoh
Year: 2025
Venue: Pathophysiology
URL: https://www.semanticscholar.org/paper/dbf8042761c1a5fc50f8cd894cc498505abac7cb
DOI: 10.3390/pathophysiology32010009
PMID: 39982365
PMCID: 12077258
Citations: 43
Influential citations: 1
Summary: This review aims to elucidate the complex link between mitochondrial dysfunction and diabetes, covering the spectrum of diabetes types, the role of mitochondria in insulin resistance, highlighting pathophysiological mechanisms, mitochondrial DNA damage, and altered mitochondrial biogenesis and dynamics.
Evidence snippets:
Snippet 1 (score: 0.341) > The landscape of DM research is continuously evolving, with emerging technologies and approaches offering new insights into the pathophysiology of the disease and potential therapeutic targets. Advancements in omics technologies, encompassing genomes, transcriptomics, proteomics, and metabolomics, have transformed the molecular mechanisms underlying DM [134]. High-throughput sequencing techniques enable comprehensive analysis of genetic variants, gene expression profiles, protein abundance, and metabolite levels associated with DM and its complications [135]. Single-cell omics approaches provide unprecedented resolution and granularity, allowing researchers to dissect cellular heterogeneity and identify novel cell types, subpopulations, and signalling pathways involved in DM pathogenesis. Integrating multi-omics data sets offers a systems-level perspective of DM, unravelling complex networks of molecular interactions and regulatory circuits underlying disease progression [136]. > In addition to omics technologies, advances in imaging modalities, such as MRI, PET, and optical imaging, enable non-invasive visualisation and quantification of metabolic, functional, and structural changes. Molecular imaging probes targeting specific biomarkers and metabolic pathways provide valuable insights into disease mechanisms and treatment responses in preclinical and clinical settings [85]. Despite significant progress in DM research, numerous unanswered questions and knowledge gaps persist, hindering the ability to develop effective prevention and treatment strategies. Key areas requiring further investigation include the role of epigenetics, environmental factors, and the microbiome in DM susceptibility and progression. Moreover, the interaction between environmental cues and genetic predisposition remains incompletely understood, highlighting the need for comprehensive multi-omics studies and large-scale epidemiological analyses to identify gene-environment interactions and modifiable risk factors for DM [137]. Furthermore, the heterogeneity of DM phenotypes and clinical outcomes poses a challenge for personalised medicine approaches, necessitating robust biomarkers and predictive models to stratify patients based on disease subtypes, prognosis, and treatment response [138].

[20] Molecular mechanisms and phenotypic diversity in Bardet-Biedl syndrome

Authors: Carlos Lopez Solarat
Year: Unknown
Venue: Unknown venue
URL: https://www.semanticscholar.org/paper/a574e514383f0a43ed35aa91418e699308c97629
DOI: 10.35869/11093/8876
Summary: This thesis primarily aims to identify and elucidate common and fundamental cellular metabolic mechanisms that could account for the considerable phenotypic diversity observed in BBS.
Evidence snippets:
Snippet 1 (score: 0.340) > Ciliopathies are a group of rare diseases characterized by a wrong function or structure of the cilia. One of them is Bardet-Biedl syndrome, a multisystemic disease whose main symptoms are retinal degeneration, obesity, polydactyly, cognitive impairment, cryptorchidism and wrong renal structure and function, as well as other less common but of great clinical relevance symptoms such as liver fibrosis, diabetes and hypertension. Ciliopathies are a group of diseases characterized by an alteration in the function or structure of the primary cilium, a cellular organelle responsible for signal transduction. One of these diseases is Bardet-Biedl syndrome (BBS MIM # 209900), which is characterized by mutations in genes that code for a series of proteins that interact to form a protein complex, the BBSome. The precise molecular process underlying BBS manifestation remains unclear. The positioning and involvement of BBSome in ciliary signal transduction suggest a specific disruption of particular metabolic pathways. Nevertheless, the extensive phenotypic variability in this syndrome coincides with distinct tissue alterations, indicating that BBSome likely affects cell signalling through a shared mechanism influencing a majority of receptors within the cell. Numerous ciliopathies exhibit a pathological phenotype that significantly overlaps not only with other ciliopathies but also with different disease types. This is exemplified by BBS and mitochondrial diseases, where both entail multiple tissues and present symptoms such as optic atrophy, neurological involvement, and metabolic irregularities. Consequently, mitochondrial dysfunction could be viewed as a potential novel mechanism contributing to specific BBS symptoms. Building upon the aforementioned points, this thesis primarily aims to identify and elucidate common and fundamental cellular metabolic mechanisms that could account for the considerable phenotypic diversity observed in BBS.

Notes

This provider combines search_papers_by_relevance with snippet_search.
No synthesis or second-stage model call is performed.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	37
Resolved	37
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	37
On topic	18
Off topic	2

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

PMID:22169837 (1 mention) - Sotos syndrome.
shared terms: none
GEO:GSE3586 (1 mention) - Dilated Cardiomyopathy and Non Failing Septal Biopsies
shared terms: disease

Weighed against this report's own most characteristic terms: disease, snippet, mechanism, year, url, molecular, pathway, gene, venue, treatment, clinical, phenotype, score, protein, therapeutic, genetic, complex, pathophysiology, cell, cellular.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

Term Validation

No ontology term identifiers were found in this report.

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 32 citations 2026-09-05T18:06:56.069269

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Sotos Syndrome
MONDO ID: MONDO:0019349 (if available)
Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Sotos Syndrome covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Present this section as an ordered causal chain first, then the detail below. Open with a numbered sequence of mechanistic steps running from the initiating lesion (mutation, exposure, infection) to the clinical manifestation, one step per line, each naming what it causes next. State the causal verb explicitly ("leads to", "results in") and say where a step is inferred rather than demonstrated. Where the mechanism branches, show the branch. The categories below are a checklist of what to cover within those steps, not the organizing structure — a step may draw on several of them, and a category may contribute to several steps.

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Sotos syndrome: comprehensive disease-characteristics report

Executive summary

Sotos syndrome is a congenital, lifelong Mendelian overgrowth–neurodevelopmental disorder caused principally by heterozygous loss of function of NSD1, an H3K36 histone methyltransferase. Its cardinal phenotype is distinctive facial appearance, developmental/learning disability, and childhood overgrowth—especially macrocephaly—although approximately 10% of molecularly confirmed individuals do not have overt overgrowth. Current care is supportive and surveillance-based; no disease-modifying therapy has been established. The most consequential recent advances are improved variant classification, broader sequencing-based diagnosis, recognition of neuropsychiatric and cardiovascular disease, and molecular definition of an NSD1-dependent transcriptional/DNA-methylation signature. (tattonbrown2007sotossyndrome pages 1-3, ocansey2025sotossyndrome pages 1-3, brennan2022nsd1mutationsderegulate pages 1-1, testa2023molecularanalysisand pages 1-2)

Domain	Best-supported quantitative/current finding	Evidence type/year	Ontology-ready terms
Identifiers	Sotos syndrome; OMIM 117550; MONDO:0019349; synonym: cerebral gigantism syndrome	Curated disease resources, 2025	MONDO:0019349; Sotos syndrome
Cardinal phenotypes	Distinctive facial appearance, learning/developmental disability, and childhood overgrowth occur in ≥90% of molecularly confirmed cases; overgrowth is not obligatory	Human cohort, 2005; clinical synthesis, 2025	HP:0001513 Overgrowth; HP:0000256 Macrocephaly; HP:0001263 Global developmental delay; HP:0001622 Premature birth is not cardinal
Neonatal features	Hypotonia ~75%, poor feeding ~70%, and neonatal jaundice ~65%	Aggregated clinical cohorts, 2025	HP:0001252 Hypotonia; HP:0011968 Feeding difficulties; HP:0000952 Jaundice
Growth and skeletal findings	Bone age is advanced in ~75–80% of prepubertal children; scoliosis occurs in ~30%; height often approaches the normal range after puberty, while macrocephaly usually persists	Human natural-history synthesis, 2005–2025	HP:0005616 Accelerated skeletal maturation; HP:0002650 Scoliosis; HP:0000256 Macrocephaly
Neurologic and behavioral findings	Non-febrile seizures occur in ~25%; intellectual impairment varies from mild to severe and is generally stable; ASD, ADHD, anxiety, expressive-language difficulty, and sleep disturbance are recurrent	Human cohorts and review, 2024–2025	HP:0001250 Seizure; HP:0001249 Intellectual disability; HP:0000729 Autistic behavior; HP:0007018 Attention deficit hyperactivity disorder; HP:0000739 Anxiety
Cardiovascular and renal complications	Historical cardiac-anomaly estimates are 15–40%; a selected 2024 molecularly confirmed cohort found heart defects in 27/45 (60%). Renal anomalies occur in ~15%	Human observational cohorts, 2024–2025	HP:0001627 Abnormal heart morphology; HP:0000077 Abnormal renal morphology; UBERON:0000948 heart; UBERON:0002113 kidney
Genetics and inheritance	Heterozygous NSD1 loss-of-function variants or 5q35 deletions cause autosomal-dominant disease; ~95% are de novo and ~5% inherited. An affected individual has a 50% transmission risk	Human molecular cohorts and curated synthesis, 2005–2025	NSD1; HGNC:14234; 5q35.3; HP:0000006 Autosomal dominant inheritance
Variant spectrum	Truncating, frameshift, nonsense, splice, pathogenic functional-domain missense, partial-gene deletion, and whole-gene/5q35 microdeletion variants occur. Microdeletions correlate with less prominent overgrowth and more severe learning disability	Human genotype–phenotype cohorts, 2005–2023	SO:0001587 stop gained; SO:0001589 frameshift variant; SO:0001574 splice acceptor variant; SO:0000159 deletion
Molecular mechanism	NSD1 haploinsufficiency reduces H3K36 methyltransferase dosage, disturbing H3K36me1/2-directed DNA methylation and PRC2 regulation; human profiling shows promoter hypomethylation and dysregulation of bivalent developmental and neural-synapse genes	Human multi-omics plus biochemical evidence, 2011–2022	GO:0046975 histone H3K36 methyltransferase activity; GO:0016571 histone methylation; GO:0006306 DNA methylation; GO:0040029 regulation of gene expression, epigenetic; GO:0000785 chromatin
Molecular diagnosis	Diagnosis is established by a heterozygous pathogenic/likely pathogenic NSD1 variant or NSD1-encompassing deletion. Testing may use sequencing plus deletion/duplication analysis, CMA, an overgrowth panel, exome, or genome sequencing	Clinical diagnostic guidance, 2023–2025	NCIT:C15709 Genetic Testing; NCIT:C17609 Chromosomal Microarray; NCIT:C101295 Whole Exome Sequencing; NCIT:C101294 Whole Genome Sequencing
Recent diagnostic development	Among 1,530 clinically suspected cases, 292 (19.1%) had NSD1 findings; 115 novel intragenic variants, nine partial deletions, and 13 whole-gene microdeletions were identified. Twenty-five of 32 assessed missense VUS (78.1%) were reclassified as likely pathogenic or likely benign	Human diagnostic cohort, 2023	NCIT:C118466 Variant Classification; NCIT:C17248 Mutation Analysis; NSD1
Tumor risk and screening	Tumors are reported in approximately 3%; sacrococcygeal-teratoma/neuroblastoma risk is ~1%. Expert guidance does not recommend routine cancer screening or routine renal ultrasound because risk is insufficient and Wilms-tumor risk is not significantly increased	Cohort synthesis and expert guidance, 2017–2025	HP:0002664 Neoplasm; NCIT:C15709 Genetic Testing; NCIT:C16210 Cancer Screening
Treatment and trials	No disease-modifying therapy is established. Care is individualized and supportive: developmental and educational services, speech/AAC, PT/OT, feeding support, behavioral/psychiatric care, antiseizure treatment, and organ-specific intervention. No relevant disease-modifying Sotos trial was identified	Expert guidance and trial-registry search, 2024–2025	NCIT:C15308 Supportive Care; NCIT:C15986 Physical Therapy; NCIT:C16020 Occupational Therapy; NCIT:C17149 Speech Therapy; NCIT:C61577 Anticonvulsant Therapy
Mouse model	Nsd1+/− mice have ~50% lower cortical Nsd1 expression, impaired social novelty and fewer pup ultrasonic vocalizations, but no overgrowth, macrocephaly, gross cortical enlargement, or active-place-avoidance deficit. Nsd1−/− embryos die by approximately E10.5 with early patterning/forebrain abnormalities	Genetically engineered mouse, 2020–2021	NCBITaxon:10090 Mus musculus; GO:0009790 embryo development; GO:0021987 cerebral cortex development; CL:0000540 neuron

Table: Concise evidence matrix summarizing the best-supported clinical, genetic, mechanistic, diagnostic, management, and model-organism findings for Sotos syndrome. Ontology-ready terms are included to support structured knowledge-base annotation.

1. Disease information

Definition. Sotos syndrome is an autosomal-dominant overgrowth syndrome characterized by (1) a distinctive long, narrow facial gestalt with a broad/prominent forehead and pointed chin, (2) learning disability or developmental delay, and (3) childhood overgrowth, usually including macrocephaly. The face is often recognizable at birth, most characteristic at ages 1–6 years, and subtler in adulthood. A landmark molecular cohort found facial dysmorphism, learning disability, and childhood overgrowth in approximately 90% of 239 NSD1-positive individuals. (baujat2007sotossyndrome pages 1-2, ocansey2025sotossyndrome pages 5-7, tattonbrown2007sotossyndrome pages 1-3)

Identifiers and terminology. Recommended knowledge-base identifiers are MONDO:0019349, OMIM #117550, and the preferred name Sotos syndrome. Common synonyms include cerebral gigantism and Sotos syndrome 1. Open Targets maps MONDO:0019349 most strongly to NSD1 (Ensembl ENSG00000165671); APC2-associated “Sotos syndrome 3” and historical “Sotos syndrome 2” terminology for NFIX-related Malan syndrome should not be merged with molecularly confirmed NSD1-related Sotos syndrome. (baujat2007sotossyndrome pages 1-2, OpenTargets Search: Sotos syndrome-NSD1, oishi2020investigatingcorticalfeatures pages 1-5)

No single highly specific ICD-10-CM code is established; cases are commonly represented under broader congenital-malformation/overgrowth categories. ICD-11 and MeSH mappings should therefore be validated against the release used by the target database rather than inferred from the disease name.

Evidence granularity. The report synthesizes aggregated disease resources, molecularly confirmed cohorts, primary molecular studies, and experimental models. It is not based on an individual EHR. Individual case reports are identified as such and should not be used to estimate prevalence.

2. Etiology

Causal factors and genetic risk

The primary cause is a heterozygous pathogenic or likely pathogenic NSD1 variant, or a 5q35 deletion encompassing NSD1, producing haploinsufficiency. Established classes include nonsense, frameshift, canonical splice, partial-gene deletion, whole-gene deletion, and pathogenic missense variants concentrated in functional domains. Truncating variants occur throughout the gene. In strictly phenotyped historical cohorts, an NSD1 abnormality was detectable in approximately 90–93%; the 266-person study estimated 83% intragenic variants and 10% 5q35 microdeletions among clinically diagnosed cases. (tattonbrown2007sotossyndrome pages 1-3, krossa2022lysinemethyltransferasensd1 pages 3-4, visser2016nsd1andsotos pages 12-16)

Disease-associated alleles are constitutional/germline, usually de novo, and are expected to be absent or exceptionally rare in population databases. A common allele is not compatible with a fully penetrant, severe dominant developmental disorder. Somatic NSD1 alterations and NUP98–NSD1 fusions occur in cancers but are biologically distinct from germline Sotos syndrome. (ocansey2025sotossyndrome pages 1-3, brennan2022nsd1mutationsderegulate pages 1-1)

Environmental, lifestyle, infectious, and protective factors

There is no established environmental, lifestyle, toxic, occupational, dietary, or infectious cause of Sotos syndrome. Maternal pre-eclampsia has been reported as an associated pregnancy feature, but it is not proven to cause the disorder. No validated genetic or environmental protective factor prevents phenotypic expression after an NSD1 pathogenic variant is present. Likewise, no reproducible gene–environment interaction explains disease occurrence. Phenotypic variability within families suggests contributions from background genotype, development, and possibly environment, but these remain unquantified. (tattonbrown2007sotossyndrome pages 1-3, saugierveber2007heterogeneityofnsd1 pages 10-10)

3. Phenotypes

The following are ontology-ready core annotations; frequencies are approximate because ascertainment and age differ between cohorts.

Overgrowth/tall stature — physical sign, usually prenatal or early childhood; HP:0001513. Height and/or head circumference is ≥2 SD in about 90%, but either may be normal in approximately 10%. Linear growth commonly becomes less extreme after puberty. (ocansey2025sotossyndrome pages 5-7, tattonbrown2007sotossyndrome pages 1-3)
Macrocephaly/macrodolichocephaly — congenital/childhood sign, HP:0000256 and HP:0000268. It generally persists even when adult height normalizes; 18/21 adults in one molecularly confirmed series had head circumference above the 97th centile. (tattonbrown2007sotossyndrome pages 1-3, fickie2011adultswithsotos pages 4-5)
Characteristic facial morphology — congenital physical manifestation; suggested terms include HP:0011220 prominent forehead, HP:0000343 long face, HP:0000307 pointed chin, and HP:0000272 malar flattening. It is most diagnostically useful at ages 1–6 years. (ocansey2025sotossyndrome pages 5-7, tattonbrown2007sotossyndrome pages 1-3)
Developmental delay/learning or intellectual disability — developmental/behavioral phenotype; HP:0001263, HP:0001249, and HP:0000750. Severity ranges from mild/borderline to severe and is generally non-progressive. Expressive language, motor coordination, adaptive function, education, and independent living may be affected. (ocansey2025sotossyndrome pages 5-7, lesinskiene2024neuropsychiatricaspectsof pages 1-2)
Neonatal hypotonia and feeding difficulty — early symptoms/signs; HP:0001252, HP:0011968. Approximate frequencies are 75% and 70%, respectively; they can impair oral safety, growth, and caregiver quality of life. (ocansey2025sotossyndrome pages 5-7, ocansey2025sotossyndrome pages 14-16)
Neonatal jaundice — laboratory/clinical sign, HP:0000952, approximately 65%. (ocansey2025sotossyndrome pages 5-7)
Advanced bone age — imaging sign, HP:0005616, approximately 75–80% of prepubertal children; historical estimates range from 74–100%. It is supportive but neither necessary nor sufficient for diagnosis. (baujat2007sotossyndrome pages 1-2, ocansey2025sotossyndrome pages 5-7)
Seizures — episodic neurologic symptom, HP:0001250; non-febrile seizures occur in roughly 25%. EEG is clinically indicated when seizures are suspected. (ocansey2025sotossyndrome pages 5-7)
Scoliosis — progressive musculoskeletal sign, HP:0002650, approximately 30%; it can affect mobility, pain, and respiratory mechanics in severe cases. (ocansey2025sotossyndrome pages 5-7, ocansey2025sotossyndrome pages 14-16)
Cardiac abnormalities — congenital structural manifestations, HP:0001627. Historical prevalence is 15–40%. A selected 2024 referral cohort found defects in 27/45 (60%), including septal defects, aortic anomalies, patent ductus arteriosus, valve disease, and left-ventricular non-compaction; this high estimate should not be generalized without accounting for referral ascertainment. (ocansey2025sotossyndrome pages 5-7)
Renal/genitourinary anomalies — congenital signs, HP:0000077, about 15%. (ocansey2025sotossyndrome pages 5-7)
Neuroimaging abnormalities — radiologic phenotype, often ventriculomegaly or prominent occipital horns. A reviewed imaging dataset reported trigeminal prominence in 90%, occipital-horn prominence in 75%, and ventriculomegaly in 63%; clinical significance varies. (lesinskiene2024neuropsychiatricaspectsof pages 1-2)
Neurobehavioral manifestations — autistic behavior (HP:0000729), ADHD (HP:0007018), anxiety (HP:0000739), aggression, phobias, and sleep disturbance. The 2024 expert review stresses slow language development and multidisciplinary psychosocial care but also notes the scarcity of longitudinal data. (lesinskiene2024neuropsychiatricaspectsof pages 1-2, lesinskiene2024neuropsychiatricaspectsof pages 6-8)

No disease-specific EQ-5D, SF-36, or validated Sotos quality-of-life dataset was identified. Functional burden is driven principally by developmental disability, communication needs, behavior, seizures, feeding problems, vision problems, scoliosis, and congenital organ disease.

4. Genetic and molecular information

Gene. NSD1 (HGNC:14234; chromosome 5q35.3; Ensembl ENSG00000165671) encodes nuclear receptor-binding SET-domain protein 1. The reported protein is 2,696 amino acids and contains two PWWP domains, five PHD zinc fingers, a C5HCH domain, SET/SAC catalytic domains, and two nuclear-receptor interaction domains. Expression is documented in fetal/adult brain, skeletal muscle, kidney, spleen, thymus, lung, and blood leukocytes. (OpenTargets Search: Sotos syndrome-NSD1, visser2016nsd1andsotos pages 1-5, ocansey2025sotossyndrome pages 16-19)

Functional consequence. The established disease mechanism is dosage-sensitive loss of NSD1 function. SET-domain missense substitutions may destabilize the catalytic structure or sterically disrupt S-adenosylmethionine/substrate access; PHD-domain substitutions may disturb binding to methylated H3K4/H3K9. These findings support loss of chromatin recruitment and/or H3K36 methyltransferase activity, rather than gain of function or dominant-negative activity, as the general mechanism. (ha2016stericclashin pages 16-18, liu2023anovelnonsense pages 8-8)

Structural variants and genotype–phenotype correlation. The principal chromosomal lesion is a 5q35.2–q35.3 deletion encompassing NSD1. In 31 deletion versus 208 intragenic-variant cases, deletions were associated with less prominent overgrowth and more severe learning disability. No consistent correlation with deletion size was found, and individuals with identical intragenic variants can differ substantially. (visser2016nsd1andsotos pages 12-16)

Modifiers and epigenetics. No clinically validated modifier gene is available. NSD1 loss is associated with reduced H3K36me2, genome-wide/promoter DNA hypomethylation, altered PRC2/H3K27me3 balance, and a recognizable blood episignature. Human patient profiling found that most differentially expressed genes were downregulated and enriched for bivalent developmental and neural-synapse genes. The investigators concluded that NSD1-deposited H3K36 methylation directs promoter DNA methylation partly by opposing PRC2 activity. Accelerated transcriptional and DNA-methylation age was also observed, but its prognostic meaning is unknown. (krossa2022lysinemethyltransferasensd1 pages 3-4, brennan2022nsd1mutationsderegulate pages 1-1)

A useful abstract quotation is: “Most abnormally expressed genes displayed reduced expression in SS; these downregulated genes consisted mostly of bivalent genes and were enriched for regulators of development and neural synapse function.” This is human transcriptomic/methylomic association evidence, not proof that each altered gene causes a specific clinical feature. (brennan2022nsd1mutationsderegulate pages 1-1)

5. Environmental information

No toxin, radiation exposure, pollutant, diet, exercise pattern, smoking, alcohol use, or pathogen is known to initiate Sotos syndrome. Ordinary health recommendations remain appropriate but do not alter the underlying germline lesion. Environmental factors may modify general health, educational attainment, behavior, and secondary complications, but disease-specific effect sizes are unavailable. Immunization follows routine age- and risk-based schedules; Sotos syndrome is neither infectious nor zoonotic.

6. Mechanism and pathophysiology

Ordered causal chain

A heterozygous loss-of-function NSD1 variant or NSD1-encompassing 5q35 deletion leads to reduced functional NSD1 dosage. (tattonbrown2007sotossyndrome pages 1-3, ocansey2025sotossyndrome pages 1-3)
Reduced NSD1 dosage leads to diminished or mistargeted H3K36 mono-/dimethylation and altered chromatin-reader interactions; catalytic impairment is demonstrated biochemically/structurally for selected variants. (krossa2022lysinemethyltransferasensd1 pages 3-4, ha2016stericclashin pages 16-18, liu2023anovelnonsense pages 8-8)
Disturbed H3K36 methylation results in abnormal recruitment/crosstalk with DNA-methylation machinery and altered opposition to PRC2, producing promoter/CpG-shore hypomethylation and abnormal H3K27me3 distribution. This step is supported by human multi-omics and cellular work. (krossa2022lysinemethyltransferasensd1 pages 3-4, brennan2022nsd1mutationsderegulate pages 1-1)
The altered epigenetic landscape leads to dysregulated transcription of bivalent developmental, cell-fate, growth, and neural-synapse genes. Human blood profiling demonstrates the signature; its precise tissue-specific developmental timing remains partly inferred. (brennan2022nsd1mutationsderegulate pages 1-1)
During embryonic and childhood development, transcriptional dysregulation is inferred to result in altered proliferation, differentiation, tissue patterning, and neuronal circuit development. Complete Nsd1 loss in mice causes endodermal, mesodermal, and neurectodermal patterning defects and embryonic lethality, supporting an essential upstream developmental role. (oishi2020investigatingcorticalfeatures pages 18-21, fallah2021impairedregulationof pages 5-6)
Growth branch: developmental/growth-gene dysregulation is inferred to lead to prenatal/childhood overgrowth, advanced skeletal maturation, and persistent macrocephaly. The exact growth-effector pathway is unresolved; a simple GH/IGF excess mechanism has not been established. (baujat2007sotossyndrome pages 1-2, brennan2022nsd1mutationsderegulate pages 1-1)
Neural branch: neuronal and synaptic gene dysregulation is inferred to lead to developmental delay, intellectual disability, language impairment, autism/ADHD/anxiety, and seizure susceptibility. Predominantly neuronal Nsd1 expression and mouse social phenotypes support, but do not fully reproduce, this branch. (lesinskiene2024neuropsychiatricaspectsof pages 1-2, oishi2020investigatingcorticalfeatures pages 18-21, oishi2020investigatingcorticalfeatures pages 13-18)
Organogenesis branch: altered developmental programs are inferred to result in craniofacial, cardiac, renal/genitourinary, and skeletal anomalies. Direct tissue-specific human causal chains remain incompletely mapped. (ocansey2025sotossyndrome pages 5-7, visser2016nsd1andsotos pages 12-16)

Pathway interpretation. Sotos syndrome is primarily a chromatin/epigenetic-regulation disorder, not a canonical single-pathway RAS/MAPK, PI3K–AKT–mTOR, immune, metabolic, or lysosomal disease. Relevant GO suggestions are GO:0046975 histone H3K36 methyltransferase activity, GO:0016571 histone methylation, GO:0006306 DNA methylation, GO:0040029 epigenetic regulation of gene expression, GO:0006355 regulation of DNA-templated transcription, GO:0009790 embryo development, and GO:0021987 cerebral cortex development. Relevant cell terms include CL:0000540 neuron, CL:0000127 astrocyte, CL:0000128 oligodendrocyte, CL:0000047 neuronal stem cell, cardiomyocyte CL:0000746, chondrocyte CL:0000138, and osteoblast CL:0000062. Neurons have the strongest direct model evidence; the other cell assignments reflect affected tissues and should be marked as inferred.

No reproducible Sotos-specific proteomic, metabolomic, or lipidomic diagnostic signature was identified. Human transcriptomics and DNA methylomics are the best-developed molecular profiles.

7. Anatomical structures affected

The nervous system and skeleton/growth axis are principal systems; the heart, kidneys/genitourinary tract, eyes, gastrointestinal/feeding apparatus, and musculoskeletal system are variably involved. Suggested anatomical mappings include brain UBERON:0000955, cerebral cortex UBERON:0000956, cerebellum UBERON:0002037, skull UBERON:0003129, bone tissue UBERON:0002481, vertebral column UBERON:0002412, heart UBERON:0000948, kidney UBERON:0002113, and eye UBERON:0000970. (ocansey2025sotossyndrome pages 5-7, fickie2011adultswithsotos pages 4-5, visser2016nsd1andsotos pages 1-5)

At the subcellular level, NSD1 acts principally in the nucleus and on chromatin/nucleosomes: GO:0005634, GO:0000785, and GO:0000786. There is no established mitochondrial, lysosomal, ER-storage, or laterality-specific pathology. Most manifestations are bilateral/systemic rather than consistently unilateral.

8. Temporal development

Sotos syndrome is congenital, with overgrowth and macrocephaly often apparent prenatally or at birth. Hypotonia, feeding difficulty, jaundice, and occasionally hypoglycemia dominate the neonatal period. The facial gestalt is most evident from one to six years; developmental and language differences emerge in infancy/early childhood. Advanced bone age and rapid linear growth are predominantly childhood findings. (baujat2007sotossyndrome pages 1-2, ocansey2025sotossyndrome pages 5-7)

The disease is chronic and lifelong, not relapsing-remitting. Intellectual impairment is usually stable rather than neurodegenerative. Height frequently approaches the normal range after puberty, while macrocephaly persists. Scoliosis, seizures, behavioral health needs, visual disorders, and organ-specific complications may require continued adult care. Adult data remain sparse; in 21 adults, mean reported height was 182 cm in men and 174 cm in women, and almost half had ocular/visual problems. (ocansey2025sotossyndrome pages 5-7, fickie2011adultswithsotos pages 4-5)

Critical intervention periods are infancy and early childhood for feeding safety, developmental therapy, communication support, hearing/vision assessment, and educational planning; adolescence is important for scoliosis and neuropsychiatric reassessment and transition planning. There is no biological remission.

9. Inheritance and population

Inheritance is autosomal dominant (HP:0000006). Approximately 95% of affected individuals have a de novo alteration and about 5% have an affected parent. Each child of an affected person has a 50% transmission probability. Expressivity is highly variable, including within families. Penetrance appears high for some recognizable developmental phenotype, but a precise age-specific penetrance estimate is unavailable. (ocansey2025sotossyndrome pages 1-3, visser2016nsd1andsotos pages 12-16)

The recurrence risk to unaffected parents after an apparently de novo event is low—historically quoted as <1%—but not zero because parental germline mosaicism cannot be completely excluded. Germline mosaicism has been rarely or not convincingly documented in older series. Genetic anticipation is not established; consanguinity is not etiologically relevant; there is no carrier state in the recessive-disease sense. (baujat2007sotossyndrome pages 1-2)

The frequently cited birth incidence is approximately 1 in 14,000, or about 7.1 per 100,000 live births, but exact prevalence remains uncertain because of variable recognition and historical underdiagnosis. No robust annual incidence, founder effect, ethnic predilection, or sex difference is established. Microdeletions have historically been relatively common in Japanese cohorts, whereas intragenic variants predominate in European cohorts, potentially reflecting genomic architecture and ascertainment rather than different overall disease prevalence. (baujat2007sotossyndrome pages 1-2, krossa2022lysinemethyltransferasensd1 pages 3-4)

10. Diagnostics

Clinical assessment

Clinical suspicion rests on the facial gestalt, developmental/learning impairment, macrocephaly/tall stature, and supportive findings such as advanced bone age. There are no universally accepted purely clinical consensus criteria, and normal height does not exclude the disease. Molecular confirmation is therefore preferred. (baujat2007sotossyndrome pages 1-2, testa2023molecularanalysisand pages 1-2)

Baseline evaluation should include serial growth and head circumference, developmental and behavioral assessment, feeding/oral-motor evaluation, cardiovascular examination with echocardiography at diagnosis, renal evaluation guided by findings, spine examination, vision and hearing assessment, and neurologic assessment. MRI, EEG, bone-age radiography, renal ultrasound, and laboratory testing are indication-driven rather than universal biochemical diagnostic tests. No serum enzyme, protein, or metabolite is diagnostic. (ocansey2025sotossyndrome pages 5-7, ocansey2025sotossyndrome pages 14-16)

Genetic-testing algorithm

In a classic phenotype, perform NSD1 sequencing plus deletion/duplication analysis.
If the phenotype overlaps multiple overgrowth/intellectual-disability syndromes, use a panel including NSD1 and important differentials such as EZH2, DNMT3A, NFIX, PTEN, SETD2, EED, SUZ12, PPP2R5D, TCF20, and BRWD3.
Use chromosomal microarray to detect 5q35 deletions and other pathogenic copy-number variants, especially in patients with congenital anomalies or more severe disability.
Use trio WES/WGS when targeted testing is negative, atypical, or a blended diagnosis is suspected. WGS can capture coding, noncoding, splice, and structural lesions but is not yet necessary in every classic case.
RNA studies can resolve suspected splice variants; methylation episignatures may support classification of a VUS, but neither presently replaces identification of a causal genomic variant. (ocansey2025sotossyndrome pages 1-3, visser2016nsd1andsotos pages 12-16, testa2023molecularanalysisand pages 1-2)

A 2023 real-world laboratory cohort screened 1,530 unrelated suspected cases and identified NSD1 findings in 292 (19.1%), including nine partial deletions, 13 whole-gene microdeletions, and 115 novel intragenic variants. Twenty-five of 32 assessed missense VUS (78.1%) moved to likely pathogenic or likely benign, emphasizing periodic reinterpretation and phenotype–laboratory communication. The authors’ abstract states that the work demonstrates “the utility of sharing variant classification and the need to improve communication between the laboratory staff and the referring physician.” (testa2023molecularanalysisand pages 1-2)

Karyotyping and FISH can detect large rearrangements but have largely been superseded by CMA and sequencing/dosage methods. Mitochondrial-DNA and repeat-expansion tests are not routine for Sotos syndrome.

Differential diagnosis and screening

Important differentials include Weaver syndrome (EZH2), Tatton-Brown–Rahman syndrome (DNMT3A), Malan syndrome (NFIX), Beckwith–Wiedemann spectrum, Simpson–Golabi–Behmel syndrome (GPC3), PTEN hamartoma-tumor syndrome, SETD2/Luscan–Lumish syndrome, Fragile X syndrome, and terminal 22q deletion. Distinguishing features include the facial gestalt, tumor spectrum, organomegaly/macroglossia, segmental overgrowth, sex-linked inheritance, and molecular findings. (baujat2007sotossyndrome pages 1-2, testa2023molecularanalysisand pages 11-13)

Sotos syndrome is not part of routine newborn biochemical screening. Cascade testing is appropriate after an inherited variant is found. Prenatal and preimplantation testing are possible once the familial variant is known, but severity cannot be predicted accurately from genotype alone. (ocansey2025sotossyndrome pages 1-3)

11. Outcome and prognosis

Life expectancy is believed to be near normal for most individuals without severe cardiac, neurologic, or other complications, but no reliable 5-year, 10-year, or disease-specific mortality estimates exist. Major long-term morbidity arises from intellectual/developmental disability, communication and behavioral needs, seizures, scoliosis, feeding problems, congenital heart/renal disease, and visual impairment. Adult natural-history evidence remains limited. (ocansey2025sotossyndrome pages 14-16, fickie2011adultswithsotos pages 4-5)

Tumors have been reported in approximately 3% of affected individuals, but the spectrum is heterogeneous and absolute risk is low. Expert guidance estimates the combined sacrococcygeal-teratoma/neuroblastoma risk near 1%; Wilms-tumor risk is not significantly increased. Consequently, routine tumor-marker testing, whole-body imaging, or renal ultrasound solely for cancer surveillance is not recommended. New masses, unexplained pain, neurologic change, cytopenic symptoms, or constitutional symptoms warrant ordinary prompt assessment. (ocansey2025sotossyndrome pages 5-7, ocansey2025sotossyndrome pages 14-16)

No validated molecular prognostic biomarker predicts individual cognitive, growth, seizure, or cardiac outcome. A 5q35 microdeletion is associated at group level with more severe learning disability, but genotype does not reliably predict an individual course. (visser2016nsd1andsotos pages 12-16)

12. Treatment

There is no approved NSD1-restoring, gene-editing, RNA, cellular, epigenetic, or other disease-modifying treatment. A ClinicalTrials.gov search identified no relevant interventional disease-modifying Sotos trial. Treatment is therefore individualized and multidisciplinary. (ocansey2025sotossyndrome pages 14-16)

Development: early-intervention services, individualized education, neuropsychology, speech/language therapy, and augmentative and alternative communication. Suggested NCIT terms: Speech Therapy, Educational Therapy, Supportive Care.
Motor/orthopedic: physical and occupational therapy; orthopedic management or surgery for progressive scoliosis, hip problems, or functional deformity. NCIT: Physical Therapy, Occupational Therapy, Orthopedic Surgery.
Feeding/GI: feeding and swallowing assessment, texture modification, reflux/constipation treatment, nutrition support, and NG or gastrostomy feeding when required. NCIT: Nutritional Support, Gastrostomy.
Neurologic: standard antiseizure medication selected by seizure type; epilepsy-surgery evaluation may be appropriate for rare focal drug-resistant epilepsy. No Sotos-specific pharmacogenomic rule is known.
Behavior/psychiatry: behavioral therapy, developmental pediatrics, school supports, and standard evidence-based treatment of ADHD, anxiety, aggression, ASD-associated impairment, and sleep disturbance. (ocansey2025sotossyndrome pages 14-16, lesinskiene2024neuropsychiatricaspectsof pages 6-8)
Cardiac, renal, visual, hearing, and endocrine complications: standard specialist-directed treatment. The elevated cardiac-defect yield in a 2024 molecular cohort supports a detailed echocardiogram at diagnosis and individualized cardiology follow-up. (ocansey2025sotossyndrome pages 5-7)

Growth-suppressing endocrine treatment is not routinely recommended merely for tall stature. Surgery and medications should target clinically meaningful complications rather than the syndrome label.

13. Prevention

Primary prevention: There is no vaccine, lifestyle change, or prophylactic medication that prevents a de novo NSD1 variant. Reproductive options after identification of a familial variant include genetic counseling, prenatal diagnosis, donor gametes, and preimplantation genetic testing.

Secondary prevention: Early molecular diagnosis, cascade testing in relatives, developmental screening, and prompt assessment of feeding, hearing, vision, heart, kidneys, spine, seizures, and behavior can reduce diagnostic delay and secondary disability. Population-wide newborn or carrier screening is not recommended because most cases are de novo and there is no validated newborn biochemical marker. (ocansey2025sotossyndrome pages 1-3, ocansey2025sotossyndrome pages 14-16)

Tertiary prevention: At routine visits, monitor growth/nutrition, oral safety, constipation, seizures and neurologic changes, development/education, neurobehavioral health, mobility/spine, self-care, hearing, vision, cardiovascular status, and family support. Physical therapy may reduce contractures and orthopedic complications; communication support can reduce frustration and improve participation. Routine cancer screening beyond population recommendations is not justified by current risk estimates. (ocansey2025sotossyndrome pages 14-16)

14. Other species and natural disease

The causal gene has conserved orthologs, including mouse Nsd1 in Mus musculus (NCBI Taxon:10090), zebrafish orthologous NSD-family genes in Danio rerio (Taxon:7955), and fly nsd in Drosophila melanogaster (Taxon:7227). Human and mouse proteins have approximately 83% amino-acid identity, supporting conserved chromatin function. (fallah2021impairedregulationof pages 5-6)

No well-established naturally occurring veterinary syndrome equivalent to human NSD1-related Sotos syndrome was identified, and no breed-specific VBO association is established. The disorder has no zoonotic potential and cannot be transmitted between species. Comparative evidence comes from engineered models rather than natural animal disease.

15. Model organisms and experimental systems

Constitutive mouse knockout. Homozygous Nsd1 loss is embryonic lethal by approximately E10.5, with abnormal endodermal, mesodermal, and neurectodermal patterning, increased apoptosis, and severe forebrain/prosencephalic abnormalities. This establishes an essential role in early development but prevents postnatal study of complete loss. (oishi2020investigatingcorticalfeatures pages 18-21, fallah2021impairedregulationof pages 5-6)

Heterozygous mouse. A CRISPR model targeting conserved exon 3 produced a premature stop and approximately 50% reduction in cortical Nsd1 mRNA. Nsd1+/− animals showed reduced SATB2-positive upper-layer neurons in retrosplenial cortex, impaired social-novelty preference, and fewer pup ultrasonic vocalizations. They did not show human-like overgrowth, macrocephaly, gross cortical enlargement, hippocampal abnormality, or active-place-avoidance learning deficit. Thus, they model selected social/cortical features but have limited face and construct validity for systemic human disease. (oishi2020investigatingcorticalfeatures pages 13-18, oishi2020investigatingcorticalfeatures pages 28-36)

Cellular systems. Mouse embryonic stem/germ-cell studies demonstrate reduced H3K36me2 after Nsd1 loss. Patient blood and cultured-cell methylome/transcriptome analyses model the molecular episignature. Patient-derived iPSC neurons, cerebral organoids, and lineage-specific conditional knockouts are rational next-generation systems, but mature, widely validated Sotos organoid or therapeutic-screen platforms were not established in the retrieved 2023–2024 literature. (krossa2022lysinemethyltransferasensd1 pages 3-4, brennan2022nsd1mutationsderegulate pages 1-1, oishi2020investigatingcorticalfeatures pages 18-21)

Non-mammalian models. Drosophila nsd deletion has been reported to cause developmental abnormalities resembling selected Sotos features, but direct quantitative evidence was not available in the retrieved full text. Zebrafish are not yet a standard NSD1-Sotos model. These systems offer high-throughput functional testing but cannot reproduce the human facial gestalt, cognition, or long developmental trajectory.

Recent-development assessment and evidence gaps

The strongest 2023–2024 development is diagnostic rather than therapeutic: large-scale NSD1 variant re-evaluation, panel/exome integration, and improved recognition of cardiac, neuroimaging, and neuropsychiatric manifestations. The 2024 neuropsychiatric review concluded that autism, ADHD, anxiety, aggressive outbursts, language delay, and altered sleep are clinically important while emphasizing the lack of longitudinal intervention research. (lesinskiene2024neuropsychiatricaspectsof pages 1-2, testa2023molecularanalysisand pages 1-2, lesinskiene2024neuropsychiatricaspectsof pages 6-8)

Important unresolved questions are: the tissue-specific route from H3K36me2 loss to overgrowth; reliable penetrance and population prevalence; adult cardiovascular and neuropsychiatric natural history; validated patient-reported quality-of-life outcomes; functional classification of many missense variants; and whether safe correction of NSD1-dependent chromatin states is therapeutically feasible. Current expert interpretation should therefore avoid treating rare case-report findings as syndrome-defining or assuming that cancer-associated NSD1 inhibitors would benefit a haploinsufficiency disorder.

References

(tattonbrown2007sotossyndrome pages 1-3): Katrina Tatton-Brown and Nazneen Rahman. Sotos syndrome. European Journal of Human Genetics, 15:264-271, Sep 2007. URL: https://doi.org/10.1038/sj.ejhg.5201686, doi:10.1038/sj.ejhg.5201686. This article has 348 citations and is from a domain leading peer-reviewed journal.
(ocansey2025sotossyndrome pages 1-3): S Ocansey, TRP Cole, and N Rahman. Sotos syndrome. Mar 2025. URL: https://doi.org/10.1002/9780470893159.ch51, doi:10.1002/9780470893159.ch51. This article has 8 citations.
(brennan2022nsd1mutationsderegulate pages 1-1): Kevin Brennan, Hong Zheng, Jill A Fahrner, June Ho Shin, Andrew J Gentles, Bradley Schaefer, John B Sunwoo, Jonathan A Bernstein, and Olivier Gevaert. Nsd1 mutations deregulate transcription and dna methylation of bivalent developmental genes in sotos syndrome. Human Molecular Genetics, 31:2164-2184, Jan 2022. URL: https://doi.org/10.1093/hmg/ddac026, doi:10.1093/hmg/ddac026. This article has 32 citations and is from a domain leading peer-reviewed journal.
(testa2023molecularanalysisand pages 1-2): Barbara Testa, Giuseppina Conteduca, Marina Grasso, Massimiliano Cecconi, Francesca Lantieri, Chiara Baldo, Alessia Arado, Laura Andraghetti, Michela Malacarne, Donatella Milani, and Domenico Coviello. Molecular analysis and reclassification of nsd1 gene variants in a cohort of patients with clinical suspicion of sotos syndrome. Genes, 14(2):295, Jan 2023. URL: https://doi.org/10.3390/genes14020295, doi:10.3390/genes14020295. This article has 16 citations.
(baujat2007sotossyndrome pages 1-2): Geneviève Baujat and Valérie Cormier-Daire. Sotos syndrome. Orphanet Journal of Rare Diseases, 2:36-36, Sep 2007. URL: https://doi.org/10.1186/1750-1172-2-36, doi:10.1186/1750-1172-2-36. This article has 193 citations and is from a peer-reviewed journal.
(ocansey2025sotossyndrome pages 5-7): S Ocansey, TRP Cole, and N Rahman. Sotos syndrome. Mar 2025. URL: https://doi.org/10.1002/9780470893159.ch51, doi:10.1002/9780470893159.ch51. This article has 8 citations.
(OpenTargets Search: Sotos syndrome-NSD1): Open Targets Query (Sotos syndrome-NSD1, 9 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(oishi2020investigatingcorticalfeatures pages 1-5): Sabrina Oishi, Oressia Zalucki, Michelle S. Vega, Danyon Harkins, Tracey J. Harvey, Maria Kasherman, Raul A. Davila, Lauren Hale, Melissa White, Sandra Piltz, Paul Thomas, Thomas H. J. Burne, Lachlan Harris, and Michael Piper. Investigating cortical features of sotos syndrome using mice heterozygous for nsd1. Jan 2020. URL: https://doi.org/10.1111/gbb.12637, doi:10.1111/gbb.12637. This article has 28 citations.
(krossa2022lysinemethyltransferasensd1 pages 3-4): Imène Krossa, Thomas Strub, Andrew E. Aplin, Robert Ballotti, and Corine Bertolotto. Lysine methyltransferase nsd1 and cancers: any role in melanoma? Oct 2022. URL: https://doi.org/10.3390/cancers14194865, doi:10.3390/cancers14194865. This article has 6 citations.
(visser2016nsd1andsotos pages 12-16): Remco Visser and Naomichi Matsumoto. Nsd1 and sotos syndrome. ArXiv, pages 1015-1020, Jun 2016. URL: https://doi.org/10.1093/med/9780199934522.003.0152, doi:10.1093/med/9780199934522.003.0152. This article has 5 citations.
(saugierveber2007heterogeneityofnsd1 pages 10-10): Pascale Saugier-Veber, Céline Bonnet, Alexandra Afenjar, Valérie Drouin-Garraud, Christine Coubes, Séverine Fehrenbach, Muriel Holder-Espinasse, Joëlle Roume, Valérie Malan, Marie-France Portnoi, Nicolas Jeanne, Clarisse Baumann, Delphine Héron, Albert David, Marion Gérard, Dominique Bonneau, Didier Lacombe, Valérie Cormier-Daire, Thierry Billette de Villemeur, Thierry Frébourg, and Lydie Bürglen. Heterogeneity of nsd1 alterations in 116 patients with sotos syndrome. Human Mutation, 28:1098-1107, Nov 2007. URL: https://doi.org/10.1002/humu.20568, doi:10.1002/humu.20568. This article has 81 citations and is from a domain leading peer-reviewed journal.
(fickie2011adultswithsotos pages 4-5): Matthew R. Fickie, Pablo Lapunzina, Jennifer K. Gentile, Nina Tolkoff‐Rubin, Daniela Kroshinsky, Enrique Galan, Esther Gean, Loreto Martorell, Valeria Romanelli, Joaquín Fernandez Toral, and Angela E. Lin. Adults with sotos syndrome: review of 21 adults with molecularly confirmed nsd1 alterations, including a detailed case report of the oldest person. American Journal of Medical Genetics Part A, 155:2105-2111, Sep 2011. URL: https://doi.org/10.1002/ajmg.a.34156, doi:10.1002/ajmg.a.34156. This article has 50 citations.
(lesinskiene2024neuropsychiatricaspectsof pages 1-2): Sigita Lesinskiene, Reda Montvilaite, Kamile Pociute, Ausra Matuleviciene, and Algirdas Utkus. Neuropsychiatric aspects of sotos syndrome: explorative review building multidisciplinary bridges in clinical practice. Apr 2024. URL: https://doi.org/10.3390/jcm13082204, doi:10.3390/jcm13082204. This article has 13 citations.
(ocansey2025sotossyndrome pages 14-16): S Ocansey, TRP Cole, and N Rahman. Sotos syndrome. Mar 2025. URL: https://doi.org/10.1002/9780470893159.ch51, doi:10.1002/9780470893159.ch51. This article has 8 citations.
(lesinskiene2024neuropsychiatricaspectsof pages 6-8): Sigita Lesinskiene, Reda Montvilaite, Kamile Pociute, Ausra Matuleviciene, and Algirdas Utkus. Neuropsychiatric aspects of sotos syndrome: explorative review building multidisciplinary bridges in clinical practice. Apr 2024. URL: https://doi.org/10.3390/jcm13082204, doi:10.3390/jcm13082204. This article has 13 citations.
(visser2016nsd1andsotos pages 1-5): Remco Visser and Naomichi Matsumoto. Nsd1 and sotos syndrome. ArXiv, pages 1015-1020, Jun 2016. URL: https://doi.org/10.1093/med/9780199934522.003.0152, doi:10.1093/med/9780199934522.003.0152. This article has 5 citations.
(ocansey2025sotossyndrome pages 16-19): S Ocansey, TRP Cole, and N Rahman. Sotos syndrome. Mar 2025. URL: https://doi.org/10.1002/9780470893159.ch51, doi:10.1002/9780470893159.ch51. This article has 8 citations.
(ha2016stericclashin pages 16-18): Kyungsoo Ha, Priya Anand, Jennifer Lee, Julie Jones, Chong Kim, Debora Bertola, Jonathan Labonne, Lawrence Layman, Wolfgang Wenzel, and Hyung-Goo Kim. Steric clash in the set domain of histone methyltransferase nsd1 as a cause of sotos syndrome and its genetic heterogeneity in a brazilian cohort. Genes, Nov 2016. URL: https://doi.org/10.3390/genes7110096, doi:10.3390/genes7110096. This article has 15 citations.
(liu2023anovelnonsense pages 8-8): Xinting Liu, Chen Chen, Lin Wan, Gang Zhu, Yan Zhao, Lizhu Hu, Yan Liang, Jing Gao, Jing Wang, and Guang Yang. A novel nonsense variant in nsd1 gene in a female child with sotos syndrome: a case report and literature review. Brain and Behavior, Oct 2023. URL: https://doi.org/10.1002/brb3.3290, doi:10.1002/brb3.3290. This article has 6 citations and is from a peer-reviewed journal.
(oishi2020investigatingcorticalfeatures pages 18-21): Sabrina Oishi, Oressia Zalucki, Michelle S. Vega, Danyon Harkins, Tracey J. Harvey, Maria Kasherman, Raul A. Davila, Lauren Hale, Melissa White, Sandra Piltz, Paul Thomas, Thomas H. J. Burne, Lachlan Harris, and Michael Piper. Investigating cortical features of sotos syndrome using mice heterozygous for nsd1. Jan 2020. URL: https://doi.org/10.1111/gbb.12637, doi:10.1111/gbb.12637. This article has 28 citations.
(fallah2021impairedregulationof pages 5-6): Merrick S. Fallah, Dora Szarics, Clara M. Robson, and James H. Eubanks. Impaired regulation of histone methylation and acetylation underlies specific neurodevelopmental disorders. Frontiers in Genetics, Jan 2021. URL: https://doi.org/10.3389/fgene.2020.613098, doi:10.3389/fgene.2020.613098. This article has 65 citations and is from a peer-reviewed journal.
(oishi2020investigatingcorticalfeatures pages 13-18): Sabrina Oishi, Oressia Zalucki, Michelle S. Vega, Danyon Harkins, Tracey J. Harvey, Maria Kasherman, Raul A. Davila, Lauren Hale, Melissa White, Sandra Piltz, Paul Thomas, Thomas H. J. Burne, Lachlan Harris, and Michael Piper. Investigating cortical features of sotos syndrome using mice heterozygous for nsd1. Jan 2020. URL: https://doi.org/10.1111/gbb.12637, doi:10.1111/gbb.12637. This article has 28 citations.
(testa2023molecularanalysisand pages 11-13): Barbara Testa, Giuseppina Conteduca, Marina Grasso, Massimiliano Cecconi, Francesca Lantieri, Chiara Baldo, Alessia Arado, Laura Andraghetti, Michela Malacarne, Donatella Milani, and Domenico Coviello. Molecular analysis and reclassification of nsd1 gene variants in a cohort of patients with clinical suspicion of sotos syndrome. Genes, 14(2):295, Jan 2023. URL: https://doi.org/10.3390/genes14020295, doi:10.3390/genes14020295. This article has 16 citations.
(oishi2020investigatingcorticalfeatures pages 28-36): Sabrina Oishi, Oressia Zalucki, Michelle S. Vega, Danyon Harkins, Tracey J. Harvey, Maria Kasherman, Raul A. Davila, Lauren Hale, Melissa White, Sandra Piltz, Paul Thomas, Thomas H. J. Burne, Lachlan Harris, and Michael Piper. Investigating cortical features of sotos syndrome using mice heterozygous for nsd1. Jan 2020. URL: https://doi.org/10.1111/gbb.12637, doi:10.1111/gbb.12637. This article has 28 citations.

Artifacts

Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	14
Resolved	14
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	14
On topic	9
Off topic	0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome	Count
Terms checked	72
Resolved	66
Unresolved (possible confabulation)	0
Obsolete	2
Unverifiable	4
Terms whose name was checked	1
Terms named correctly	0
Terms named as a different term	1

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

MONDO:0019349 (5 mentions) - the report calls it "if available"; MONDO calls it Sotos syndrome

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

GO:0016571 (obsolete histone methylation) (2 mentions)
GO:0006306 (obsolete DNA methylation) (2 mentions)

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: Taxon.

Ask OpenScientist

OpenScientist Report

Classifications

Definitions

Inheritance

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Progression

Prevalence

Epidemiology

Differential Diagnoses

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Sotos Syndrome. Core disease mechanisms, molecular and cellular pathways,...

Relevant Papers

[1] Sotos syndrome.

[2] Histone Lysine Methylation and Neurodevelopmental Disorders

[3] Molecular Genetics of Bartter Syndrome: Bridging Genotype–Phenotype Correlations and Precision Therapeutics

[4] New therapeutic targets in rare genetic skeletal diseases

[5] Nasopharyngeal Carcinoma Signaling Pathway: An Update on Molecular Biomarkers

[6] Phenotypic categorization of genetic skin diseases reveals new relations between phenotypes, genes and pathways

[7] Clinical Manifestations of Sotos Syndrome

[8] Human Dermal Fibroblast: A Promising Cellular Model to Study Biological Mechanisms of Major Depression and Antidepressant Drug Response

[9] Precision Therapeutics in Lennox–Gastaut Syndrome: Targeting Molecular Pathophysiology in a Developmental and Epileptic Encephalopathy

[10] Changes in Serum Proteomic Profiles at Different Stages of Pregnancy Toxemia in Goats

[11] Investigating the role of NPR1 in dilated cardiomyopathy and its potential as a therapeutic target for glucocorticoid therapy

[12] Modeling psychiatric disorders: from genomic findings to cellular phenotypes

[13] Modelling Mitochondrial Disease in Human Pluripotent Stem Cells: What Have We Learned?

[14] Investigating the impact of gut microbiota-derived metabolites on benign prostatic hyperplasia using network pharmacology approaches

[15] DNA-damage-associated protein co-expression network in cardiomyocytes informs on tolerance to genetic variation and disease

[16] Computational modelling of TNFα related pathways regulated by neuroinflammation, oxidative stress and insulin resistance in neurodegeneration

[17] Role of Transcriptomics in Precision Oncology

[18] ‘Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics’

[19] Mitochondrial Dysfunction in Diabetes: Shedding Light on a Widespread Oversight

[20] Molecular mechanisms and phenotypic diversity in Bardet-Biedl syndrome

Notes

Reference Validation

References that may not be about this subject

Term Validation

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Sotos syndrome: comprehensive disease-characteristics report

Executive summary

1. Disease information

2. Etiology

Causal factors and genetic risk

Environmental, lifestyle, infectious, and protective factors

3. Phenotypes

4. Genetic and molecular information

5. Environmental information

6. Mechanism and pathophysiology

Ordered causal chain

7. Anatomical structures affected